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Abstract  
This thesis investigates the urotoxic effects of the commonly used cytoxic drugs 
cyclophosphamide and ifosfamide.  Both drugs are well recognised for causing haemorrhagic 
cystitis and lasting adverse effects in the bladder including pain, increased urinary frequency 
and urgency and sensations of incomplete bladder emptying.  These adverse effects have been 
largely attributed to the formation of the toxic metabolite acrolein which is excreted in the urine.  
However, another urinary metabolite of these drugs is chloroacetaldehyde and its role in 
urotoxicity has not been explored.  Understanding more about what effects these drugs and 
their metabolites have on the bladder and its function may uncover possible targets for 
preventing, alleviating or treating the adverse urological effects and could lead to better drug 
toleration and better treatment outcomes. 
The effects of acrolein and chloroacetaldehyde were investigated using cultured human 
urothelial cells as well as full thickness porcine bladder sections.  Systemic administration of 
cyclophosphamide and ifosfamide was also performed in mice to study the effects of the 
endogenously produced metabolites on whole bladder and nerve function.  A combination of 
pharmacological agents and chemical, mechanical and electrical stimuli were used to 
investigate and compare the responses of control and treated tissues.   
Experiments measuring mediator release from urothelial cells implicated both acrolein and 
chloroacetaldehyde in the urotoxicity of cyclophosphamide and ifosfamide as both metabolites 
caused increased excitatory transmitter release from the cells.  It was thought that the increase 
in excitatory transmitter release may contribute to bladder hyperactivity by activating and/or 
sensitising afferent nerves.  Both metabolites also caused urothelial damage when applied to 
the luminal side of porcine bladder sections.  However, despite loss of urothelial cells, the 
mediator release was comparable to controls suggesting enhanced release from each cell 
compensated for overall cell loss.  Total afferent nerve activity was found to be increased in 
mice after treatment with either cyclophosphamide or ifosfamide due to enhanced activity of the 
low threshold nerve fibres.   However, the heightened afferent activity observed in mice was not 
associated with increased excitatory urothelial mediator release or altered detrusor tone.  This 
suggests that cyclophosphamide or ifosfamide treatment is able to enhance nerve activity via a 
mechanism independent of bladder function and that the bladder pain and urinary hyperactivity 
experienced by patients is primarily due to sensitisation of the afferent pathways. 
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1.1 RATIONALE 
Cyclophosphamide (CPO) and ifosfamide (IFO) are cytotoxic drugs used extensively in the 
treatment of cancer and autoimmune diseases (Furlanut and Franceschi, 2003, Brode and 
Cooke, 2008).   A major limiting factor in the use of CPO and IFO is the resulting bladder toxicity 
which can manifest as urinary frequency, feelings of incomplete bladder emptying, dysuria, 
urgency, pain and in some cases life threatening hemorrhagic cystitis (Coggins et al., 1960, 
Bryant et al., 1980, Boddy and Yule, 2000, Furlanut and Franceschi, 2003, Klastersky, 2003, 
Korkmaz et al., 2007).   
The urotoxicity of CPO and IFO is thought to be due to the formation of a metabolite called 
acrolein which is excreted in the urine and as a result comes into direct contact with the 
epithelial lining of the bladder (urothelium) (Dore et al., 1989, Boddy and Yule, 2000, Batista et 
al., 2006).  The mechanisms of cytotoxic action in the urothelium are not fully understood 
although overproduction of reactive oxygen and nitrogen species (ROS/RNS), and depletion of 
antioxidant defences are believed to play a causal role (Korkmaz et al., 2007).  Normal bladder 
function is dependent on the release of mediators from the urothelium induced by stretch during 
bladder filling and changes in the release of these factors are associated with bladder 
dysfunction (Kumar et al., 2010).   Sensory nerves in the bladder are also imperative for normal 
bladder function. They sense chemical and mechanical changes and relay information about 
bladder fullness to the central nervous system, ultimately controlling the storage and micturition 
reflexes of the bladder (Kanai and Andersson, 2010).  Disruption of afferent signalling can lead 
to storage and/or voiding dysfunction as well as pain.   
The following review will cover the anatomy and physiology of the healthy bladder, detailed 
information about the drugs CPO and IFO and the known effects of these drugs on bladder 
function.  This will highlight the gaps in the current literature and introduce the rationale and 
aims of this thesis.  
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1.2 SIGNIFICANCE 
CPO and IFO are commonly used to treat a variety of malignant and non-malignant neoplastic 
diseases as well as being used as immunosuppressive agents in bone marrow transplantation 
and chronic autoimmune disorders (Lawson et al., 2008, de Jonge et al., 2005, Buda et al., 
2003, Bergh, 2003, Nichols, 1995, Sladek, 1988). As these drugs are used in numerous 
therapeutic situations it is difficult to assess how many patients are treated with CPO or IFO 
each year.  However, it is clear that the number of patients which may be affected by the 
toxicities of these drugs is substantial. CPO and IFO toxicity can adversely affect both short 
term and long term patient quality of life, can be life threatening, may limit the dose and duration 
of treatment possibly affecting treatment outcomes and may contribute to both the medical and 
nonmedical costs of treatment (Hensley et al., 1999). 
It has been found that between 2-40% of CPO or IFO treated patients develop hemorrhagic 
cystitis (Hader et al., 1993, Takamoto et al., 2004).  Incidence of micturition pain after treatment 
with CPO has been reported to be 19.6% and the incidence of the feeling of incomplete 
emptying of the bladder to be 15.2% (Fukuoka et al., 1991).  Mortality rates of 2% to 4% have 
been reported for patients who develop severe bladder haemorrhage (Hensley et al., 1999).  
These adverse effects not only affect the tolerability of CPO and IFO treatment but also affect 
the ongoing quality of life of the patient.  Furthermore, it has been estimated that the economic 
cost of managing CPO toxicities (not limited to urotoxicity) is between AU$1,600 - $6,500 per 
patient depending on country and chemotherapy regimen (Herold and Hieke, 2002).   
During 2011 in Australia, a total of 45,168 out-patient scripts were filled for CPO and 2,025 for 
IFO at a total government cost of AU$2.7milllion (Mabbott et al., 2013).  A common 
uroprotectant used with CPO and IFO is mesna and a total of 2,230 out-patient scripts were 
filled in Australia in 2011 at a cost of AU$344,778 (Mabbott et al., 2013).  The low number of 
out-patient mesna prescriptions is thought to be due to the likelihood it is administered in 
hospitals, its cost, as well as the mixed reports on its efficacy.  These costs are for 
pharmaceuticals prescribed to out-patients only while the number of prescriptions of CPO and 
IFO to patients in public hospitals is unknown.  Another study places the in-hospital costs of 
mesna at US$1500 per patient (Ballen et al., 1999).   Furthermore, time spent in hospital and 
the cost of treatment would be increased in the event that treatment is stopped or delayed due 
to toxicities and to treat the toxicities themselves (Malliti et al., 2003).  Accordingly, these figures 
are only suggestive of the significant costs associated with prevention and treatment of CPO 
and IFO urotoxicity.  In addition, the cost of discomfort, pain and an overactive bladder on 
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quality of life after treatment cannot be represented in monetary values.  A better understanding 
of what changes are occurring in the bladder as a result of CPO and IFO toxicity may lead to 
identification of possible targets for preventing or treating the adverse effects of these drugs as 
well as increased drug toleration and better treatment outcomes. 
1.3 BLADDER 
The urinary bladder is a hollow, muscular organ that temporarily stores urine which is formed by 
the kidneys and transported to the bladder via paired tubes called ureters.  On emptying the 
bladder, urine passes through the urethra which conducts the urine to the exterior of the body in 
a process termed urination or micturition.  Micturition involves contraction of the muscular 
bladder which forces urine through the urethra and out of the body (Martini and Nath, 2009). 
Anatomy 
The urinary bladder has several different regions, as shown in Figure 1.1, including an apex 
(dome), a base (trigone), a superior surface and two inferolateral surfaces (Drake et al., 2005).  
Each of the two ureters enters the bladder at one of the upper corners of the trigone while the 
urethral entrance lies at the lower corner of the trigone (Drake et al., 2005, Martini and Nath, 
2009).  The trigone acts as a funnel that channels urine into the urethra when the bladder 
contracts (Martini and Nath, 2009). The region surrounding the urethra entrance is known as the 
neck of the bladder.  The control of continence at this section of the bladder is involuntary and 
the anatomy involved differs between males and females (Martini and Nath, 2009).  Males have 
a well-defined ring of smooth muscle fibres between the base of the bladder and the upper 
border of the prostate (Jung et al., 2012). In females, there is not a well-defined ring of smooth 
muscle and it is the smooth muscle of the bladder neck and urethra that contribute to 
continence (Ashton-Miller and DeLancey, 2007).  However, for the purpose of this thesis, both 
the male and female anatomy contributing to continence at the bladder neck will be refered to 
as the internal urethral sphincter (IUS). In both males and females, where the urethra passes 
through the urogenital diaphragm, there is a circular band of skeletal muscle which forms the 
external urethral sphincter (EUS).  The EUS has resting tone and must be voluntarily relaxed to 
allow micturition (Martini and Nath, 2009).   
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Figure 1.1 has been removed due to Copyright restrictions. 
 
 
 
 
 
Figure 1.1: The anatomy of the urinary bladder (adapted from (McKinley and O'Loughlin, 2008)). 
 
The bladder wall consists of an outer serosal layer, a muscle layer (detrusor) and an inner 
urothelial/lamina propria layer (Figure 1.1). The inner lining of the bladder has been given 
several names including the mucosa, the urothelium/suburothelium or the urothelium/lamina 
propria and much international debate has surrounded which terminology accurately describes 
this layer.  For clarity, throughout this thesis, the term urothelium/lamina propria will be used to 
collectively refer to the bladder layers of the urothelium, basement membrane and lamina 
propria (LP).   
The urothelium is a layer of transitional epithelium and below it, separated by the basement 
membrane, is the LP which consists of blood vessels, nerves and interstitial cells (Guedes et al., 
2008, Birder et al., 2010b).  The urothelium/LP is loosely attached to the underlying smooth 
muscle and is usually thrown into folds, or rugae, that disappear as the bladder fills.  However, 
the urothelium/LP of the trigone region is smooth, thick and firmly attached to the smooth 
muscle (Drake et al., 2005, Martini and Nath, 2009).  The detrusor is formed by a circular layer 
of smooth muscle between an inner and outer layer of longitudinal smooth muscle.  Contraction 
of the detrusor is responsible for compression of the bladder and expulsion of urine into the 
urethra (Martini and Nath, 2009). 
As the urothelial layer is the outermost layer of the bladder it comes into contact with urine and 
any toxins present in the urine.  Accordingly, it is this layer of cells that is of particular interest in 
the study of CPO and IFO induced urotoxicity and it will be discussed in more detail below.  
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Regulation of bladder function 
Control of urine storage and micturition depends on coordination between the bladder muscle 
and the bladder outlet (the bladder neck, IUS and the EUS) (Sugaya et al., 2005).  During 
micturition the bladder muscle contracts while the neck and the sphincters relax.  Accordingly, 
during urine storage the neck and the sphincters contract while the bladder muscle remains 
inactive.  The coordination of these opposing actions is regulated by a complex neural system in 
the brain, spinal cord and peripheral ganglia (Yoshimura et al., 2014).  The peripheral nerves 
that control bladder function include the sympathetic, parasympathetic, and somatic nerves 
(Andersson, 1993, de Groat et al., 1993, Sugaya et al., 2005).  The preganglionic sympathetic 
nerves emerge from the thoracolumar spinal cord (T11-L2) and synapse with postganglionic 
nerves in the inferior mesenteric ganglion travelling mainly via the hypogastric nerve. The 
preganglionic parasympathetic nerves from the sacral spinal cord (S2-S4) join the pelvic nerves 
to synapse with postganglionic neurones in the terminal ganglia (pelvic ganglia and intramural 
ganglia within the bladder wall).  While the somatic nerves also emerge from the sacral spinal 
cord (S2-S4) and join the pudendal nerve (Yoshimura et al., 2014). These nerves also have 
afferent fibres which carry sensory information from the bladder to the spinal cord.   
Bladder voiding is primarily due to the parasympathetic efferent nerves which provide sustained 
excitatory cholinergic inputs to the bladder smooth muscle and nitric-oxide-mediated inhibitory 
inputs to the IUS (de Groat et al., 1993, Sugaya et al., 2005). Bladder filling is primarily 
controlled by the sympathetic nerves which provide noradrenergic inhibitory inputs to the 
bladder smooth muscle and excitatory inputs to the IUS (Andersson, 1993, de Groat et al., 1993, 
Sugaya et al., 2005). Control of the EUS is due to somatic cholinergic nerves which excite the 
muscle and must be voluntarily inhibited to allow bladder voiding (de Groat et al., 1993).  The 
afferent nerves sense chemical and mechanical changes in the bladder and relay information 
about bladder volume during storage and the amplitude of contractions during voiding to the 
central nervous system (Kanai and Andersson, 2010).  Figure 1.2 illustrates the innervation of 
the bladder. 
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Figure 1.2: The innervation of the human lower urinary tract.  Coordination between the detrusor and the 
bladder neck/urethra is mediated by sympathetic, parasympathetic and somatic nerves. Primary cell bodies of 
pelvic and pudendal afferents nerves are contained in lower lumbar and sacral dorsal root ganglia (DRG), and 
afferents in the hypogastric nerve are found in upper lumbar DRG (from (Kanai and Andersson, 2010) 
reproduced with permission from the publisher). 
 
Efferent Nerves  
Somatic Supply  
Somatic supply to the bladder is via motor neurones in the ventral-ventromedial part of the 
anterior horn of S2 to S4 (nucleus of Onufrowicz).  These neurones join the pudendal nerve and 
innervate the EUS. The somatic nerves provide cholinergic excitatory inputs to the striated 
muscle of the EUS which must be voluntarily inhibited to allow micturition (Sugaya et al., 2005). 
Parasympathetic Supply  
The majority of nerve fibres of the parasympathetic system release acetylcholine (ACh) which 
acts on nicotinic and muscarinic receptors.  However, non-adrenergic, non-cholinergic (NANC) 
transmitters are often co-released along with ACh. 
Early studies by Elliot, (1907) demonstrated that parasympathetic nerve stimulation in the cat 
resulted in relaxation of the IUS and contraction of the bladder muscle to cause micturition.  It 
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has since been established that nitric oxide (NO) released from parasympathetic nerves is 
responsible for the relaxation of the IUS (Andersson et al., 1991) and ACh acting via muscarinic 
receptors is largely responsible for contraction of the detrusor (Clark and Ursillo, 1956).   Most 
species studied also have an atropine resistant, NANC contribution to bladder contraction.  
Burnstock et al., (1972) were the first to provide evidence that adenosine 5‘-triphosphate (ATP) 
was the transmitter responsible for the NANC contractions in rat and guinea pig bladder. Each 
of these transmitters is discussed further below.  
ACh 
Detrusor contractions of dog and rabbit bladder, elicited by electrical field stimulation, were 
largely abolished by the muscarinic receptor antagonist atropine (Clark and Ursillo, 1956).  In 
the same study, it was found that direct stimulation of muscarinic receptors with ACh also 
resulted in contraction of the detrusor muscle.  Subsequent studies in possum (Burnstock and 
Campbell, 1963) and rat (Vanov, 1965) also demonstrated that detrusor contractions were 
largely due to ACh release from pelvic parasympathetic nerves. 
There are five subtypes of muscarinic receptor including M1-M5 (Caulfield and Birdsall, 1998).  
As shown in Figure 1.3, M1, M3 and M5 receptors couple to Gq/11 proteins that, once activated, 
stimulate phospholipase C (PLC) which leads to an up-regulation of the second messengers 
inositol trisphosphate (IP3) and diacylglycerol (DAG) (Caulfield and Birdsall, 1998).  IP3 
mobilises intracellular calcium (Ca
2+
) stores and DAG activates the enzyme protein kinase C 
which phosphorylates cellular proteins and causes the influx of extracellular calcium to induce a 
response. These responses cause an excitatory effect in the cell and should manifest as a 
contraction.  M2 and M4 receptors cause contraction indirectly by inhibiting the relaxatory effect 
of noradrenaline (NA).  Specifically, M2 and M4 receptors are coupled to Gi/o proteins which 
inhibit adenylate cyclase (Peralta et al., 1988) resulting in a reduction of 3'-5'-cyclic adenosine 
monophosphate (cAMP) (Uchiyama and Chess-Williams, 2004) as shown in Figure 1.4. 
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Figure 1.3 Cellular signalling in a smooth muscle cell.  Receptors mediating activation of phospholipase C (PLC) 
include muscarinic receptors M1, M3 and M5 and α1-adrenoceptors. DAG = Diacylglycerol, IP3 = inositol 
triphosphate. 
 
Figure 1.4 Cellular mechanism of muscarinic receptors M2 and M4 and β-adrenoceptor stimulation in a smooth 
muscle cell. 
Northern blot and reverse transcription polymerase chain reaction (RT-PCR) studies have 
identified mRNA for only the M2 and M3 receptors in pig bladder (Maeda et al., 1988) and 
human bladder (Yamaguchi et al., 1996).  Receptor immunoprecipitation studies have also 
identified the presence of only the M2 and M3 receptor protein in guinea-pig, rabbit and human 
bladder with the M2 receptor density being 3 times greater than that of the M3 receptor (Wang 
et al., 1995). However, direct contraction of the bladder detrusor has been shown to be 
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mediated via M3 receptors in all species so far examined (for review see (Chess-Williams, 
2002)) including the human bladder (Fetscher et al., 2002). 
The role of M2 receptors remains unclear and conflicting results have been reported.  The M2 
receptors have been shown to be functional at second messenger level causing a decrease in 
cAMP levels in human detrusor smooth muscle following stimulation with the muscarinic agonist 
carbachol (Harriss et al., 1995).  Receptor manipulation studies have been used to investigate 
the role of M2 receptors in pig bladder whereby inactivation of the M3 receptors and elevation of 
cAMP levels with a β-adrenoceptor agonist resulted in muscarinic agonists eliciting a response 
at least partially mediated by the M2 receptors (Yamanishi et al., 2002a).  As discussed further 
below, stimulation of sympathetic nerves results in relaxation of the bladder detrusor via β-
adrenoceptor activation leading to an increase in cAMP.  Therefore it has been proposed that 
stimulation of M2 receptors during parasympathetic activation may switch off the sympathetic 
inhibitory mechanism resulting in greater contraction and emptying of the bladder (Hegde et al., 
1997, Yamanishi et al., 2002b).  
Prejunctional muscarinic receptors have been identified in the bladder of several species which 
alter the release of neurotransmitters from the nerve endings (Somogyi and de Groat, 1999, de 
Groat and Yoshimura, 2001).  Tobin & Sjogren (1998) showed that stimulation of prejunctional 
M1 receptors was responsible for increased release of ACh from parasympathetic nerves only 
at high frequency nerve stimulation of rabbit urinary bladder, while stimulation of prejunctional 
M2 receptors was responsible for decreased ACh release at both low and high frequency 
stimulation.  Similar M1 facilitatory effects were also observed in rat bladders (Somogyi et al., 
1994).  Accordingly, it has been suggested that inhibitory M2 receptors are activated during 
short periods of low-frequency nerve activity and thereby suppress cholinergic transmission 
during urine storage (Somogyi and de Groat, 1999, de Groat and Yoshimura, 2001). On the 
other hand, M1 auto feedback receptors are activated during prolonged, high-frequency nerve 
firing that would occur during voiding, and therefore are thought to provide an amplification 
mechanism to promote complete bladder emptying (Somogyi and de Groat, 1999, de Groat and 
Yoshimura, 2001).  In addition, M2 and M4 receptors are present on sympathetic nerves and 
their stimulation causes decreased release of noradrenaline (Mattiasson et al., 1984, 
Mattiasson et al., 1987, Trendelenburg et al., 2005).   
Muscarinic receptor stimulation in the bladder has been shown to release a diffusible mediator 
capable of inhibiting smooth muscle contraction (Fovaeus et al., 1999).  The urothelium has 
since been identified as the source of this unidentified factor which can inhibit contraction of the 
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underlying detrusor muscle in response to muscarinic receptor stimulation (Hawthorn et al., 
2000).  The urothelium will be discussed in more detail below. 
Acetylcholine also acts at nicotinic receptors which are present throughout the body including at 
neuromuscular junctions between somatic motor neurones and skeletal muscle as well as in the 
ganglia of the autonomic nervous system.  The nicotinic acetylcholine receptor family is 
currently known to consist of at least 17 different subunits (α1–10, β1–4, γ, δ and ε) which form 
pentameric channels that can be categorised into two different groups; neuronal nicotinic 
receptors (consisting of α 2–10 and β 2–4 subunits) and muscle nicotinic receptors (consisting 
of α1-, β1-, γ, δ and ε-subunits) (Lindstrom et al., 1996, Mamalaki and Tzartos, 1994). When 
nicotinic receptors are stimulated they undergo a conformational change and become 
cation-selective pores through the cell membrane.  The pore allows movement of potassium 
(K
+
), Ca
2+
 and sodium (Na
+
) causing depolarisation of the cell and resulting in either muscle 
contraction or nerve depolarisation (Figure 1.5).   
Nicotinic receptors are mediators of fast synaptic transmission in both the parasympathetic and 
sympathetic autonomic ganglia in the bladder (De Biasi, 2002).  A study by Beckel et al., (2006) 
has also indicated a role for nicotinic receptors in bladder reflex function.  Using RT-PCR and 
western blot analysis, the study detected mRNA in the urothelium for several nicotinic receptor 
subunits known to form functional receptors. The receptors were shown to be functional through 
calcium imaging studies while stimulation of these receptors in cultured urothelial cells with 
nicotine increased intracellular calcium.  
However, a more recent study has demonstrated that the urothelium of the rat contains two 
subtypes of nicotinic receptor mediating distinct effects (Beckel and Birder, 2012).  Specifically, 
these effects include inhibition of bladder reflexes via α7 receptors and excitation of reflexes via 
α3-containing receptors. These effects also appeared to be due to regulation of mediator 
release from the urothelium.  Specifically, the excitatory response to α3 receptor stimulation 
could be blocked by the purinergic antagonist PPADS suggesting nicotinic receptor regulation of 
ATP release which then enhances afferent activity (Beckel and Birder, 2012).    
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Figure 1.5: Nicotinic receptor stimulation by acetylcholine causes an influx of sodium and calcium and cellular 
depolarisation. 
ATP 
Studies have demonstrated that exogenous ATP causes contractions of the bladder which 
mimic the NANC contractions in response to electrical field stimulation (EFS).  Desensitisation 
of receptors with purinergic agonists suppressed ATP-induced and NANC contractions and both 
were enhanced by ATP‘ase inhibitors which reduce the breakdown of ATP (Burnstock et al., 
1972, Ralevic and Burnstock, 1998).  
ATP is a purine and acts on purine receptors which can be divided into two main families, 
adenosine receptors called P1 receptors, and P2 receptors recognising primarily ATP, 
adenosine 5‘-diphosphate (ADP), uridine 5‘-triphosphate (UTP), and uridine 5‘-diphosphate 
(UDP) (Ralevic and Burnstock, 1998). The P2 receptors divide into two families of ligand-gated 
ion channels and G protein-coupled receptors termed P2X and P2Y receptors respectively.  
P2X binds primarily ATP while P2Y binds ADP, UTP and UDP (Ralevic and Burnstock, 1998). 
There are seven ionotropic P2X receptors, P2X1-7.  Upon activation, P2X receptors become 
permeable to monovalent cations as well as a relatively high permeability to calcium. P2X1 and 
P2X3 show fast desensitisation to agonists (within 1-2 seconds), P2X2, 4 and 5 show slow 
desensitisation to agonist application (minutes) and P2X7 does not desensitise (North, 2002).  
Various species are known to express purinergic receptors in the bladder including human, 
mouse, rat, cat and guinea pig (Burnstock and Kennedy, 1985, Lee et al., 2000, Vial and Evans, 
2000, O'Reilly et al., 2001, Birder et al., 2004).  Specifically, it has been demonstrated that the 
P2X1 subtype is primarily responsible for mediating the NANC contraction of the mouse 
detrusor (Vial and Evans, 2000).  However, excitatory transmission in the normal human 
bladder appears to be entirely cholinergic (Sjogren et al., 1982, Sibley, 1984, Kinder and Mundy, 
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1985, Chen et al., 1994), with an atropine-resistant component appearing only in bladders from 
patients with bladder pathologies such as interstitial cystitis and is thought to be due to ATP 
(Sjogren et al., 1982, Palea et al., 1993).  The P2X1 is also the most abundant P2X receptor 
subtype in the adult human bladder which may be responsible for the ATP response in disease 
(O'Reilly et al., 2001).   
It has also been demonstrated that the P2X3 subtype is present on suburothelial nerve plexi 
and urothelium (Birder et al., 2004, Cockayne et al., 2000, Lee et al., 2000). In addition, P2Y 
receptors have been identified on cat, rat and guinea pig urothelial cells (Sui et al., 2006, Birder 
et al., 2004) and specifically the P2Y2 and P2Y4 subtypes (Chopra et al., 2008). The roles of 
purinergic receptors on the urothelium and suburothelial plexus are discussed below. 
Nitric Oxide 
Early studies in rabbit identified that nitric oxide (NO) was the neuronal messenger responsible 
for the relaxation of the urethra (Andersson et al., 1991).  NO has a short half life and is very 
reactive so it cannot be stored or packaged in vesicles in nerves.  Rather, NO is formed on 
demand by the hydroxylation of L-arginine to citrulline (Palmer and Moncada, 1989) which is 
catalysed by one of three isoforms of nitric oxide synthase (NOS) (Forstermann et al., 1994).  
Three types of NOS have been identified in the lower urinary track and the neural pathways 
controlling the bladder including endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible 
NOS (iNOS) (Dokita et al., 1991, Andersson and Persson, 1994, Ehren et al., 1994a, Ehren et 
al., 1994b, Burnett et al., 1997, Lemack et al., 1999, Johansson et al., 2002, Masuda et al., 
2002, Felsen et al., 2003).  The three isoforms were named after the cells in which they were 
first isolated, purified and cloned (Forstermann et al., 1994).  Despite their names, eNOS and 
nNOS are normal constituents of cells while the expression of iNOS is induced by certain 
cytokines or bacterial endotoxins (Moncada et al., 1991).  
The pelvic ganglia of the parasympathetic system show NOS immunoreactivity (Vizzard et al., 
1994).  Studies in rat have shown that nNOS is most prominent in the parasympathetic 
postganglionic innervation of the urethra and non-existent in the innervations of the detrusor 
(Vizzard et al., 1994).  Studies in rabbit, pig and rat have demonstrated that administration of 
L-arginine decreases the pressure of the IUS while NOS inhibitors, inhibit the relaxation of the 
IUS in response to neuronal stimulation (Andersson et al., 1992, Persson and Andersson, 1992, 
Persson et al., 1992, Kawahara, 1994, Bennett et al., 1995). Furthermore, both endogenous NO 
and stimulation of the parasympathetic nerves supplying the urethra elicits NO-dependent 
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urethral smooth muscle relaxation but does not relax the detrusor (Bennett et al., 1995, de 
Groat and Yoshimura, 2001, Persson et al., 1992). 
In summary, the parasympathetic nerves provide excitatory cholinergic inputs (a role for 
purinergic transmitters in disease) to the bladder and have an inhibitory nitrergic effect on the 
IUS (de Groat et al., 1993, Ralevic and Burnstock, 1998, Sugaya et al., 2005).  
Sympathetic Supply  
Sympathetic nerves release noradrenaline, which acts on adrenoceptors, and provides 
excitatory inputs to the bladder neck and the urethra, inhibitory inputs to the detrusor as well as 
both facilitatory and inhibitory inputs to parasympathetic ganglia (Andersson, 1993, de Groat et 
al., 1993, Sugaya et al., 2005).   
Early studies by Burnstock and Campbell, (1963) demonstrated that the possum detrusor 
relaxed in response to both adrenaline and noradrenaline.  Subsequent work in cats by Gjone 
(1965) and Edvardsen (1968) demonstrated that transection of the vesical sympathetic nerves 
resulted in increased spontaneous and reflex evoked contractions of the bladder. As a result it 
was proposed that the sympathetic fibres exert tonic inhibitory influences on the bladder (De 
Groat and Saum, 1972). Hamberger & Norberg (1965) found that adrenergic terminals in the 
bladder were located primarily in the intramural plexus, often in synaptic contact with 
parasympathetic ganglion cells suggesting that that sympathetic inhibition of bladder contraction 
may also result from inhibition of transmission of the parasympathetic excitatory pathway to the 
bladder.  Furthermore, nerves immunoreactive for tyrosine hydroxylase, required in the 
production of noradrenaline and neuropeptide Y, a co-transmitter of noradrenaline, are rare in 
the detrusor however they are moderately frequent in the suburothelium (Birder et al., 2010a).  
Nerves immunoreactive for tyrosine hydroxylase and neuropeptide Y have also been found to 
synapse with presynaptic parasympathetic nerve terminals in the bladder where they affect ACh 
release (Birder et al., 2010a). 
Noradrenaline 
De Groat & Saum, (1972) demonstrated that stimulation of sympathetic nerves elicited an initial 
contraction of the bladder of short duration followed by a prolonged relaxation below control 
levels. In addition, administration of catecholamines to the bladder depressed spontaneous and 
nerve-evoked contractions of the bladder, decreased the resting bladder tone and these effects 
were reduced or completely blocked by β-adrenergic blocking agents.  
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There are two types of adrenoceptor (AR) being the α- and β-ARs.  Both α- and β-ARs are 
expressed in the bladder of various species including humans and rats (Walden et al., 1997, 
Hampel et al., 2002).  There are two subtypes of α-adrenoceptor, α1 and α2-ARs. Both 
subtypes are linked to G-proteins; α1-ARs are linked to a Gq-protein and α2-ARs are linked to a 
Gi-protein.  When stimulated, the α1-ARs activate the Gq-protein which activates the enzyme 
PLC and causes the production of the second messengers IP3 and DAG (See Figure 1.3). The 
overall effect of these second messengers is generally an excitatory effect.  When an α2-AR is 
stimulated it activates a Gi-protein which reduces cAMP production by inhibiting the enzyme 
adenylate cyclase. The Gi-protein also activates K
+
 channels causing cell hyperpolarisation 
having an overall inhibitory effect on the cell.  These receptors tend to be found on nerve 
terminals and their activation leads to inhibition of neurotransmitter release.   
Walden et al., (1997) demonstrated that overall expression of α-ARs in the human bladder 
detrusor is low however it is the α1-AR subtype which is predominant.  In most species, 
stimulation of the α1-ARs with high concentrations of agonist results in detrusor contraction 
(Andersson, 1993). Similarly, in normal human detrusor, selective stimulation of the α-ARs 
produces small and variable contractile responses (Andersson, 1993). 
Three β-AR subtypes exist including β1, β2, β3. Similar to α-ARs the β-ARs are also linked to a 
G-protein (see Figure 1.4).  Li et al. (2004) observed that β1 and β3-ARs activated a Gi/o-protein 
subunit stimulating the enzyme guanylate cyclase and increasing 3',5'-cyclic guanosine 
monophosphate (cGMP) production; whereas the β2-ARs activate both the Gs and the Gi/o-
protein subunits and stimulate adenylate cyclase and guanylate cyclase producing cAMP and 
cGMP respectively.  These second messengers have various effects within the cell but 
generally result in relaxation of smooth muscle.   
Early studies investigating the β-ARs in bladder detrusor showed that the β2-ARs predominate 
(Andersson, 1993).  However, in some species, such as guinea pig, it was shown that the 
β1-ARs mediate relaxation despite the β2-AR subtype predominating (Andersson, 1993). 
Human detrusor expresses β-ARs which have functional characteristics of a subtype other than 
β1- or β2-ARs.  These receptors mediate a relaxation that can be blocked by a β-AR antagonist 
(propranalol) but not a β1-AR selective antagonist (practolol) or a β2-AR selective antagonist 
(butoxamine) suggesting the β3-AR is responsible for the relaxation (Nergardh et al., 1977, 
Larsen, 1979). Since then various methods such as RT-PCR, in situ hybridization and in vitro 
contractile experiments have been used to demonstrate that human detrusor can express all 
three β-AR subtypes (Andersson and Arner, 2004).  However, β3-AR agonists are the most 
 17 
 
effective at relaxing the human detrusor (Badawi et al., 2007, Yamaguchi, 2002, Igawa et al., 
2001, Takeda et al., 1999, Igawa et al., 1999) suggesting that the most important β-AR in 
bladder relaxation is the β3-AR, at least in humans (Andersson and Arner, 2004).  Β3-ARs have 
also been demonstrated in the detrusor of the pig (Yamanishi et al., 2002c, Yamanishi et al., 
2002d) as well as the rat (Clouse et al., 2007). 
Adrenoceptors have also been found on parasympathetic nerves where they affect release of 
ACh.  Specifically, release of ACh from parasympathetic nerves can be increased by stimulation 
of facilitatory α1-ARs and decreased by stimulation of inhibitory α2-ARs (Keast et al., 1990, 
Tobin and Sjogren, 1998).  In addition, α2-AR‘s have also been found prejunctionally on 
sympathetic nerves and their activation also results in decreased noradrenaline release thereby 
acting as a negative feedback loop (Mattiasson et al., 1984, Mattiasson et al., 1987).   
Other Neurotransmitters 
A wide range of other transmitters have been proposed in human bladder including vasoactive 
intestinal peptide, calcitonin gene-related peptide (CGRP), tachykinins, substance P, bradykinin, 
pituitary adenylate cyclase activating peptide (PACAP), adenosine, prostaglandins, serotonin, 
cannabinoids and neurotrophic factors (reviewed by de Groat & Yoshimura (2001). However, 
these will not be covered as the purpose of this review is to provide an overview of the function 
of the bladder and the main neurotransmitters have been discussed above. 
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Table 1.1: Summary of receptor expression in the detrusor 
Receptor  Subtype present  Species Reference 
 
Muscarinic 
 
M2 & M3  
 
Pig  
 
 
Human, guinea pig, rat & 
rabbit 
 
Human  
 
 
 
(Maeda et al., 1988, 
Sellers et al., 2000) 
 
(Wang et al., 1995) 
 
 
(Yamaguchi et al., 1996, 
Harriss et al., 1995)   
Purinergic P2X1 
 
 
P2X1 & P2X2 
 
 
P2X1, (P2X2, 
P2X5, P2X6) 
Mouse  
 
 
Cat 
 
 
Rat 
(Vial and Evans, 2000)   
 
 
(Birder et al., 2004) 
 
 
(Lee et al., 2000) 
 
 
Adrenergic 
 
α1- AR 
 
β3-AR 
 
 
β3-AR 
 
 
β3-AR 
 
β3-AR 
 
Rat, monkey and human 
 
Human 
 
 
Pig   
 
 
Rat 
 
Mouse 
 
 
(Walden et al., 1997) 
 
(Larsen, 1979, Nergardh 
et al., 1977) 
 
(Yamanishi et al., 2002c, 
Yamanishi et al., 2002d)  
 
(Clouse et al., 2007) 
 
(Deba et al., 2009) 
 
 
Afferent Nerves 
The bladder contains a complex network of afferent axons projecting mostly via the pelvic nerve 
but also via the hypogastric and pudendal nerves to the dorsal root ganglia of the upper sacral 
and lumbar levels of the spinal cord (Gabella and Davis, 1998). Pelvic and pudendal nerves 
predominantly have their cell bodies in the sacral spinal cord (S1-S4) whilst hypogastric nerves 
project to the thoracolumbar segments (T10-L2) of the spinal cord.  
Location of Afferent Nerves 
In both humans and animals afferent nerves have been found both suburothelially and in the 
detrusor muscle (Gosling and Dixon, 1974, Dixon et al., 1983, Gabella and Davis, 1998, 
Wakabayashi et al., 1993, Gabella, 1999). Specifically, afferent axons have been found in 
distinct regions including (1) at the base of the urothelium, where they form a suburothelial 
plexus, (2) inside the urothelium, (3) on blood vessels, and (4) along muscle bundles (Gabella 
and Davis, 1998, Wakabayashi et al., 1993, Morrison, 1999).  The suburothelial plexus was 
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found to be thickest in the neck of the bladder and initial portion of the urethra and progressively 
less dense in the adjacent regions.  Whereas the afferent innervation of the smooth muscle was 
diffuse and appeared uniform throughout the bladder. 
Pelvic sensory nerve terminals are uniformly distributed to all areas of the detrusor and urethra 
with receptive fields in the mucosa and serosa of the body, base, and at the ureterovesical 
junction.  The lumbar afferent nerve terminals are most frequent in the trigone and sparse in the 
bladder body with receptive fields in the mucosa and serosa and associated with blood vessels 
(Andersson, 2002, Jung et al., 2012, de Groat and Yoshimura, 2009). Pelvic afferent nerves 
exhibit dynamic responses to stimulation and adapt to maintained stimulus, whereas lumbar 
nerves do not give dynamic responses or adapt to maintained forces (de Groat and Yoshimura, 
2009). The pelvic nerves are the primary pathway for sensations related to filling, voiding, 
discomfort and pain (de Groat, 1997) and is the primary pathway considered in this thesis. 
Classification of Afferent Nerves  
There are two main types of afferent fibres in the bladder, myelinated A-δ fibres and 
unmyelinated C-fibres (Kanai and Andersson, 2010, Birder et al., 2010a, Gabella and Davis, 
1998).  Unmyelinated C-fibres are more common than myelinated A-δ fibres comprising 
approximately 60-70% of total nerve fibres (Shea et al., 2000, Vera and Nadelhaft, 1990).  The 
afferent nerves can be classified based on their size, function, content or sensitivity to various 
substances.   Functional classification can be based on conduction velocity and their response 
to mechanical or chemical stimuli.  
The A-δ fibres are larger in diameter and conduct action potentials more rapidly (~11.0m/s) than 
the C-fibres (~1.7 m/s) (Sengupta and Gebhart, 1994, Shea et al., 2000).  Bladder afferents can 
also be characterised as stretch-sensitive mechanoreceptors, stretch-insensitive 
chemoreceptors and silent afferents that do not respond to distension or chemical stimuli but 
may become mechanosensitive during inflammation (Shea et al., 2000, Zagorodnyuk et al., 
2006, Habler et al., 1990).  However, Shea et al., (2000) also reported a population of fibres that 
were both chemosensitive and mechanosensitive responding to both stretch and an 
inflammatory mixture.  In the mouse pelvic nerve, four classes of mechanosensitive bladder 
afferents (muscular, urothelial, muscular/urothelial, and serosal) have been identified based on 
responses to receptive field stimulation by probing, stretch or urothelial stroking (Jung et al., 
2012). Similar classes of nerves have also been reported in the guinea pig bladder including 
muscle and mucosal mechanoreceptors (Zagorodnyuk et al., 2006).  These classes are 
discussed further in Chapter 5.   
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The mechanical threshold at which the afferent fibres become active can also be used to 
classify fibres as low threshold or high threshold.  Low threshold fibres become active at 
intravesical pressures below 15mmHg and high threshold fibres become active at pressures 
above 15mmHg (Daly et al., 2007, Rong et al., 2002, Shea et al., 2000).  Low threshold fibres 
are mainly involved in normal bladder distensions and are more common than high threshold 
fibres which are involved in painful sensations (de Groat, 1997, de Groat and Yoshimura, 2009).   
Both A-δ fibres and C-fibres can have low or high thresholds (Sengupta and Gebhart, 1994, 
Shea et al., 2000).  
Neurofilament is a cytoskeletal protein synthesised in A-δ fibres only and can be visualised by 
immunohistochemical labelling.  In rats, approximately one third of bladder afferent neurones 
were immunoreactive to neurofilament (A-δ fibres) with the remaining two thirds being 
neurofilament poor (C-fibres) (Yoshimura et al., 1998).  Other immunocytochemical studies 
have revealed that numerous neuropeptides are localised alone or together in most bladder 
afferent neurones including substance P, CGRP, vasoactive intestinal polypeptide, neurokinin A, 
PACAP, enkephalins, and cholecystokinin (de Groat and Yoshimura, 2001, Keast and De Groat, 
1992). Axons containing these peptides are found throughout the bladder but are particularly 
dense in the suburothelial plexus (de Groat and Yoshimura, 2009). These peptides may 
function as transmitters at afferent terminals in the spinal cord or may be released in the bladder 
by noxious stimulation and cause plasma extravasation, vasodilation and alterations in smooth 
muscle activity (Morrison, 1999).   
The majority of C-fibre afferents are sensitive to capsaicin and can be termed capsaicin 
sensitive primary afferent nerves whereas, very few A-δ fibres are sensitive to capsaicin 
(Szallasi and Blumberg, 1999, de Groat and Yoshimura, 2009).  In response to treatment with 
capsaicin, C-fibres release CGRP, substance P, and PACAP in the bladder wall and can trigger 
inflammation (Maggi, 1995).  
Receptor Expression  
Afferent neurones also express various receptors which may be activated in an autocrine 
fashion or by other transmitters released from the urothelium or interstitial cells. These receptors 
include transient receptor potential (TRP) channels, purinoceptors, nicotinic, tachykinin, and 
prostanoid receptors (Andersson, 2002). 
TRP channels are a group of cation channels that can be found on the surface of various 
human and animal cells. The TRP superfamily can be divided into seven sub families including 
the TRPC (canonical) and TRPM (melastatin), TRPV (vanilloid), TRPA (ankyrin), TRPP 
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(polycystin) and TRPML (mucolipin) families (Nilius et al., 2007).  The TRPV subfamily is the 
most investigated of the subfamilies in the lower urinary tract.  TRPV1 channels are widely 
distributed in bladder afferent nerve terminals and urothelium and are thought to play a role in 
normal and painful sensations in the bladder (Birder et al., 2002a). TRPV1, previously known as 
the vanilloid receptor type 1 or the capsaicin receptor, is a nonselective cation channel with a 
preference for calcium and can be activated by noxious stimuli, heat, protons, pH <5.9, 
capsaicin, and endogenous agonists, such as anandamide (Tominaga et al., 1998, Tominaga 
and Tominaga, 2005, Everaerts et al., 2008). The activation of these receptors in nerves 
initiates a complex cascade of intracellular events which results in excitation, desensitisation or 
neurotoxicity (Szallasi and Blumberg, 1999). In the rat bladder, most TRPV1 immunoreactive 
fibres co-expressed the neuropeptides substance P and CGRP (Ost et al., 2002). Another 
subtype, TRPA1, has been found to be expressed in C-fibre afferents as well as the urothelium 
and stimulation of these channels results in bladder hyperreflexia (Du et al., 2007b, Streng et al., 
2008).  The gaseous molecule hydrogen sulphide, which may be formed during infection or 
inflammation, is an activator of TRPA1 suggesting a possible role for this channel in 
inflammatory conditions (Streng et al., 2008). 
It has been shown that of the seven P2X purinoceptors receptor subtypes, the P2X3 receptors 
are expressed on afferent neurones in the bladder and predominantly on small-diameter 
nociceptive neurones (Chen et al., 1995, Dunn et al., 2001).  ATP, released by urothelial cells 
when stretched, is believed to act on these receptors to increase micturition reflexes and 
convey information of bladder fullness (Cockayne et al., 2000, Vlaskovska et al., 2001, 
Burnstock, 2001).   The role of the urothelium is discussed in more detail below.   
Nicotinic receptors are present in sensory neurones and nicotine can induce inwards currents in 
rat dorsal root ganglia (DRG) neurones (Haberberger et al., 2004).  Furthermore, mRNA 
expression of various nicotinic receptor subtypes has been recently shown in bladder sensory 
nerves in mice (Nandigama et al., 2013).  In particular, the α3-containing subtype was 
expressed in 69% of sensory nerves.  
Prostanoids, such as prostaglandins, are synthesised in bladder smooth muscle and urothelium 
by cyclooxygenase (COX) enzymes (Maggi, 1992, Andersson, 1993). Two types of COX 
enzymes have been identified being COX-1, which is normally expressed and responsible for 
the production of prostanoids involved in physiological processes, and COX-2, which is induced 
by inflammatory stimuli. Synthesis can be induced by various stimuli including stretch of the 
detrusor muscle, injury, nerve stimulation, chemical mediators such as ATP and inflammatory 
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mediators (Andersson, 2002).  Prostanoids, especially prostaglandin E2 (PGE2), have been 
implicated  as endogenous mediators of bladder function and may act directly on bladder 
smooth muscle and/or an indirectly as neuromodulators of efferent and afferent 
neurotransmission (Andersson, 2002). PGE2 acts on the family of G-protein coupled EP 
receptors which includes 4 subtypes EP1-4.  EP1 is coupled to Ca
2+ 
mobilisation, EP3 inhibits 
adenylate cyclase and EP2 and 4 both stimulate adenylate cyclase (Beppu et al., 2011).  PGE2 
has been shown to facilitate micturition and increase basal intravesical pressure in conscious 
rats (Ishizuka et al., 1995b, Ishizuka et al., 1995a). The EP1 and EP3 receptor subtypes appear 
to have a role in overactivity of the detrusor muscle, while EP4 receptors have been found in 
dorsal root ganglion sensory neurons and induce an increase in cAMP production and peptide 
release from nerves leading to nerve sensitisation (Kopp et al., 2004, Southall and Vasko, 2001, 
Beppu et al., 2011).  It was suggested that this effect may be due to PGE2 stimulated release of 
tachykinins from nerves in and/or immediately below the urothelium which initiate a micturition 
reflex by stimulating NK-1 and NK-2 receptors on the urothelium or possibly on the nerves 
themselves (Ishizuka et al., 1995b, Ishizuka et al., 1995a).   
Mechanosensensitivity  
Mechanosensitivity refers to the ability of an afferent nerve to sense a mechanical force.  In the 
bladder, mechanical information from afferent nerves is responsible for the micturition reflexes, 
the sensation of bladder fullness and the desire to void and controls activity in the 
parasympathetic and sympathetic efferent nerves to the lower urinary tract (Andersson, 2002).  
Exactly how the bladder afferents sense these mechanical forces is unknown. However, there 
are both direct and indirect ways in which this can occur.  
Direct   
The purpose of mechanosensitivity is to rapidly tranduct sensory information to the central 
nervous system.  Accordingly, it has been thought that afferent nerves may have ion channels 
that can respond directly to mechanical stimuli to elicit an immediate response, without the need 
for second messengers or gene transcription (Araki et al., 2008).  In the bladder this means a 
transduction channel must be sensitive to incremental increases in bladder pressure/muscle 
stretch producing a graded increase in frequency of the action potentials.  There are two main 
theories about how mechanosensitive channels are activated (Figure 1.6).  The first is via direct 
deformation of the channel due to membrane compression, expansion, thickness, or local 
curvature.  The second hypothesis involves tugging on the channel protein by cytoskeletal or 
extracellular tethers (Gillespie and Walker, 2001, Hamill and Martinac, 2001).  In either process, 
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mechanical stimuli changes the open probability of the channel and thereby alters the 
mechanosensory signal (Gillespie and Walker, 2001). 
 
Figure 1.6: Proposed models by which a mechanotransduction channel is gated by mechanical stimuli (Brierley, 
2010). Reproduced with persmission of the publisher.  
The exact identity of such a channel in bladder afferents is unknown, however some of the 
channels that have been identified in other mechanosensitive systems include the epithelial 
sodium channel (ENaC), acid sensing ion channel (ASIC), degenerin Na+ channels (Deg) and 
TRP channels (Gillespie and Walker, 2001). Recently, ENaC, ASIC 1 & 2 and TRPV1, TRPM8 
and TRPA1 channels have been found in various parts of the urinary tract (Araki et al., 2008, 
Birder et al., 2001, Du et al., 2007a, Mukerji et al., 2006a, Nagata et al., 2005, Stein et al., 2004).  
However, given the diverse locations of these channels it is not clear whether they contribute to 
direct or indirect mechanisms of mechanosensitivity or both.  
Indirect 
Mechanotransduction may also occur indirectly through the interaction of other structures with 
the afferent nerves.  Such interactions may include the release of mediators from the urothelium 
in response to stretch activating or sensitising afferent nerves or the ability of the interstitial cells 
to communicate electrically with the afferent nerves.  As discussed above, the urothelium 
releases various mediators in response to stretch, with ATP thought to be a crucial mediator of 
mechanotransduction. The P2X3 receptors on sub-urothelial afferents appear to be particularly 
important as their absence leads to bladder hyporeflexia (Cockayne et al., 2000).  Furthermore, 
in a study by Vlaskovska et al., (2001) the stretch induced activity in pelvic sensory nerves 
could be mimicked by ATP and αβmATP and attenuated by P2X3 antagonists as well as in 
P2X3 knockout mice.  See Figure 1.7 for an overview of this mechanism.  
Interstitial cells (ICs) in the lamina propria may also play a role in the indirect 
mechanotransduction.  ICs respond to ATP by firing Ca
2+
 transients (Fry et al., 2007, 
McCloskey and Gurney, 2002, Sui et al., 2006, Wu et al., 2004) potentially linking the urothelial 
ATP to afferent nerve excitation. The interaction between urothelium and ICs is discussed 
further below.  
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Figure 1.7: Schematic diagram showing the indirect role of ATP from the urothelium on P2X receptors on the 
peripheral terminals of Aδ- and C-fibre bladder afferents, where it may convey mechanosensory and 
nociceptive information to the spinal cord (Ford et al., 2006). Reproduced with persmission of the publisher. 
Micturition Reflexes 
Coordination of the storage of urine and micturition is mediated by multiple reflex pathways 
organised in the brain and spinal cord and are initiated by afferent input (de Groat and 
Yoshimura, 2001).  Storage reflexes in the spinal cord involve the activation of 
mechanoreceptors on afferent nerves during bladder filling which result in firing in the 
cholinergic somatic efferent nerves to the EUS and in sympathetic adrenergic nerves to the IUS 
(de Groat and Yoshimura, 2001).  Afferent projections to the brain terminate in various nuclei 
including the periaqueductal gray (PAG) which conveys information to a micturition centre in the 
dorsolateral pons, called the pontine micturition centre (PMC).   When the bladder volume 
reaches the micturition threshold, the afferent activity activates the PAG which then conveys 
this information to the PMC to initiate the micturition reflex.  The micturition reflex involves 
activation of the parasympathetic pathway to the bladder, inhibition of the spinal storage 
reflexes and results in bladder contraction, sphincter relaxation and bladder emptying 
(Yoshimura et al., 2008).   
The PMC, is thought to serve as a relay centre or ―on-off‖ switch, receiving information from the 
PAG as well as inhibitory and excitatory influences from areas of the brain rostral to the pons  
(de Groat and Yoshimura, 2001, Sugaya et al., 2005).  Central nervous system regulation of 
voiding is further complicated by the fact that these pathways are also under voluntary control. 
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Higher brain centres can suppress excitatory signals from the PAG to the PMC during bladder 
filling to suppress the voiding reflex (Drake et al., 2010).  
The PAG also transmits efferent information back to the bladder from the PMC to initiate voiding.  
The efferent signals inhibit the thoracolumbar sympathetic nucleus and the pudendal nerve 
nucleus in the sacral cord, resulting in relaxation of the IUS and EUS respectively as well as 
exciting the parasympathetic nucleus in the sacral cord inducing detrusor contraction and 
further IUS relaxation (Sugaya et al., 2005).  
Myogenic & Spontaneous Tone 
Myogenic activity is the ability of a smooth muscle cell to contract independent of external 
stimuli.  Normally during the filling or storage stage there is no parasympathetic input to the 
bladder (de Groat, 1997) however, the bladder exhibits spontaneous phasic contractions or 
myogenic activity (Andersson and Arner, 2004).  The spontaneous contractions demonstrated in 
vitro are resistant to tetrodotoxin (TTX) and cannot be blocked by hexamethonium, atropine, α- 
and β-ARs blockers or suramin, supporting a myogenic origin (Andersson and Arner, 2004).  
Some evidence suggests that the smooth muscle cells of the detrusor are electrically coupled 
by gap junctions and that these connections may be important in the initiation and maintenance 
of detrusor tone (John et al., 2003, Neuhaus et al., 2002, Wang et al., 2001).  The myogenic 
contractile activity of the detrusor cells may be reinforced by mediators released from neurones 
and other sources such as the urothelium (Andersson and Arner, 2004).  Spontaneous 
contractile activity is increased in conditions with detrusor overactivity (Andersson and Arner, 
2004) and therefore its regulation is of interest in the bladder dysfunction seen after CPO or IFO 
treatment.   
The urothelium/lamina propria also develops spontaneous, phasic contractions (Moro et al., 
2011).  Contraction of the lamina propria region was first demonstrated in rabbit urethra in 
response to various agonists and electrical field stimulation (Mattiasson et al., 1985, Zygmunt et 
al., 1993). The urothelial/lamina propria layer of the pig bladder has also been shown to exhibit 
contractile properties in response neurokinin A and muscarinic receptor stimulation despite the 
absence of smooth muscle (Sadananda et al., 2008).  Furthermore, the spontaneous phasic 
contractions of the urothelial/lamina propria layer of the pig bladder become more frequent in 
response to stretch and muscarinic receptor stimulation (Moro et al., 2011).  The increased 
contraction rate seen after stretch and muscarinic receptor stimulation was attributed to M3 
receptor activation by endogenous ACh release.  It has been suggested that the contractile 
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property of the urothelial/lamina propria region is due to the network of interstitial cells in the 
lamina propria (Sadananda et al., 2008).   
Urothelium 
Structure 
As briefly mentioned above, the urothelium is the stratified squamous epithelial lining of the 
bladder and is composed of at least a basal cell layer attached to the basement membrane, an 
intermediate layer and a superficial layer (or apical layer) composed of large hexagonal cells 
known as umbrella cells (Birder et al., 2010c).  These umbrella cells are interconnected by tight 
junctions and are covered nearly completely (70-80%) by crystalline hexagonal arrays of 16 nm 
proteins called uroplakins (Figure 1.8) (Liang et al., 2001, Sun, 2006, Birder et al., 2010c). Four 
types of uroplakins exist on the mammalian urothelium including UPIa, UPIb, UPII, and UPIII 
(Lee, 2011).   
 
Figure 1.8 The 3D structure of the 16nm mouse uroplakin particle at 10 Å resolution.  (A) A top view of the 
uroplakin particle. (B) A hexagonal crystalline array with one unit cell illustrated (from (Min et al., 2003) 
reproduced with persmission of the publisher). 
 
The outer surface of the urothelial apical cell membrane also includes a layer of 
glycosaminoglycans (GAGs) (Hurst et al., 1987, Parsons et al., 1990) (see Figure 1.9).  GAGs 
are extremely hydrophilic as the sulfate moieties of the polysaccharide chains readily bind water 
(Hurst et al., 1987, Parsons et al., 1990).  It has been proposed that GAGs on the surface of the 
urothelium tightly bind a layer of water forming a mucus like layer which acts as a permeability 
barrier, preventing the absorption and adherence of small molecules, bacteria and proteins 
(Parsons et al., 1990, Parsons, 2007).  It has been hypothesised that infection, interstitial 
cystitis, radiation and chemical cystitis may be due to loss or damage of this water/mucus layer 
(Parsons, 2007).   
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Figure 1.9 has been removed due to Copyright restrictions.  
The original image can be viewed in Metts, J. F. 2001, 'Interstitial cystitis: urgency and 
frequency syndrome', Am Fam Physician, vol. 64, no. 7, pp. 1199-206 (refer to Figure 1).  
 
 
Figure 1.9 Cross section of bladder wall and close up of bladder epithelial surface showing the uroplakin and 
GAG layers on the luminal surface of the urothelium (Metts, 2001). 
Barrier Function 
The barrier function of the bladder is dependent on several features of the umbrella cells 
including the tight junctions that reduce movement of ions, solutes and toxins between cells as 
well as the uroplakin molecules and GAGs which reduce permeability of the cells to small 
molecules such as water, urea and protons (Acharya et al., 2004, Apodaca, 2004).  This barrier 
function must be maintained even during filling and emptying of the bladder.   The increased 
volume of the bladder during the filling or storage stages is accommodated by the urothelium in 
at least two ways, the first being the unfolding of the highly wrinkled mucosal surface as well as 
a change in morphology of the urothelial cells (Apodaca, 2004).  The urothelial cells become 
thinner as a result of intermediate and basal cells being pushed laterally as well as the umbrella 
cells changing shape from roughly cuboidal to flat and squamous (Apodaca, 2004).  There is 
evidence that this shape change is accompanied by vesicular exocytosis adding membrane to 
the surface of the umbrella cell (Balestreire and Apodaca, 2007, Truschel et al., 2002, Wang et 
al., 2005).   
Sensory & Secretory Function 
However, the urothelium is not just a barrier as recent evidence suggests that it can respond to 
physical and chemical stimuli and communicate with underlying cells including nerves, 
interstitial cells and smooth muscle (Fry et al., 2007, Birder et al., 2010b).  Additionally, the 
urothelial cells express a number of sensory receptors and ion channels which are similar to 
those found in sensory nerves (Andersson et al., 2010, Birder et al., 2010b).  The sensory 
receptors/ions channels that have been found in urothelium include receptors for purines 
(P2X1–7 and P2Y1,2,4), adenosine (A1, A2a, A2b and A3) noradrenaline (α and β) and 
acetylcholine (muscarinic and nicotinic) among others (Burnstock, 2001, Birder et al., 2002b, 
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Chess-Williams, 2002, Beckel et al., 2006, Chopra et al., 2008). The expression of these 
receptors enables the urothelium to respond to sensory inputs such as ACh, ATP, adenosine or 
noradrenaline released from nearby nerves (Apodaca et al., 2007, Birder et al., 2010b).   
Furthermore, the urothelial cells themselves are capable of secreting transmitters or mediators 
such as ATP, ACh, peptides, prostaglandins, NO and cytokines that can modulate, activate or 
inhibit afferent nerves, smooth muscle, interstitial cells or even inflammatory cells (Downie and 
Karmazyn, 1984, Ferguson et al., 1997, Morrison, 1999, Namasivayam et al., 1999, Pinna et al., 
2000, Apodaca et al., 2007, Birder and de Groat, 2007, Fry et al., 2007, Birder et al., 2010b).   
The sensory and secretory actions of urothelial cells are discussed in more detail below. 
ATP  
ATP can be released from cells by exocytosis, membrane transporters or anion-selective 
channels (Sabirov and Okada, 2004).  ATP is released from urothelial cells in response to 
stretch during bladder filling (Ferguson et al., 1997, Vlaskovska et al., 2001).  ATP released 
from the urothelium can act on P2X2 and P2X3 receptors on the urothelial cells in an autocrine 
manner to induce membrane exocytosis to accommodate a larger bladder volume (Wang et al., 
2005).  The presence of P2Y receptor subtypes has also been reported.  Birder et al., (2004) 
demonstrated the presence of P2Y1, P2Y2 and P2Y4 subtypes in feline urothelium while 
Chopra et al., (2008) reported the presence of P2Y2 and P2Y4 in rat urothelial cells.  Activation 
of the P2Y receptors in rat urothelial cells resulted in increased intracellular calcium and ATP 
release (Chopra et al., 2008).  
The urothelial-derived ATP can also activate P2X3 receptors on sub-urothelial afferent nerves in 
a paracrine manner which then convey afferent information of bladder fullness to the central 
nervous system, leading to altered micturition reflexes (Cockayne et al., 2000, Burnstock, 2001, 
Vlaskovska et al., 2001).   A study in P2X3 knockout mice demonstrated that a deficiency in the 
P2X3 receptor resulted in infrequent urination, increased bladder capacity, and failure to 
undergo bladder contractions when experimentally filled (Cockayne et al., 2000). 
Nitric Oxide 
Immunocytochemical studies in rats, cats and rabbits have revealed that urothelial cells contain 
NOS and that NO release can be stimulated by various chemicals and neurotransmitters 
including capsaicin, nicotine, acetylcholine, noradrenaline, CGRP and substance P (Birder et al., 
1998, de Groat and Yoshimura, 2001, Birder et al., 2010b).  It is believed that NO released from 
the urothelium may play a role in sensory mechanisms in the bladder (de Groat and Yoshimura, 
2001).  This is supported by studies showing that administration of an NO donor or L-arginine 
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reduces bladder reflex hyperactivity and reduces the pain and voiding frequency in interstitial 
cystitis (Smith et al., 1997, Ozawa et al., 1999).  Specifically, rats with cyclophosphamide 
induced cystitis were given NO donors which increased the intercontraction interval without 
changing contraction amplitude indicating an inhibitory effect on bladder reflexes not the smooth 
muscle itself (Ozawa et al., 1999).  
ACh 
The urothelium releases ACh in response to stretch (Yoshida et al., 2006) which is thought to 
act in an autocrine fashion on muscarinic and nicotinic receptors on the urothelium (Wessler et 
al., 1998).  It has also been shown that there is basal release of ACh from the human 
urothelium and that this may contribute to an auto-feedback mechanism to suppress its own 
release (Yoshida et al., 2004, Yoshida et al., 2006). Additionally, ACh from cholinergic nerves in 
the lamina propria adjacent to the urothelium may activate receptors on the urothelium (Birder 
et al., 2010b).   
The urothelium of several species has been shown to express muscarinic receptors including 
rat, pig and human (Tyagi et al., 2006, Giglio et al., 2005, Hawthorn et al., 2000).  In the human 
urothelium all muscarinic receptor subtypes have been found (M1-M5) with the M1 subtype 
reported on basal cells, M2 on umbrella cells, M3 and M4 throughout the urothelium and M5 in 
a decreasing gradient from luminal to basal cells (Bschleipfer et al., 2007).  The activation of 
muscarinic receptors in the urothelium leads to release of several transmitters including ATP, 
NO and PGE2 (Birder et al., 1998, Kullmann et al., 2008, Giglio and Tobin, 2009, Yokoyama et 
al., 2011, Nile and Gillespie, 2012).   
The release of ACh may also affect afferent nerve activity in the bladder.  The effect of 
muscarinic receptor stimulation on afferent nerve activity is still unclear however several studies 
report that intravesical and systemic administration of muscarinic antagonists decreased 
afferent nerve activity and increased micturition interval and bladder capacity (Yokoyama et al., 
2005, Hedlund et al., 2007, Iijima et al., 2007).  However, another study has reported that 
antagonism of muscarinic receptors had no effect on afferent nerve activity and rather 
stimulation of muscarinic receptors inhibited afferent responses to distension (Daly et al., 2010).  
Accordingly, the role of ACh released from urothelium is not yet clear and further investigation is 
required.  
Nicotinic α7- and α3-containing receptors have also been shown to be present in the urothelium 
and their activation leads to inhibition and excitation of bladder voiding reflexes respectively 
(Beckel and Birder, 2012).  These effects appeared to be due to regulation of mediator release 
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from the urothelium.  Specifically, the excitatory response to α3 receptor stimulation could be 
blocked by the purinergic antagonists PPADS suggesting nicotinic receptor regulation of ATP 
release which then enhances afferent activity (Beckel and Birder, 2012).    
Urothelium Derived Inhibitory Factor  
Muscarinic receptor stimulation also causes the urothelium to release an unidentified factor that 
inhibits contraction of the underlying smooth muscle called the urothelium derived inhibitory 
factor (UDIF) (Hawthorn et al., 2000, Chaiyaprasithi et al., 2003).  Removal of the urothelium 
resulted in a significant increase in the detrusor muscle contraction in response to ACh 
(Hawthorn et al., 2000, Chaiyaprasithi et al., 2003).  The UDIF has been investigated in various 
species including pig and human and is neither NO, noradrenaline, a COX product, a 
catecholamine, adenosine, gamma-aminobutyric acid nor an endothelium-derived 
hyperpolarising factor sensitive to apamin (Hawthorn et al., 2000, Chaiyaprasithi et al., 2003).  
Noradrenaline 
Excitatory β-AR are also present in the urothelium and stimulation of these receptors leads to 
NO release (Birder et al., 2002b).  As discussed above, NO released from the urothelium is 
believed to have an inhibitory effect on bladder reflexes leading to increased intercontraction 
interval and decreased voiding frequency (Smith et al., 1997, Ozawa et al., 1999). 
Prostaglandins 
The urothelium expresses COX-1 and COX-2 enzymes which are responsible for the synthesis 
of prostanoids including prostaglandins (de Jongh et al., 2009).  Prostaglandins released from 
the urothelium are thought to activate or sensitise afferent nerves (de Groat and Yoshimura, 
2001).  In addition, PGE2, released from afferent nerves or the urothelial cells and acting via 
EP1 and/or EP3 receptors on urothelial cells stimulates the release of ATP (Tanaka et al., 2011).  
TRP Channels 
Recent evidence has suggested that TRP channels can be found on urothelial cells not just on 
sensory neurones in the bladder of mice and humans (Everaerts et al., 2010a, Apostolidis et al., 
2005, Lazzeri et al., 2005, Lazzeri et al., 2004, Birder et al., 2002a). Yu et al., (2011) 
demonstrated, using Western blotting, the urothelial expression of TRPC1, TRPC4, TRPV1, 
TRPV2, TRPV4, TRPM4, TRPM7 and TRPML1 proteins. Specifically, they found that TRPV2 
and TRPM4 were prominently localised to the umbrella cell apical membrane, while TRPC4 and 
TRPV4 were identified on their abluminal surfaces and TRPC1, TRPM7, and TRPML1 were 
localised to the cytoplasm (Yu et al., 2011).  This study did not identify whether these receptors 
were functional.  However, TRP channels are activated by various physical stimuli, such as heat 
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and stretch, as well as chemical stimuli such as low pH, osmolality and noxious stimuli and are 
therefore thought to act as sensors of stretch or chemical irritation in the bladder (Everaerts et 
al., 2008, Tominaga et al., 1998, Tominaga and Tominaga, 2005).  
A study using wild type and TRPV1 knockout mice indicated that activation of TRPV1 channels 
on urothelial cells may cause NO release (Birder et al., 2002a).  Furthermore, the TRPV1 
knockout mice had a lower level of stretch evoked ATP release indicating a role for TRPV1 
channels in purinergic signally by the urothelium (Birder et al., 2002a). The TRPV1 (-/-) mice 
had a higher frequency of low-amplitude, non-voiding bladder contractions accompanied by 
decreased spinal cord signalling and reflex voiding during bladder filling suggesting a role in 
urine storage (Birder et al., 2002a).  Another study using cultured mouse urothelial cells 
demonstrated the presence of functional TRPV2, 4 and 7 channels (Everaerts et al., 2010a).  
Functional TRPV4 channels, which can be activated by hypo-osmolarity, heat or certain lipid 
compounds, have been found in rat and mouse urothelium (Gevaert et al., 2007) and TRPV4-
null mice demonstrated a lower frequency of voiding and higher frequency of nonvoiding 
contractions (Gevaert et al., 2007).  Another study found that activation of TRPV4 channels 
resulted in the release of ATP and increased detrusor muscle contraction after micturition 
(Birder et al., 2007). 
The role of the TRP channels in bladder function is still not well understood, however from the 
evidence these channels appear to be involved in the sensory mechanisms of the urothelium.   
Epithelial Sodium Channels 
Epithelial Sodium Channels (ENaC) are cation channels characterised by amiloride-sensitivity, 
and can be activated by mechanical stimuli and/or by ligands such as peptides or protons (Araki 
et al., 2008).  ENaC have been identified in the urothelium (Araki et al., 2004, Smith et al., 1998) 
and have been shown to be mechanosensitive, changing sodium transport properties in 
response to hydrostatic pressure changes (Ferguson et al., 1997).  It has also been suggested 
that ENaCs are involved in mechanosensory transduction by modulating stretch-evoked ATP 
release.  For example, the basal ATP release from the rabbit bladder epithelium is altered by 
amiloride, a blocker of ENaC (Ferguson et al., 1997).  In cultured cat urothelial cells amiloride 
significantly reduced the ATP released by hypotonic stimulus (Birder et al., 2003). In rats, 
amiloride has also been shown to inhibit ATP release from urothelial cells in response to stretch 
(Du et al., 2007a) and hydrostatic pressure (Olsen et al., 2011).  Furthermore, ENaC were 
found to be over expressed in the urothelium of patients with bladder outlet obstruction 
potentially indicating a role for these channels in the detrusor overactivity experienced by these 
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patients (Araki et al., 2004).  Therefore, it appears that ENaCs may also be involved in the 
mechanosensory mechanisms in the bladder.  
Peptides 
As mentioned above, bladder afferent neurones contain various neuropeptides that can be 
released as a result of noxious stimulation of the nerves (de Groat and Yoshimura, 2001, Keast 
and De Groat, 1992, Morrison, 1999).  Substance P can act on NK receptors on the urothelium 
to cause release of ATP and NO (Munoz et al., 2010, de Groat and Yoshimura, 2001).  
Neurokinin A and neurokinin B have been demonstrated to activate NK receptors, specifically 
the NK2 subtype, in the urothelium in normal unanaesthetised rats resulting in micturition, 
however the mechanism of this action is unclear (Ishizuka et al., 1995a). 
Nerve growth factor 
Nerve growth factor (NGF) is produced in the urothelium and its expression is increased in 
bladder dysfunction such as interstitial cystitis (Liang et al., 2010, Lowe et al., 1997, Ochodnicky 
et al., 2011).  It is thought that NGF may be released from the urothelium and may act in a 
paracrine or autocrine manner.  Intravesical application of NGF induces rapid and enduring 
sensitisation of A-δ and C afferent fibres to mechanical stimuli in rats which results in bladder 
overactivity, reduced micturition volume and increased number of bladder contractions 
(Dmitrieva and McMahon, 1996).   NGF binds to tyrosine kinase receptors (Trks) and the TrkA 
and TrkB subtypes have been found in the normal urothelium  (Murray et al., 2004).  The role of 
these receptors in the urothelium is not known. 
Relevance of the Urothelium 
As the urotoxic metabolites of CPO and IFO come into direct contact with the urothelium, it is 
this layer which is of particular interest in this project.  Understanding what changes are 
occurring in this layer and how they affect the function of the bladder as whole may lead to 
identification of possible targets for preventing or alleviating the adverse effects of these drugs, 
potentially leading to increased drug toleration and better treatment outcomes.  
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Table 1.2: Summary of receptor expression in the urothelium 
Receptor  / 
stimulus 
Subtype present  Species Reference 
Muscarinic  M1-M5 
 
 
 
Rat  
 
Human  
 
 
 
(Giglio et al., 2005) 
 
(Bschleipfer et al., 2007, 
Mansfield et al., 2005, 
Tyagi et al., 2006) 
 
Nicotinic  
 
α3 , α7, α5, β3-4 
 
α7, α9, α10 
 
 
Rat 
 
Human  
 
(Beckel et al., 2006) 
 
(Bschleipfer et al., 2007) 
 
Adrenergic  β-AR 
 
β-AR 
 
Rat 
 
Human 
(Birder et al., 2002b) 
 
(Harmon et al., 2005) 
 
Purinergic  P2X5, P2X6, P2X7 
 
P2X3 
 
P2X1-7 
P2Y1, 2, 4 
 
P2Y2, P2Y4 
Rat 
 
Rat & human 
 
Cat 
 
 
Rat 
(Lee et al., 2000) 
 
(Elneil et al., 2001) 
 
(Birder et al., 2004)  
 
 
(Chopra et al., 2008) 
 
Prostaglandin E2 EP1 / EP3 Rat (Tanaka et al., 2011) 
 
TRP Channels TRPC1, TRPC4, 
TRPV1, TRPV2, 
TRPV4, TRPM4, 
TRPM7, TRPML1 
 
TRPV1 
 
TRPV4 
 
 
TRPV2, 4, 7 
 
TRPA1 
Mouse 
 
 
 
 
Mouse 
 
Rat & mouse 
 
 
Mouse  
 
Rat 
(Yu et al., 2011)  
 
 
 
 
(Birder et al., 2002a)   
 
(Gevaert et al., 2007, Birder 
et al., 2007) 
 
(Everaerts et al., 2010a)   
 
(Streng et al., 2008) 
 
Neurokinin NK2 Rat (Ishizuka et al., 1995a) 
 
Nerve Growth 
Factor 
 
TrkA and TrkB  Rat (Murray et al., 2004)  
 
Amiloride 
sensitive Na
+
 
channel 
ENaC Rat & rabbit 
 
 
Human 
(Watanabe et al., 1999, 
Burton et al., 2002) 
 
(Araki et al., 2004) 
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Interstitial cells  
Cells resembling the interstitial cells of Cajal of the gastrointestinal tract have been identified in 
the bladder (Smet et al., 1996). These cells have been given various names in the literature but 
are referred to throughout this thesis as simply interstitial cells (IC).  Two populations of IC have 
been identified, one in the lamina propria referred to as IC-LP and the second in the detrusor 
muscle referred to as intramuscular or IC-IM (McCloskey, 2010, Davidson and McCloskey, 
2005). The IC-LP are stellate shaped with branches showing interaction with nearby nerves in 
the lamina propria. The IC-LP express the gap junction protein connexin-43 which allows cells 
to communicate with each other, potentially forming an electrical network (Ikeda et al., 2007, Sui 
et al., 2002).   In the detrusor two types of IC-IM were identified (Davidson and McCloskey, 
2005).  The first type were characterised by an elongated cell morphology and were not 
interconnected but were found running in parallel with smooth muscle bundles and in close 
connection with intramural nerves.  The second type had stellate cell morphology and were 
located in the interstitial space between muscle bundles and formed isolated areas of 
interconnected cells (Davidson and McCloskey, 2005).   
There has been much debate about whether IC are involved in the initiation of spontaneous 
activity of the bladder smooth muscle (Brading and McCloskey, 2005).  In patients with 
overactive bladder increased IC-LP have been reported suggesting that their upregulation is 
linked to the increased spontaneous contractions experienced by patients during bladder filling 
(Roosen et al., 2009).  The IC have calcium-activated chloride channels which are necessary 
for a pacemaking role (Wu et al., 2004). The IC-IM also exhibit spontaneous Ca
2+ 
fluctuations 
which were suggested to mediate the spontaneous activity of the detrusor smooth muscle 
(Hashitani et al., 2004, Johnston et al., 2008). However, electrophysiological measurements of 
isolated IC demonstrated that the fluctuations in membrane potential do not reach a level 
sufficient to cause an action potential (0mV) and therefore are unlikely to act as pacemakers 
(Sui et al., 2004).  Rather, it was suggested that a group of cells stimulated simultaneously 
could spread or amplify an excitatory effect.  
However, there is growing evidence that the IC-LP may be involved in the sensory response to 
bladder wall changes mediating signals between the urothelium and the afferent nerves or 
detrusor muscle (Brading and McCloskey, 2005, Fry et al., 2007, Sui et al., 2008).  The 
urothelium responds to bladder filling by releasing chemical mediators such as ATP, ACh and 
PGE2 (Birder et al., 2010b). The ICs express various receptors for these agonists which 
suggests they may be able to sense and respond to inputs from the urothelium.  Wu et al., 
 35 
 
(2004) showed that isolated guinea-pig IC-LP responded to exogenous ATP by generating an 
intracellular Ca
2+
 transient followed by inward currents and this response was concentration-
dependent.  Similar transients were generated by UTP and ADP but not by αβmATP suggesting 
that ATP acts via a P2Y receptor. Tissue sections and isolated cells from guinea-pig bladder 
showed strong labelling with the P2Y6 antibody and weak labelling for P2X3, P2Y2 and P2Y4 
(Sui et al., 2006).  Immunoreactivity for M2 and M3 receptors has also been reported in cells 
resembling IC in the lamina propria (Mukerji et al., 2006b, Grol et al., 2009).  However, 
conflicting evidence exist about whether IC respond to muscarinic stimulation (Johnston et al., 
2008, Lagou et al., 2006, McCloskey and Gurney, 2002, Sui et al., 2004).  In addition, IC 
expression of PGE2 receptors EP1 and EP2 has been demonstrated suggesting they may be 
able to respond to PGE2 release by the urothelium (Rahnama'i et al., 2010).  Therefore, current 
research indicates a regulatory or facilatory role for bladder ICs in transducing the urothelial 
sensory information to nerves and detrusor. 
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1.4 CYCLOPHOSPHAMIDE AND IFOSFAMIDE  
Cyclophosphamide (CPO) and isofosfamide (or ifosfamide) (IFO) are commonly used to treat a 
variety of malignant and non-malignant neoplastic diseases including malignant lymphomas, 
leukaemias, neuroblastoma, retinoblastoma and carcinomas of the ovary, breast, endometrium 
and lung, advanced stage solid tumours, as well as being used as immunosuppressive agents 
in bone marrow transplantation and chronic autoimmune disorders such as rheumatoid arthritis, 
autoimmune skin disease, multiple sclerosis, systemic vasculitides and systemic lupus 
erythematosus (Sladek, 1988, Nichols, 1995, Bergh, 2003, Buda et al., 2003, de Jonge et al., 
2005, Lawson et al., 2008). 
The dose, timing and route of CPO and IFO administration vary with age of the patient and the 
condition being treated.  However, the reported doses of CPO range from 50-1000mg/m
2
 per 
oral (p.o.) or 500 – 6000 mg/m
2
 intravenously (i.v.) over varying times of 1-96 hours (for review 
see (de Jonge et al., 2005)).  Reported doses of IFO range from 1000-2000mg/m
2
 p.o. or 
1000mg-18g/m
2
 i.v. over 1-120 hours (for review see (Kerbusch et al., 2001a)).  A more detailed 
discussed of the doses of CPO and IFO given and the relevant urinary concentrations can be 
found later in this Chapter.   
Structure 
The structure of cyclophosphamide 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-
oxazaphosphorine 2-oxide  is characterised by a nitrogen-mustard group (bis-chloroethylamine) 
attached to an oxazaphosphorine ring (Cox, 1979, de Jonge et al., 2005).  Ifosfamide [3-(2-
chloroethyl)-2-(2-chloroethylami 2-oxide]  is a structural isomer of cyclophosphamide, the only 
difference between the two being that the chloroethyl functions are located on different nitrogen 
atoms (Cox, 1979, Wagner, 1994). Figure 1.10 shows the structural formulas of 
cyclophosphamide and ifosfamide.  
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                 Cyclophosphamide                                   Ifosfamide  
Figure 1.10 Cyclophosphamide and ifosfamide structural formulas.  
Both CPO and IFO are inactive pro-drugs that must be activated by enzymes, primarily in the 
liver, to produce the active drug (Furlanut and Franceschi, 2003, de Jonge et al., 2005). CPO 
and IFO are metabolised to produce the active alkylating or cytotoxic agent which is 
phosphoramide mustard or ifosforamide mustard respectively (Connors et al., 1974, Struck et 
al., 1975, Colvin et al., 1976, Sladek, 1988, Kerbusch et al., 2001a, Furlanut and Franceschi, 
2003, de Jonge et al., 2005). Ifosforamide mustard is an analogue of the phosphoramide 
mustard of cyclophosphamide (Kerbusch et al., 2001a).  Figure 1.11 shows the structural 
formulas of phosphoramide mustard and ifosforamide mustard. 
                     
Phosphoramide mustard                                        Ifosforamide mustard 
Figure 1.11 Phosphoramide mustard and ifosforamide mustard structural formulas. 
 
Metabolism  
Although the structural formula of each drug is different the metabolic pathway is similar and 
both drugs are extensively metabolised into active and inactive metabolites (Sladek, 1988, 
Wagner, 1994, Furlanut and Franceschi, 2003).  The metabolism of both CPO and IFO is 
broken into the activation pathway and the deactivation pathway.  Error! Reference source not 
found. and Figure 1.13 show the metabolism pathway of cyclophosphamide and ifosfamide 
respectively.   
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Figure 1.12 has been removed due to Copyright restrictions.  
The original image can be viewed in Boddy, A. V. & Yule, S. M. 2000, 'Metabolism and 
pharmacokinetics of oxazaphosphorines', Clin Pharmacokinet, vol. 38, no. 4, pp. 291-304. (refer 
to Figure 1).  
 
 
 
 
 
 
 
 
 
 
Figure 1.12 Metabolism of cyclophosphamide (Boddy and Yule, 2000). 
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Figure 1.13 has been removed due to Copyright restrictions.  
The original image can be viewed in Boddy, A. V. & Yule, S. M. 2000, 'Metabolism and 
pharmacokinetics of oxazaphosphorines', Clin Pharmacokinet, vol. 38, no. 4, pp. 291-304. (refer 
to Figure 2).  
 
 
 
 
 
 
 
 
 
 
Figure 1.13 Metabolism of ifosfamide (Boddy and Yule, 2000). 
Activation  
Cyclophosphamide and ifosfamide are activated by the hydroxylation of the oxazaphosphorine 
ring at the carbon-4 position to form 4-hydroxycyclophosphamide and 4-hydroxyifosfamide in 
equilibrium with their ring-open tautomer aldophosphamide and aldoifosfamide respectively 
(Connors et al., 1974, Friedman et al., 1976, Fenselau et al., 1977, Furlanut and Franceschi, 
2003, de Jonge et al., 2005).   Both CPO and IFO are activated primarily in the liver by hepatic 
microsomal mixed-function oxidases (cytochrome P450 [CYP] enzyme system) (Connors et al., 
1974, Fenselau et al., 1977, de Jonge et al., 2005).  Numerous CYP isoenzymes are involved in 
the bioactivation of CPO and IFO in humans including CYP2A6, 2B6, 3A4, 3A5, 2C9, 2C18 and 
2C19 (Chang et al., 1993, Chang et al., 1997, de Jonge et al., 2005, Griskevicius et al., 2003, 
Huang et al., 2000, Ren et al., 1997, Roy et al., 1999, Xie et al., 2003, Yu and Waxman, 1996).  
Analysis of CYP enzyme expression in human liver suggests that CYP2B6 has the greatest 
involvement in CPO activation while CYP3A3 and 3A4 appear to have the highest involvement 
in IFO activation (Chang et al., 1993, Roy et al., 1999, Xie et al., 2003). 
Of an administered dose of cyclophosphamide, approximately 70-80% is activated in the liver 
and the remainder is either inactivated by side-chain oxidation to 
dechloroethylcyclophosphamide and chloracetaldehyde or is excreted unchanged in the urine, 
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bile, breath and faeces (Bagley et al., 1973, Dooley et al., 1982, Bailey et al., 1991, Joqueviel et 
al., 1998, Busse et al., 1999, Boddy and Yule, 2000, de Jonge et al., 2005).   The activation of 
IFO is similar to that of CPO, however closer to 50% of a dose of ifosfamide will be activated to 
4-hydroxyifosfamide with the remainder inactivated via side-chain oxidation or excreted 
unchanged (Sladek, 1988, Boddy and Yule, 2000, Kerbusch et al., 2001a).  
4-Hydroxycyclophosphamide/aldophosphamide and 4-hydroxyifosfamide/aldoifosfamide are not 
cytotoxic themselves but readily diffuse into cells where they spontaneously form 
phosphoramide mustard and ifosforamide mustard respectively by β-eliminatation of acrolein 
(Alarcon and Meienhofer, 1971, Friedman et al., 1976, Connors et al., 1974, Boyd et al., 1986, 
Sladek, 1988, Busse et al., 1999, Kerbusch et al., 2001a, de Jonge et al., 2005, Misiura, 2006). 
The decomposition of 4-hydroxycyclophosphamide/aldophosphamide and 
4-hydroxyifosfamide/aldoifosfamide may be partly catalysed by albumin or other proteins 
(Hohorst et al., 1986, Kwon et al., 1987, Sladek, 1988). 
Deactivation  
In addition to the activation pathway discussed above, a number of inactive metabolites are also 
produced during metabolism of CPO and IFO.  One of the inactive metabolites of CPO is 
dechloroethylcyclophosphamide which is produced by an oxidative N-dealkylation reaction (de 
Jonge et al., 2005) producing an equimolar amount of chloroacetaldehyde (CAA) (Connors et 
al., 1974, Bohnenstengel et al., 1996, Yu and Waxman, 1996, Ren et al., 1997, Huang et al., 
2000).  The intermediate 4-hydroxycyclophosphamide may be deactivated to ketophosphamide 
by an alcohol dehydrogenase (Sladek, 1988, Joqueviel et al., 1998, Busse et al., 1999). While, 
aldophosphamide can be deactived by oxidation to carboxycyclophosphamide by an aldehyde 
dehydrogenase (Sladek, 1988, Dockham et al., 1992, Joqueviel et al., 1998, Busse et al., 1999).  
The production of carboxyphosphamide from aldophosphamide is the most important 
detoxification pathway of cyclophosphamide (de Jonge et al., 2005).   
The primary deactivation pathway for ifosfamide involves the removal of a chloroethyl group 
from either the exo- or endocyclic nitrogen atom to form nontoxic 2-dechloroethylifosfamide and 
3-dechloroethylifosfamide respectively as well as an equimolor amount of CAA (Kerbusch et al., 
2001a).  Dechloroethylation accounts for 25 to 60% of the metabolism of ifosfamide (Misiura et 
al., 1983, Sladek, 1988, Kaijser et al., 1994, Kerbusch et al., 2001a).  The intermediate 
4-hydroxyifosfamide can be inactivated to 4-ketoifosfamide and 4-thioifosfamide  while the 
detoxification of aldoifosfamide yields both carboxyifosfamide and alcoifosfamide (Kerbusch et 
al., 2001a).   
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Detoxification of phosphoramide mustard, ifosforamide mustard, acrolein and CAA occurs via 
conjugation with intracellular glutathione (GSH) either spontaneously or mediated by the 
enzyme glutathione-S-transferase (Gurtoo et al., 1981, Dirven et al., 1994, Gamcsik et al., 1999, 
Sood and O'Brien, 1993).   
Mode of Action  
Intracellular activation of CPO and IFO to phosphoramide mustard and ifosforamide mustard 
results in the conversion of both 2-chloroethyl groups of each molecule into reactive 
electrophilic alkyl groups (R-CH2+) which in turn react with the nucleophilic moieties of DNA 
bases such as N
7
-guanine (Kerbusch et al., 2001a, de Jonge et al., 2005).  The bifunctional 
character of phosphoramide mustard and ifosforamide mustard derives from their ability to form 
two reactive alkyl groups (Kerbusch et al., 2001a).  Specifically, phosphoramide mustard has 
two exocyclic 2-chloroethyl groups while ifosforamide mustard has one 2-chloroethyl group on 
the exo and one of the endocyclic oxazaphosphorine nitrogen atom (Brock, 1983, Kerbusch et 
al., 2001a).   
The two reactive alkyl groups can attach to two bases in the same DNA strand to form an 
intra-strand link or can attach to one base on two different DNA strands forming an inter-strand 
link.  Inter-strand links, in particular, impair DNA replication by inhibiting double-strand 
separation prior to cell division leading to cell death by apoptosis (O'Connor et al., 1991, Povirk 
and Shuker, 1994, Dong et al., 1995, Shulman-Roskes et al., 1998, de Jonge et al., 2005)  
Therefore, since tumour cells have a high rate of cellular divisions, they will be affected by CPO 
and IFO at a greater rate than normal cells (Kerbusch et al., 2001a, de Jonge et al., 2005).  
In addition, the metabolites acrolein and CAA may enhance the cytotoxicity of phosphoramide 
mustard and ifosforamide mustard by depletion of intracellular GSH (Lind et al., 1989, 
Bruggemann et al., 1997, Borner et al., 2000, Gurtoo et al., 1981, Crook et al., 1986a, Crook et 
al., 1986b). 
Elimination  
Most of the literature reports urinary excretion of CPO, IFO and their metabolites as a 
percentage of the initial dose and very little information is available concerning the actual 
urinary concentrations of these substances as found in patients.  In addition, there is large 
inter-individual variability seen in the urinary excretion of CPO and IFO. This makes it difficult to 
define a clinically relevant concentration of CPO, IFO or their metabolites to use in this study.   
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However, several studies have shown that the urinary elimination of CPO and IFO and its 
metabolites is almost complete 24 hr after the start of treatment (Bagley et al., 1973, Jardine et 
al., 1978, Sladek et al., 1980, Joqueviel et al., 1997).  Specifically, Joqueviel et al., (1998) 
analysed urine samples from patients treated with CPO on two consequtive days and measured 
CPO as well its metabolites and their degradation products.   They found that only 6% of the 
injected dose on day one and and 3% on day two were recovered in the urine samples collected 
18-24 hours after the beginning of CPO infusion and saw little interpatient variability.   
Furthermore, approximately 15% of the dose of CPO was excreted unchanged while 
carboxycyclophosphamide and its two degradation products were found to be the major 
metabolites of CPO (11.5% and 23% after the first and second doses, respectively) (Joqueviel 
et al., 1998). 
Similar excretion results have been reported for IFO.  In a study of 11 patients who received 
IFO in a number of treatment cycles with bolus doses or intravenous infusions (Singer et al., 
1998).   The study reported that approximately 23% of the administered dose of IFO was 
excreted in urine unchanged while 5.4% was excreted as the metabolite 
2-dechloroethylifosfamide, 12.3% as 3-dechloroethylifosfamide, 14.8% as carboxyifosfamide 
and 9.9% as ifosforamide mustard.   
Dechloroethylcyclphosphamide and CAA are primarily eliminated in the urine and account for 
<5% of total elimination of cyclophosphamide (Boddy et al., 1992, Joqueviel et al., 1998, Busse 
et al., 1999).   However, the dechloroethylation pathway accounts for 25-60% of IFO 
metabolism in adults (Misiura et al., 1983, Sladek, 1988, Kaijser et al., 1994, Kerbusch et al., 
2001b). 
Another study measured urinary acrolein excretion in 16 bone marrow transfer patients 
receiving cyclophosphamide wherein urine samples were taken over a 24 hour period (Al-
Rawithi et al., 1998). The amount of acrolein excreted in 24 hours was between 0.47% and 6.1% 
of administered cyclophosphamide with a mean of 1.96% ± 0.35.  The variation between 
patients was investigated and no correlation between dose, hydration status, previous 
chemotherapy or concomitant medication was found and was contributed to the high 
interpatient variability in metabolising CPO (Al-Rawithi et al., 1998).  
Urinary Concentrations 
For the purpose of this review, it is important to estimate the clinically relevant urinary 
concentrations of CPO, IFO and their major metabolites acrolein and CAA as it is the urinary 
concentration that is in contact with the urothelium that must be replicated in vitro.  One study of 
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16 breast cancer patients receiving intravenous CPO at a dose of 600 or 1200 mg/m
2 
reported 
actual urinary concentrations of CPO to be approximately 10-400µM at approximately 20-24 
hours after administration of CPO (Hedmer et al., 2008). Unfortunately, this study did not 
measure plasma or urine concentrations of CPO before 20 hours.   
For the parent drug IFO, no reliable urinary concentration data could be found in the literature.  
However, in a study by Kurowski & Wagner (1993), the plasma concentrations of IFO and its 
metabolites were investigated in 11 patients with bronchogenic carcinoma receiving intravenous 
IFO on a 5-day divided-dose schedule (1.5 g/m
2
 daily).  Peak plasma concentrations of IFO on 
day 1 and 5 were approximately 200µM.   
For acrolein, one study measured the urinary concentrations in 19 patients between the ages of 
1 year and 21 years receiving varying intravenous doses of CPO and IFO for different diseases. 
Urinary acrolein concentrations peaked at times between 1 and 12 h after starting therapy 
(mean±S.D., 5.0±2.7) and maximum urinary acrolein concentrations ranged from 0.3 to 
406.8nM (mean± S.D., 39.7±76.7 nM)  (Takamoto et al., 2004). The measurement of 406.8nM 
was an outlier in the data with the next highest peak urine concentration being 111.3nM.   
Kurokwski & Wagner (1993) also measured CAA and found plasma concentrations on day 1 
and 5 reached a maximum of 2-5µM respectively. In another study, blood samples from one 
patient treated with a ten-day continuous infusion of IFO revealed plasma concentrations of 
CAA that did not exceed 10µM (Kaijser et al., 1993).  Furthermore, Pendyala et al., (2000) 
measured various metabolites in 24 patients receiving intravenous IFO ranging from 2 to 8g/m2 
and found that the maximum plasma CAA concentrations were 10–35µM.  The only study found 
to report actual urinary concentrations in six children receiving 1.6g/m
2
 ifosfamide intravenously 
every day for 5 days reported concentrations up to 221µM while average plasma concentrations 
in the same patients ranged from 22µM-109µM (Goren et al., 1986).  Peak concentrations of 
CAA were also seen within 24 hours.   
Accordingly, the range of concentrations deemed to be clinically relevant for CPO, IFO, acrolein 
and CAA was 10nM – 100µM.   This range was tested initially and then toxic concentrations 
used in subsequent experiments.   
Urotoxicity - Mechanisms, Effects & Protection  
The urotoxic effects of CPO or IFO can be split into anatomical and functional effects.  The 
metabolites of CPO and IFO come into direct contact with the urothelium causing damage and 
resulting in inflammation.  This inflammation causes oedema, ulceration, neovascularisation, 
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haemorrhage and necrosis or apoptosis (Cox, 1979, Lima et al., 2007).  Whereas, the functional 
effects can manifest as bladder pain, urinary frequency, urgency, dysuria and feelings of 
incomplete emptying (Korkmaz et al., 2007, Fukuoka et al., 1991) and these effects can last 
well beyond the resolution of inflammation and damage.  
Mechanism of toxicity  
Almost exclusively, the toxic effects of CPO and IFO have been attributed to acrolein damaging 
and infiltrating the urothelium and initiating an inflammatory response.  Mice treated with CPO 
showed intense protein-acrolein adduct formation localised to the lamina propria accompanied 
by the most intense focal damage including oedema, haemorrhage, schistocyte formation, 
albumin extravasation, ulcerative dissolution of connective tissue, inflammatory cell infiltration, 
and apoptosis (Conklin et al., 2009).   
Acrolein is a highly electrophilic, reactive α,β-unsaturated aldehyde which will rapidly bind to 
and deplete nucleophilic cell constituents, such as GSH.  Acrolein can also bind to lysine, 
histidine and cysteine residues of proteins and nucleophilic sites in DNA resulting in widespread 
protein and DNA modification (Beauchamp et al., 1985, Kehrer and Biswal, 2000, Korkmaz et 
al., 2007).  In high concentrations acrolein is cytotoxic and can lead to necrosis or apoptosis of 
cells (Beauchamp et al., 1985, Li et al., 1997). At lower concentrations acrolein can react rapidly 
at many cellular sites including depleting or binding cellular thiols and proteins, activating lipid 
peroxidation (Adams and Klaidman, 1993) and activating genes, either directly or subsequent to 
effects of transcription factors such as nuclear factor-kappaB (NF-κB) (Horton et al., 1999) and 
activator protein-1 (AP-1) (Biswal et al., 2002, Korkmaz et al., 2007). Acrolein has also been 
shown to cause single-stranded DNA breaks (Erickson et al., 1980).  
It has been suggested that the main mechanism by which acrolein causes bladder damage is 
through the production of reactive oxygen species (ROS) and NO (Korkmaz et al., 2007).  The 
inhibition of NO synthesis leads to a reduction of both oedema and haemorrhage caused by 
CPO treatment of rats (Souza-Fiho et al., 1997). Acrolein rapidly enters urothelial cells and 
activates intracellular ROS and NO production either directly or via various mediators including 
NF-κB and AP-1 ultimately producing peroxynitrite (ONOO-).  The increased level of ONOO- 
results in lipid peroxidation, protein oxidation and DNA damage leading to poly ADP-ribose 
polymerase (PARP) activation (Korkmaz et al., 2007). PARP is a DNA repair enzyme that can 
become over activated when DNA is damaged which can lead to the depletion of oxidised 
nicotinamide-adenine dinucleotide (NAD) and ATP, and consequently in apoptotic or necrotic 
cell death (Korkmaz et al., 2007).  Figure 1.14 shows this proposed mechanism in more detail.  
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Figure 1.14 has been removed due to Copyright restrictions.  
The original image can be viewed in Korkmaz, A., Topal, T. & Oter, S. 2007, 'Pathophysiological 
aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of 
reactive oxygen and nitrogen species as well as PARP activation', Cell biology and toxicology, 
vol. 23, no. 5, pp. 303-12. (refer to Figure 2).  
 
 
 
 
 
 
 
 
Figure 1.14: Proposed mechanism of acrolein urotoxicity.  (I) Acrolein enters urothelial cell and causes ROS 
production, iNOS induction, and activation of transcription factors (e.g. NF-κB and AP-1). Activated 
transcription factors cause cytokine (TNF-α, IL-1β) gene expression, iNOS induction and further ROS 
production. (II–III) Cytokines diffuse out into other urothelial cells, smooth muscle cells and into the 
bloodstream. ROS and NO form peroxynitrite (ONOO-) in urothelium and detrusor, leading to lipid peroxidation, 
protein oxidation, and DNA damage. DNA damage leads to PARP activation, depletion of NAD and ATP and 
eventually cellular necrosis. (IV) During necrosis, harmful intracellular contents are released into surrounding 
tissue potentially damaging neighbouring cells (Korkmaz et al., 2007). 
 
Acrolein is not only a urotoxic metabolite of CPO and IFO but is an environmental pollutant 
which humans are exposed to in many common situations including as part of cigarette smoke, 
forest and house fires and part of automotive exhaust (Tanel and Averill-Bates, 2007).  Acrolein 
has been implicated in chronic obstructive pulmonary disease (Borchers et al., 1999) as well as 
neurodegenerative disorders such as Alzheimer‘s disease (Lovell et al., 2001).   Acrolein toxicity 
has been demonstrated in a number of tissues other than bladder and induces apoptosis in 
some tissues such as keratinocytes (Takeuchi et al., 2001), bronchial epithelial cells (Nardini et 
al., 2002), cultured neurons (Pugazhenthi et al., 2006), and Chinese hamster ovary cells (Tanel 
and Averill-Bates, 2005).  However, studies in other tissues have reported acrolein induced 
necrotic cell death including in neutrophils (Finkelstein et al., 2005) as well as cultured neuronal 
cells (Liu-Snyder et al., 2006, Luo et al., 2005).  However, several of these studies reported cell 
death by apoptosis at low concentrations of acrolein and necrotic cell death at higher 
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concentrations which may also explain these variable findings (Finkelstein et al., 2005, Tanel 
and Averill-Bates, 2005).   
Acrolein induced apoptosis appears to be due to activation of the intrinsic/mitochondrial 
pathway which involves the activation of various caspases and altered activation of various 
transcription factors and promoters that are involved in apoptosis and cell survival (Tanel and 
Averill-Bates, 2005).   Altered activation of these factors ultimately leads to chromatin 
condensation, cytoskeletal changes, nuclear membrane breakage, DNA fragmentation, cell 
blebbing, and formation of apoptotic bodies which are then phagocytosed by macrophages 
(Tanel and Averill-Bates, 2005).  Acrolein-induced apoptosis in cultured bronchial epithelial cells 
was also associated with depletion of cellular GSH and intracellular generation of oxidants 
(Nardini et al., 2002).  Another study in cultured neuroblastoma cells treated with acrolein 
demonstrated that acrolein induced the production of ROS, nicotinamide-adenine dinucleotide 
phosphate-oxidase activity, depletion of GSH, protein oxidation/nitration and lipid peroxidation 
(Huang et al., 2000).   
However another toxic metabolite excreted in the urine is chloroacetaldehyde (CAA) which is 
produced during detoxification of cyclophosphamide and ifosfamide (Shaw et al., 1983).  CAA 
has been suggested to play a role in the cardio- neuro- and nephro-toxicity of CPO and IFO 
(Goren et al., 1986, Sladek, 1988, Joqueviel et al., 1997) however no data has reported its role, 
if any, in urotoxicity. CAA is also highly electrophilic and toxicity occurs by similar mechanisms 
to acrolein including depletion of cellular reduced GSH, NAD and ATP, disturbed Ca
2+
 signalling, 
and lipid peroxidation, potentially leading to cell death via apoptosis or necrosis (Nissim et al., 
2006, Schwerdt et al., 2006, Sood and O'Brien, 1993). This evidence suggests that CAA may 
be involved in the urotoxicity of CPO and IFO and accordingly CAA urotoxicity was investigated 
in the following studies.  
Effects of urotoxicity    
As mentioned above, CPO or IFO treatment can cause anatomical and functional effects.   
Anatomical effects 
Anatomical effects such as oedema, ulceration, neovascularisation, haemorrhage are thought to 
be due to the initiation of an inflammatory response.  Various prostaglandins and cytokines are 
thought to be produced by the urothelial cells leading to inflammation (Gomes et al., 1995, 
Ribeiro et al., 2002, Hu et al., 2003, Klinger et al., 2007, Korkmaz et al., 2007, Macedo et al., 
2008a, Macedo et al., 2008b, Conklin et al., 2009). One study, in rats, has found that CPO 
induces a significant increase in bladder mRNA expression of the cytokines interleukin (IL)-1β, 
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IL-2, IL-4, IL-6 and tumour necrosis factor (TNF)-α and TNF-β mRNA after acute cystitis (4 
hours after CPO treatment) (Malley and Vizzard, 2002). The protein expression of the cytokines 
was generally equal to that of mRNA (Malley and Vizzard, 2002).  In particular, the inhibition of 
TNF-α and IL-1β in mice treated with CPO induced a significant reduction in urothelial erosion, 
haemorrhage, oedema, leukocyte migration, fibrin deposition and ulcerations suggesting these 
cytokines are crucial mediators involved in the inflammatory response to CPO. Furthermore, 
antiserum treatments to TNF-α or IL-1β also inhibited the expression of iNOS in the urothelium 
of mice in response to IFO treatment (Gomes et al., 1995, Ribeiro et al., 2002).   
In addition, several studies in rats and mice have found that systemic treatment with CPO, IFO 
or intravesical treatment with acrolein induces COX-2 expression in urothelium and ICs within 
12-24 hours of treatment (Macedo et al., 2008b, Macedo et al., 2008a, Wang et al., 2008b, 
Macedo et al., 2011).  One study found that the plasma PGE2 concentration was increased after 
IFO administration in rats and that co-administration of a COX-2 inhibitor had a protective effect 
against IFO induced cystitis (Macedo et al., 2011).  Therefore, it appears that COX-2 and PGE2 
may also contribute to the CPO or IFO induced bladder inflammation.   
Functional effects 
Functional effects such as bladder pain, urinary frequency, urgency, dysuria and feelings of 
incomplete emptying may be due to direct damage or alteration of the bladder or nerves by 
reactive drug metabolites or as a result of urothelial damage or the inflammatory response.  
Animals treated with CPO, IFO or intravesical acrolein demonstrate typical urotoxic storage 
symptoms including reduced bladder capacity, increased urinary frequency and decreased 
contractile force leading to decreased voiding pressure (Okinami et al., 2014, Macedo et al., 
2008a, Wang et al., 2008b, Kageyama et al., 2008).   
Isolated bladder tissue from animals treated with CPO or IFO demonstrated reduced contraction 
in response to potassium chloride (KCl) suggestive of damage to bladder smooth muscle 
(Macedo et al., 2011, Giglio et al., 2005).  However, the bladder muscle also showed reduced 
contractility to the muscarinic agonist carbachol as well as altered muscarinic receptor 
expression, indicating that functional changes may involve more than just reduced muscle 
contractility (Giglio et al., 2005).  Similarly, contractile responses to the P2X receptor agonist 
β,γ-methylene ATP (β,γ-mATP) were reduced in CPO treated animals and may be due to 
changes in receptor expression (Mok et al., 2000, Kageyama et al., 2008). 
Alterations to afferent nerve function may also lead to the bladder pain and dysfunction seen 
after CPO or IFO treatment.  Studies using isolated DRG from animals treated with CPO have 
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demonstrated increased firing rate to stimulus and activation at lower stimulus thresholds 
suggesting that nerves may become sensitised and hyperactive after CPO treatment 
(Yoshimura and de Groat, 1999, Dang et al., 2008).  
Uroprotection 
Mesna (sodium-2-mercaptoethanesulfonate) is a thiol compound that is commonly used in 
combination with CPO or IFO to reduce or ameliorate the urotoxic symptoms of these drugs. 
Mesna, once activated to dimesna, has free sulfhydryl groups that can combine directly with the 
double bond of acrolein thereby inactivating acrolein and preventing it from damaging the 
bladder (Stofer-Vogel et al., 1993).  Shepherd and colleagues (1991) treated 100 patients 
undergoing bone marrow transplant conditioning with regimens that included high-dose 
cyclophosphamide randomly with either mesna or forced saline diuresis to study how effective 
mesna is in preventing hemorrhagic cystitis. The incidence of consistent or severe haematuria 
was 33% in the mesna treated patients as opposed to 20% in the hyperhydrated patients 
(P = 0.31) (Shepherd et al., 1991).  Furthermore, Lima et al., (2007) studied the histological 
changes in bladders of patients treated with ifosfamide in combination with mesna and found 
that even after use of mesna, 66.7% of patients presented cystoscopic alterations and 100% 
showed microscopic alterations in the urothelial/LP such as oedema, exocytosis, and 
haemorrhage.   
Sakurai and colleagues, (1986) treated patients receiving high-dose ifosfamide with or without 
mesna to investigate the effect of mesna on urotoxic side effects.  Although mesna appeared to 
reduce the incidence of haematuria, other symptoms, such as frequency and dysuria were not 
statistically different between the groups.  This suggests that despite the clinical use of mesna, 
a significant percentage of patients treated with CPO or IFO are still likely to suffer from urotoxic 
side effects of these drugs. Accordingly, additional or alternative protective agents are required.  
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Summary   
In summary, we are only starting to understand the changes induced by CPO, IFO, acrolein and 
CAA in the bladder.  It is known that acrolein has adverse effects on the bladder, causing 
bladder inflammation and hyperactivity resulting in micturition pain, frequency and urgency.  
However, despite CAA being linked to the neuro-, cardio- and nephrotoxicity of these drugs, it 
has received little attention in relation to urotoxicity.  Additionally, despite the clinical use of 
mesna, a significant percentage of patients treated with CPO or IFO are likely to suffer from 
urotoxic side effects of these drugs.   Therefore, studies into the mechanisms of cytotoxic action 
of CPO and IFO and the functional changes they cause in the bladder are needed.  This may 
uncover potential targets for preventing, alleviating or treating the adverse urological effects of 
these drugs potentially leading to better drug toleration and better treatment outcomes.  
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1.5 AIMS 
The overall aim of this thesis was to increase our understanding of the bladder toxicity caused 
by the commonly used chemotherapeutics cyclophosphamide and ifosfamide and the 
implications of this toxicity on bladder function.  Understanding how these drugs cause bladder 
damage and what functional changes occur as a result may reveal future targets for preventing 
the adverse effects of these drugs or restoring normal bladder function after treatment. This 
thesis used various experimental approaches to investigate the following aims:  
1. To determine whether acrolein or chloroacetaldehyde are toxic to urothelial cells and 
whether urothelial function changes as a result. 
2. To investigate whether acrolein or chloroacetaldehyde induced urothelial toxicity can be 
prevented by vitamin C or N-acetylcysteine. 
3. To explore whether acrolein or chloroacetaldehyde can cause functional changes in the 
detrusor.  
4. To investigate the effect of systemic cyclophosphamide and ifosfamide treatment on 
bladder afferent nerve activity.  
5. To examine the possible interaction between changes in urothelial function and detrusor 
or afferent nerve function.  
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CHAPTER 2: Materials and Methods  
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This Chapter provides general information on the materials and methods used throughout the 
following studies.  Specific and detailed information regarding the experimental protocol used in 
each study is detailed in the relevant Chapters.   
2.1 SOLUTIONS 
The composition of Krebs-bicarbonate solution was (in mM): NaCl 118, NaHCO3 24.9, CaCl2 1.9, 
MgSO4 1.15, KCl 4.7, KH2PO4 1.15, and D-glucose 11.7.  Hypotonic Krebs solution contained 
half the NaCl (59mM) while all other components were at the same concentration as for normal 
Krebs solution. All reagents were obtained from Sigma Aldrich Co. LLC (St. Louis, USA). The 
carbogen gas (95% O2 and 5% CO2) was obtained from BOC Gases Australia Ltd. (Australia). 
The cell culture medium, McCoys 5A, was obtained in powder form containing L-glutamine and 
phenol red (Sigma, St. Louis, USA).  The powder was reconstituted in distilled water and 
supplemented with 2.2 g/L sodium bicarbonate (Sigma), 10% fetal bovine serum (Life 
Technologies, of USA origin) and 500 U/mL penicillin-streptomycin (Invitrogen™). Other 
solutions used during cell culture included 0.25% trypsin and phosphate buffered saline from 
Life Technologies (Auckland, New Zealand). 
2.2 DRUGS 
All of the drugs used in the following studies, including their source and solvent, are listed in 
Table 2.1.  The concentration of drugs used was either determined using preliminary 
experiments or derived from the concentrations used in the literature.  All drugs were obtained 
from Sigma-Aldrich (St. Louis, USA), except those indicated (*), which were obtained from 
Tocris Bioscience (Bristol, UK) and those indicted (**) which were from Cayman Chemical 
Company (Michigan, USA). 
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Table 2.1: Details of the pharmacological agents used in this thesis 
Compound Main Action Solvent Cat No. 
1,1-Dimethyl-4-
phenylpiperazinium iodide 
(DMPP) 
Non-specific nicotinic agonist H2O D5891 
1-[3’,4’-Dihydroxyphenyl]-2-
isopropyl-aminoethanol 
(isoprenaline) 
β-adrenoceptor agonist H2O I5627 
2’,7’-Dichlorofluorescin 
diacetate (DCF-DA) 
Cell permeable probe for 
ROS 
DMSO D6883 
3-Methyladenine (3MA) ** Autophagy inhibitor Culture 
Medium 
13242 
α,β-Methyleneadenosine 5’-
triphosphate lithium salt (αβm-
ATP) 
P2X receptor agonist H2O M6517 
Acetylcholine chloride Cholinergic receptor agonist H2O A6625 
Acrolein Reactive metabolite of 
cyclophosphamide and 
ifosfamide 
H2O 01679 
Adenosine 5’-triphosphate 
disodium salt (ATP) 
P2 purinoceptor agonist H2O A7699 
ARL 67156 trisodium salt ATP‘ase inhibitor H2O A265 
Atropine Sulfate Salt Non-selective muscarinic 
antagonist 
H2O A0257 
Capsaicin TRPV1 agonist Ethanol M2028 
Carbamylcholine chloride 
(carbachol) 
Cholinergic receptor agonist 
(muscarinic >nicotinic) 
H2O C240-9 
Chloroacetaldehyde solution  
(50 wt. % in H2O) 
Reactive metabolite of 
cyclophosphamide and 
ifosfamide 
H2O 317276 
Cyclophosphamide 
monohydrate 
Commonly used 
chemotherapeutic agent 
H2O C0768 
Ifosfamide Commonly used 
chemotherapeutic agent 
H2O I4909 
L-Ascorbic acid (Vitamin C) Antioxidant H2O A4403 
N-Acetyl-L-cysteine (NAC) Antioxidant and GSH 
precursor 
H2O A9165 
Nifedipine L-type Ca
2+
 channel blocker Ethanol N7634 
NѠ-Nitro-L-Arginine (L-NNA) Nitric oxide synthase inhibitor H2O N-1522 
Polygodial * TRPA1 agonist Ethanol 3197 
Prostaglandin E2 E prostanoid receptor agonist Ethanol P0409 
Resazurin sodium salt Probe for detection of 
metabolically active cells 
H2O R7017 
Sodium Nitroferricyanide 
(Sodium Nitroprusside [SNP])  
Nitric oxide donor H2O S0501 
Tetrodotoxin Na
+
 channel blocker Citrate Buffer 
(ph 4-5) 
T8024 
WS-12 * TRPM8 agonist Ethanol 3040 
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2.3 ASSAYS  
The following assays were used in each of the studies in this thesis. Other assays used 
specifically in one study only are described in the appropriate Chapter.  
ACh 
Concentrations of ACh in the various samples collected were measured using an Amplex Red 
ACh/AChesterase Assay Kit (Molecular Probes, Cat # A12217).  In the assay, ACh esterase 
(AChE) converts ACh to choline which is in turn oxidised by choline oxidase to betaine and 
hydrogen peroxide (H2O2).  In the presence of horseradish peroxidise, H2O2 reacts with the 
amplex red reagent to produce the highly fluorescent product resorufin.  Equal volumes of 
sample (50µl) and reaction solution (50µl) (containing AChE, choline oxidase, horseradish 
peroxidise and amplex red in a buffer) were incubated at room temperature protected from light 
for 30 minutes according to the recommended protocol.  Fluorescence by resorufin was then 
measured using a Modulus Microplate Multimode Reader (Turner Biosystems, California, USA) 
(excitation 571nm and emission 585nm).  As the assay measures the metabolite choline, the 
assay calculates both the current and metabolised ACh in the sample.  ACh content in samples 
was calculated from a standard curve of fluorescence plotted using known concentrations of 
ACh (Figure 2.1). 
 
Figure 2.1: Representative standard curve of fluorescence readings to known concentrations of ACh. 
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ATP 
Concentrations of ATP in the various samples collected were measured using a luminescence 
based ATP Determination Kit (Molecular Probes, Cat #A22066). The assay is based on a 
reaction of the enzyme firefly luciferase converting the substrate D-luciferin, in an ATP 
dependant reaction, to a product and light (emission maximum is approximately 560nm at pH 
7.8). Luciferase requires ATP to produce light and thereby the luminescence of the reaction 
directly reflects the amount of ATP present in the sample. 
 
The kit requires that reaction solution (containing firefly luciferase, D-luciferin, and dithiothreitol 
in a buffer) be combined with sample so that the volume of sample amounts to no more than 10% 
of the total assay volume.  Accordingly, 10µl of sample was combined with 100µl of reaction 
solution and incubated at room temperature for 5 minutes before reading the luminescence. 
Luminescence was measured using a Modulus Microplate Multimode Reader (Turner 
Biosystems, California, USA) and ATP content in samples was calculated from a standard curve 
of luminescence plotted using known concentrations of ATP (Figure 2.2). 
 
Figure 2.2: Representative standard curve of luminescence readings to known concentrations of ATP. 
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PGE2  
The kit used to determine PGE2 levels in samples was the Cayman‘s PGE2 EIA Kit - Monoclonal 
(Cat #514010).  This assay uses a 96 well plate coated with goat polyclonal anti-mouse IgG as 
well as PGE2 monoclonal antibodies, PGE2-acetylcholinesterase conjugate (PGE2 Tracer) and 
AChE substrate which produces a coloured product measureable by spectrophotometry.  The 
PGE2 Tracer (50µl) was added to each well along with sample (50µl) and PGE2 monoclonal 
antibody (50µl).  The PGE2 Tracer and the PGE2 in the sample compete for the limited amount 
of monoclonal antibody.  The antibody-PGE2 complex binds to the goat polyclonal anti-mouse 
IgG attached to the well.  After incubation for 18 hours at 4°C, the plate was washed five times 
with a buffer to remove any unbound reagents.  Next, Ellmans reagent (200µl) (which contains 
the substrate to AChE) was added to the well and incubated at room temperature for 30 
minutes on an orbital shaker (300rpm) protected from light.  The product of this enzymatic 
reaction has a distinct yellow colour and absorbance was measured at 412 nm using a Modulus 
Microplate Multimode Reader (Turner Biosystems, California, USA). The intensity of the colour 
is proportional to the amount of PGE2 Tracer bound to the well, which is inversely proportional 
to the amount of sample PGE2 present in the well during the incubation. PGE2 content in 
samples was calculated from a standard curve of absorbance plotted using known 
concentrations of PGE2 (Figure 2.3). 
 
Figure 2.3: Representative standard curve of % of maximum absorbance readings to known concentrations of 
PGE2. 
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2.4 HISTOLOGY 
Histological chemistry was performed on various tissues including porcine and murine bladder 
tissues.  Porcine tissues were dissected to an approximate size of 5mm long, 3mm wide and 
3mm thick.  Murine bladders were approximately 1-2mm thick.  All histology processes were 
performed according to the following protocol.  
1. Fixing: Tissues were placed into neutral buffered formalin (10%) and left for 24 hours at 
4°C.  For whole mouse bladder a catheter was secured in the urethra and formalin was 
injected into the bladder to gently distend the bladder and then placed in formalin to fix 
the tissue in a distended state.  
2. Processing: The tissues were removed from the formalin and placed in the following 
solutions: 
a. 70% ethanol (15 minutes for murine tissue, 30 minutes for porcine tissue), 
b. 90% ethanol (15 minutes for murine tissue, 30 minutes for porcine tissue), 
c. 100% ethanol (15 minutes for murine tissue, 30 minutes for porcine tissue), 
d. 1:1 xylene:ethanol (7 minutes for murine tissue, 15 minutes for porcine tissue), 
e. 100% xylene (7 minutes for murine tissue, 15 minutes for porcine tissue), 
f. Fresh 100% xylene (7 minutes for murine tissue, 15 minutes for porcine tissue), 
g. 1:1 xylene:paraplast at 57°C (15 minutes for murine tissue, 30 minutes for 
porcine tissue), 
h. Liquid paraplast at 57°C (15 minutes for murine tissue, 30 minutes for porcine 
tissue), and 
i. Change paraplast at 57°C (15 minutes for murine tissue, 30 minutes for porcine 
tissue). 
Tissues were positioned in aluminium moulds and completely covered with liquid 
paraplast.  A plastic cassette was placed in the paraplast and left for 12 hours to set.  
3. Mounting: Tissue sections were cut at 4-5µm using an Accu-Cut
®
 SRM™ 200 Rotary 
Microtome (Sakura Finetek Europe B.V., The Netherlands).  Sections were placed in a 
small water bath at 48°C and then gently positioned on a glass microscope slide and 
left until dry.  
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4. Rehydrating: Slides were placed in a heat box for 5-10 minutes and then placed in the 
following solutions:  
a. 100% xylene for 1 minute, 
b. Fresh 100% xylene for 1 minute, 
c. 1:1 ethanol:xylene for 3 minutes, 
d. 100% ethanol for 3 minutes, 
e. 90% ethanol for 3 minutes, 
f. 70% ethanol for 3 minutes, 
g. 50% ethanol for 3 minutes, and 
h. Distilled water for 3 minutes. 
5. Staining: Slides were placed in the following solutions:  
a. Haematoxylin stain (mayers) for 4 minutes 
b. Distilled water for 30 seconds 
c. Acid alcohol (0.5 or 1%) for 30 seconds 
d. Distilled water for 30 seconds 
e. Scott‘s Blue for 30 seconds 
f. Distilled water for 30 seconds 
g. Eosin stain for 2 minutes 
h. Distilled water for 30 seconds 
6. Dehydrating: Stained slides were then placed in the following solutions:  
a. 50% ethanol for 3 minutes 
b. 70% ethanol for 3 minutes 
c. 90% ethanol for 3 minutes 
d. 100 % ethanol for 3 minutes 
e. Fresh 100% xylene for 1 minute 
7. Visualisation: Slides were allowed to dry and then visualised under a microscope 
(Infinity 2, Olympus, Tokyo).  Photographs were taken using an Infinity 2 miscroscope 
camera (Olympus, Japan) attached to a computer using Infinity Capture software 
(version 5.0.2 Lumenera Corporation, Canada). 
All histology solutions and chemicals were Fronine Pathology products obtained from Thermo 
Fisher Scientific, Taren Point, Australia.  
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2.5 STATISTICAL ANALYSIS 
Various statistical tests were used where appropriate and details of analysis are stated in the 
relevant sections of each Chapter.   Statistical differences were considered significant at p<0.05. 
All graphical analyses used in this thesis were performed using GraphPad Prism (Version 5.04 
for Windows, Graph Pad Software, San Diego, USA) and all statistical analyses were performed 
using GraphPad InStat (version 3.06 for Windows, GraphPad Software, San Diego, USA).  
Normality of distribution was determined using InStat during statistical analyses and parametric 
or non-parametric methods used according to whether results were normally distributed or not.  
In the cases where the n-value was too small for InStat to accurately measure distribution of the 
data, the more powerful program IBM
® 
SPSS
®
 Statistics (version 19, SPSS Inc., an IBM 
Company) was used to test the normality of distribution. The test used in each analysis is stated 
in figure legends.  
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CHAPTER 3: Effects of 
Cyclophosphamide, Ifosfamide, 
Acrolein or Chloroacetaldehyde on 
Cultured Human Urothelial Cells 
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3.1 INTRODUCTION  
Urothelial Function  
As discussed in Chapter 1, the urothelium is important for normal function of the bladder.  Firstly, 
it provides a barrier protecting the bladder from toxins, pH and bacteria present in the urine.  It 
also has a complex role in sensing and releasing various mediators which may regulate 
detrusor contraction (Hawthorn et al., 2000) and mechanosensation (Birder, 2010).  The 
urothelium responds to bladder filling by releasing chemical mediators such as ATP, 
acetylcholine (ACh), prostaglandin E2 (PGE2) and cytokines to communicate with underlying 
cells such as sensory nerves, interstitial cells and smooth muscle (Birder et al., 2010b). 
Disruption of these mechanisms are associated with bladder dysfunction (Kumar et al., 2010, 
Chen et al., 2003, Sun and Chai, 2006, Sun et al., 2001).    
CPO & IFO  
CPO and IFO are chemotherapeutics commonly used to treat various cancers and autoimmune 
conditions and cause urotoxic side effects such as bladder haemorrhage, pain, urgency and 
frequency.  CPO and IFO are pro-drugs that undergo activation in the liver producing their 
active forms as well as various metabolites including acrolein and chloroacetaldehyde (Furlanut 
and Franceschi, 2003, de Jonge et al., 2005).  Acrolein is excreted in the urine and as a result 
comes into direct contact with the urothelium potentially altering bladder function or 
compromising the urothelial barrier allowing toxins to pass into the bladder wall (Al-Rawithi et al., 
1998, Brock et al., 1979).  However chloroacetaldehyde (CAA) is also excreted in the urine 
(Shaw et al., 1983) and although it has been linked to the neuro-, cardio- and nephro-toxicity of 
these drugs (Goren et al., 1986, Sladek, 1988, Joqueviel et al., 1997), its possible contribution 
to uro-toxicity has been ignored.  
It has been suggested that the main mechanism by which acrolein causes bladder damage is 
through the production of reactive oxygen species (ROS) and nitric oxide (NO), depleting 
intracellular gluathione (GSH) and then causing oxidative damage (Korkmaz et al., 2007) and 
leading to cell death by apoptosis or necrosis (Beauchamp et al., 1985, Kehrer and Biswal, 
2000, Korkmaz et al., 2007).  CAA toxicity has been suggested to occur by similar mechanisms 
including depletion of cellular GSH, NAD and ATP, disturbed Ca
2+
 signalling, and lipid 
peroxidation, potentially leading to cell necrosis or apoptosis and death (Sood and O'Brien, 
1993, Schwerdt et al., 2006, Nissim et al., 2006).  Furthermore, these metabolites would be 
present in urine together and their combined effects are yet to be investigated in the bladder. 
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Cell Death Mechanisms 
Programmed cell death can occur by apoptosis, autophagy or necrosis (Galluzzi et al., 2012). 
Apoptosis is an important homeostatic process that allows removal of unwanted cells during 
development, homeostasis and disease (Favaloro et al., 2012).  Apoptotic cell death is 
characterised by nuclear and cytoplasmic condensation, cell membrane blebbing resulting in 
the release of small membrane-enclosed particles that are rapidly phagocytosed.  There are two 
pathways that can lead to apoptosis in a cell including extrinsic and intrinsic apoptosis.  
Extrinsic apoptosis is initiated by extracellular molecules binding to trans-membrane death 
receptors (Favaloro et al., 2012).  Upon ligand binding, death receptors undergo conformational 
changes leading to the assembly of a protein complex (Death Initiation Signalling Complex) that 
leads to activation of the caspase cascade.  The intrinsic apoptotic pathway is activated in 
response to intracellular stress such as DNA damage and oxidative stress (Favaloro et al., 
2012).  These stressors converge on the mitochondria and influence mitochondrial membrane 
potential leading to cessation of ATP production and release of various proteins that result in 
activation of the caspase cascade. Accordingly, caspases are essential in the execution of 
apoptosis and in particular caspase-3 is an early indicator of cell death by apoptosis (Porter and 
Janicke, 1999).   
Necrosis is different from apoptosis in that it involves mitochondrial swelling and plasma 
membrane rupture.  Necrosis was considered an accidental cell death mechanism caused by 
cell trauma however, recent work has shown that necrosis can occur in a regulated manner 
(Galluzzi et al., 2012).  Cell stress, such as DNA damage, excitotoxins and binding of death 
receptors can trigger necrosis.  Necrosis does not always exhibit the same features but 
generally starts with clumping of chromatin and swelling of organelles, followed by swelling of 
the cell, and the rupture of nuclei, mitochondria, and the plasma membrane (Searle et al., 1982).  
Cells also tend to develop increased cytosolic Ca
2+
, increased ROS and a depletion of ATP 
during necrosis (Golstein and Kroemer, 2007). 
Autophagy is a process of intracellular degradation that occurs at basal levels in virtually all 
cells, performing repair and stress response functions (Glick et al., 2010).  It balances energy 
sources in the cell during times of stress and can remove misfolded proteins, damaged cell 
organelles and pathogens.  Organelles and proteins are sequestered into autophagic vesicles 
that then fuse with lysosomes and are degraded thereby preventing accumulation of damaged 
components or recycling unnecessary parts to maintain energy homeostasis.  Autophagy is 
generally thought of as a survival mechanism given its housekeeping role in the cell as well as 
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its ability to protect against genome instability and necrosis, however deregulation of autophagy 
has been linked to non-apoptotic cell death (Glick et al., 2010).  The activity of caspase-3 and 
autophagy were measured in this study to investigate the effects of acrolein and CAA on cell 
death pathways.  
Inflammation in the bladder  
Painful bladder syndrome (PBS) (also interstitial cystitis or bladder pain syndrome) is a disease 
with very similar urinary symptoms to CPO/IFO urotoxicity such as increased urinary frequency, 
urgency and suprapubic pain (Parsons, 2007).  The cause of PBS is still unknown however 
evidence suggests that afferent sensitisation as a result of bladder inflammation, production of 
inflammatory cytokines/chemokines and urothelial dysfunction is involved in the development of 
symptoms (Amaravadi et al., 2011, Erickson et al., 2002, Keay, 2008).   Inflammation has been 
shown in biopsies in many patients diagnosed with PBS (Erickson et al., 2008, Wyndaele et al., 
2009).  Furthermore, PBS patients have increased cytokine and chemokines in their urine 
including IL-2, IL-6, IL-8 and TNF-α (Erickson et al., 2002, Keay, 2008, Ogawa et al., 2010, 
Peters et al., 1999).   
Inflammation is associated with the release of irritant chemicals or inflammatory mediators from 
the urothelium or afferent nerves, such as ATP (Burnstock, 2013, Smith et al., 2005), PGE2  
(Maggi, 1990, Maggi, 1992) and neurotrophic factors such as NGF (Dmitrieva and McMahon, 
1996, Ochodnicky et al., 2011), that can activate or sensitise afferent nerves.   Bladder 
inflammation has been reported in response to intravesical instillation of various toxic 
substances including hydrogen peroxide and protamine sulphate which induce bladder 
overactivity and dysfunction (Homan et al., 2013, Lv et al., 2013).  Accordingly, it is possible that 
CPO and IFO induced cystitis involves a similar inflammatory response and the question 
remains as to whether acrolein and/or CAA contributes to this mechanism.   
Effects of CPO & IFO on the Urothelium  
Within 24 hours of treatment with CPO, the urothelium suffers widespread destruction by 
necrosis and apoptosis of the urothelial cells (Lee et al., 2014). It is thought that acrolein is to 
blame for the damaging effects of CPO and IFO.  In support of this, acrolein (2µM) has been 
shown to reduce proliferation of cultured rat urothelial cells by almost 60% after 24 hours 
(Nirmal et al., 2014). However, to my knowledge, these effects have not been confirmed in 
human urothelial cells.  Furthermore, no studies have looked at whether CAA causes urothelial 
cell damage.   
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One study suggests that reduction of uroplakin expression is a contributing factor to the damage 
caused by CPO and IFO (Kyung et al., 2011).  In bladders from rats treated with CPO, the level 
of all uroplakin mRNA and the protein expression of UP II and IIIa were maximally suppressed 
within 12 hours and partial and complete recoveries were seen at 24 and 72 hours post 
administration respectively.  
Changes in mediator release from the urothelium have been reported in various painful or 
overactive bladder conditions.  Specifically, stretch-induced ATP release has been reported in 
tissue samples from patients with PBS (Chen et al., 2003, Sun and Chai, 2006, Sun et al., 2001) 
and bladder overactivity (Kumar et al., 2010).   Rats treated with CPO have also demonstrated 
increased urothelial ATP release in response to hypo-osmotic stimulation (Smith et al., 2005).  
Any changes in ACh release are yet to be assessed.  
Furthermore, several studies in rats and mice have found that systemic treatment with CPO, 
IFO or intravesicular treatment with acrolein induces COX-2 expression in urothelium within 
12-24 hours of treatment (Macedo et al., 2008b, Macedo et al., 2008a, Wang et al., 2008b, 
Macedo et al., 2011).  One study found that the plasma PGE2 concentration was increased after 
administration of IFO in rats and that co-administration of a COX-2 inhibitor had a protective 
effect against IFO induced cystitis (Macedo et al., 2011).  Therefore, it appears that COX-2 and 
PGE2 may also contribute to the acrolein induced bladder inflammation.   
Protection of the Urothelium  
As discussed previously, mesna is commonly used in combination with CPO or IFO to inactivate 
acrolein and prevent it from damaging the bladder (Stofer-Vogel et al., 1993).  However, several 
studies have found that despite the clinical use of mesna, a significant percentage of patients 
treated with CPO or IFO are still likely to suffer from uro-toxic side effects of these drugs (Lima 
et al., 2007, Shepherd et al., 1991, Sakurai et al., 1986).  Accordingly, alternative or additional 
methods of protecting the bladder from CPO and IFO toxicity are required.  
The mechanism of toxicity of acrolein and CAA is via the production of ROS and NO leading to 
GSH depletion and oxidative damage. In addition, both molecules have the ability to react with 
proteins, lipids and potentially DNA causing direct damage themselves.   Accordingly, the use of 
antioxidants or GSH precursors has been suggested as a logical method of protecting the 
bladder from oxidative damage after GSH depletion.   Numerous different agents have been 
tested for protective effects against CPO induced cystitis.  Some promising results were 
demonstrated using flavanoid antioxidants either alone or in combination with mesna (Ozcan et 
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al., 2005, Sadir et al., 2007).  The antioxidant and GSH precursor N-acetylcysteine (NAC) has 
also shown promising results protecting mice urothelial cells from genotoxic damage due to 
CPO treatment (Gurbuz et al., 2009). In addition, NAC has also been shown to protect Chinese 
hamster ovary cells from apoptosis due to acrolein (Tanel and Averill-Bates, 2007).  Therefore, 
NAC may protect urothelial cells from functional changes due to CPO and IFO toxicity and 
should be further investigated in human tissues.  A common nutritional antioxidant, vitamin C, 
has received little attention in relation to preventing CPO or IFO induced cystitis.  Given the 
success of antioxidants in protecting the bladder and the relative safety and availability of 
vitamin C, it also warrants further investigation.  
Evaluation of Urothelial Function  
Urothelial cell culture provides an invaluable in vitro model for investigating biological processes 
at the cellular level.  Two commonly used human urothelial cell lines include the RT4 and T24 
cells.  The RT4 cell line is derived from a non-malignant transitional cell papilloma of human 
urinary bladder, demonstrating growth and motility characteristics of normal epithelial cells 
(Rigby and Franks, 1970, Kabaso et al., 2011).  Whereas, the T24 cell line is derived from a 
transitional cell carcinoma of human urinary bladder, showing malignant behaviour including 
spreading and separating during cell motility (Bubenik et al., 1973, Kabaso et al., 2011).  RT4 
cells have similar size and shape and form tight connections between cells while T24 cells grow 
less uniformly with varied size and shape and tend to grow one on top of another (Kabaso et al., 
2011).  The RT4 cell line expressed all four uroplakin transcripts, whereas less differentiated 
cell lines lose their uroplakin expression (Lobban et al., 1998) with expression in T24s being 
undetectable (Huang et al., 2007).    
RT4 cells have been shown to release ATP during basal (unstimulated) conditions with release 
increasing during hypotonic stimulation (Mansfield and Hughes, 2014, Kang et al., 2013, 
McDermott et al., 2012).  The RT4 cells have also been shown to release ACh and PGE2 in 
basal and hypotonic conditions (McDermott et al., 2012, Kang et al., 2013).  Accordingly, the 
RT4 cells appear to be a good model for studying the function of normal urothelial cells.  No 
studies have measured release of mediators from T24 cells however, they may also be useful 
for investigations into urothelial function and whether the loss of normal urothelial interactions 
affects function.  
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Aims 
The aim of the present study was to investigate the urothelial cell viability and function after 
treatment with CPO, IFO, acrolein or CAA. Specific aims were:  
 To determine the effect of acrolein on viability of human urothelial cells; 
 To determine if CAA is toxic to human urothelial cells; 
 To assess if ATP, ACh and PGE2 release from human urothelial cells is changed by 
acrolein or CAA treatment;  
 To investigate whether acrolein or CAA treatment affects autophagy or caspase-3 
activation; 
 To determine if vitamin C or N-acetylcysteine protect urothelial cells from damage by 
acrolein or CAA.     
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3.2 METHODS  
Cell Lines 
The established cell lines RT4 and T24 were used to study urothelial function. The cell lines 
were obtained from the European Collection of Cell Cultures and stored in freeze medium 
containing DMSO (10%) in liquid nitrogen until required.  The cells were maintained in McCoy‘s 
5A culture medium (Sigma Aldrich, St. Louis, USA) containing L-glutamine, phenol red, 10% 
fetal bovine serum and 500 U/ml penicillin-streptomycin (Invitrogen™), as described previously 
(McDermott et al., 2012). All cultures were maintained at 37°C in a humidified atmosphere of 5% 
CO2 in air and passaged at approximately 90% confluence by detachment with 0.25% (w/v) 
trypsin for 2-4 minutes. Cells were routinely passaged every 3-4 days with a typical split of 1:4 
for RT4 and 1:8 for T24 cells respectively.  Figure 3.1 shows the different growth pattern of the 
RT4 (A) and T24 (B) cells.  
RT4 T24 
  
Figure 3.1: RT4 (A) and T24 (B) human urothelial cell lines at magnification of 40x. 
 
Compound Screening Concentrations 
The parent drugs CPO and IFO are not cytotoxic themselves and therefore were not expected 
to be directly implicated in the urotoxicity of CPO and IFO treatment (Furlanut and Franceschi, 
2003, de Jonge et al., 2005).  However, initial screening of the drugs was performed to ensure 
that this assumption was correct and that CPO and IFO are not damaging urothelial cells.  The 
toxic metabolites of CPO and IFO, acrolein and chloroacetaldehyde, were investigated for their 
effects on urothelial function. 
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As discussed previously, very little is known about the actual concentrations of acrolein and 
CAA appearing in the urine of patients treated with cyclophosphamide and ifosfamide.    The 
excretion of these drugs and their metabolites varies from patient to patient as well as between 
subsequent treatments within the same individual.  In addition, the initial level of hydration and 
the ongoing fluid intake of the patient are likely to lead to variable urine volumes and urine 
concentrations of the drugs and metabolites.  Accordingly, a range of concentrations are likely 
to be relevant in the urotoxicity of CPO and IFO.  Therefore, this study investigated a range of 
concentrations of CPO, IFO, acrolein and chloroacetaldehyde extrapolated from available urine 
and plasma concentration data discussed in Chapter 1.  The concentration range that was 
initially investigated for each substance was 10nM-100µM.  This range is consistent with 
previous studies which have tested concentrations of IFO, CPO, acrolein and CAA of 15-300µM 
in human proximal tubule cells (Schwerdt et al., 2006), 5-100µM of acrolein in human bronchial 
epithelial cells (Nardini et al., 2002) and 50-500µM of CAA and acrolein in human hepatocytes 
(Macallister et al., 2012).  Acrolein has also been instilled directly into bladders of mice at a 
concentration of 400µM in order to induce cystitis (Wang et al., 2008b).  Again, as outlined 
above, in most CPO and IFO treatment regimens, very little excretion of the parent drug and its 
metabolites is observed after 24 hours.  Therefore, drug treatments in this study used a single 
concentration over a 24 hour period.   
Experimental Setup and Procedures 
To prepare experiments with the RT4 and T24 cell lines, 24 or 96 well plates or T25 flasks were 
seeded with cells at a density determined during initial optimisation experiments, see Table 3.1.  
Cell number and cell viability was assessed by trypan blue exclusion. The cells were then left 
for 24 hours to attach before being treated with one of CPO, IFO, acrolein or 
chloroacetaldehyde for a further 24 hours. After treatment various tests were performed to 
determine changes in viability and function.   
Table 3.1 – Typical seeding densities used for experiments with RT4 and T24 cell lines 
Cell Line Seeding Density in 
96 well plates 
Seeding Density 
in 24 well plates 
Seeding Density 
in T25 Flasks 
Typical Split for 
Passaging in 
T75 Flasks 
RT4 1.35 x 10
4 
per well 2 x 10
5 
per well 1.5 x 10
6 
per flask 1:4 
T24 1.35 x 10
4 
per well 1 x 10
5 
per well 1 x 10
6 
per flask 1:8 
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Cell Viability Assay 
Resazurin (alamar blue) is a redox dye that can be used to measure cell viability (Gonzalez and 
Tarloff, 2001).  Resazurin can be reduced intracellularly by viable, metabolically active cells into 
resorufin and dihydroresorufin, with resorufin measurable flurometrically to indicate cell viability 
(excitation 530n; emission 590nm) (O'Brien et al., 2000). The fluorescence of resorufin 
increases proportionally to the number of cells present in the well and there was a significant 
positive correlation between live cell number and resorufin fluorescence (p<0.01) (Figure 3.2). 
After treatment in 96 well plates, cells were washed twice with phosphate buffered saline and 
incubated at 37°C for 1 hour (T24 cells) or 2 hours (RT4 cells) with fresh medium containing 
44µM resazurin.  The reduction of resazurin to resorufin by viable cells was measured using a 
Modulus Microplate Multimode Reader (Turner Biosystems, California, USA).  A cell free control 
was also included to account for any background fluorescence.  
 
Figure 3.2: Resazurin in a 96 well plate (A) cell number increasing from left to right and Pearson correlation 
analysis of the relationship between live cell number and resorufin fluorescence (B).  
ROS Production Assay 
The probe 2′,7′-Dichlorofluorescein diacetate (DCF-DA) can readily cross the cell membrane 
where reactive oxygen species can oxidise it, removing the acetate groups and producing a 
fluorescent product (DCF).  This fluorescent product can then be measured using spectrometry 
to quantify ROS production.  
Again, after treatment in 96 well plates, cells were washed with phosphate buffered saline and 
incubated at 37°C, protected from light for 40 mins with fresh unsupplemented medium 
containing 10µM DCF-DA. Fluorescence of the oxidised dye (excitation 530nm; emission at 
590nm) was measured using a Modulus Microplate Multimode Reader (Turner Biosystems, 
California, USA) and normalised to the corresponding viability. 
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Caspase 
Caspase-3 activity was measured using a Caspase-3 Fluorescence Assay Kit (Cayman 
Chemicals, Michigan, USA [Cat #10009135). The kit uses a specific caspase-3 substrate (N-Ac-
DEVD-N‘-MC-R110) which produces a highly fluorescent product when cleaved by caspase-3.  
The fluorescence (excitation 485nm and emission 535nm) of the product was measured using a 
Modulus Microplate Multimode Reader (Turner Biosystems, California, USA).   
RT4 and T24 cells were seeded at 2x10
4
 and 1x10
4
 respectively in 96 well plates and incubated 
for 24 hours. Cells were then treated with acrolein (100µM), CAA (10µM) or the combination of 
acrolein (100nM) with CAA (10µM) for 24 hours.  The culture medium was removed and cells 
were washed with a buffer solution.  Next, the cells in each well were lysed to release the 
intracellular contents (including any caspase-3 enzyme) and the cell lysates were incubated 
with the caspase-3 substrate at 37°C, protected from light for 30 minutes.  Caspase-3 activity in 
cells in the absence and presence of 300µM NAC was also investigated.  Caspase-3 activity 
was normalised to cell viability and represented as a percentage of control levels. 
Autophagy  
A Cyto-ID
®
 Autophagy Detection Kit (Enzo Life Sciences, New York, USA, Cat #ENZ-51031) 
was used to measure autophagic activity in cultured human urothelial cells.  The kit uses a 
novel dye that selectively labels autophagic vacuoles.  The dye is a cationic amphiphilic tracer 
that rapidly partitions into cells and exhibits bright fluorescence upon incorporation into 
pre-autophagosomes, autophagosomes, and autolysosomes.  Functional moieties on the dye 
are selective for autophagic vacuoles and prevent its accumulation within lysosomes.  Nuclear 
material was stained using Hoechst 33342 Nuclear Stain.    
RT4 and T24 cells were seeded at 2x10
4
 and 1x10
4
 respectively in 96 well plates and incubated 
for 24 hours. Cells were then treated with acrolein (100µM), CAA (10µM) or the combination of 
acrolein (100nM) with CAA (10µM) for 24 hours.  The culture medium was removed from the 
cells and they were washed gently with phosphate buffered saline.  Both the autophagic Cyto-ID 
stain and the nuclear Hoechst 33342 stain were added to culture medium without Phenol Red 
Indicator and supplemented with 5% FBS.  The culture medium containing the stains was 
applied to each well of cells and incubated at 37°C, protected from light for 30 minutes.  The 
culture medium was then removed and the cells gently washed twice with phosphate buffered 
saline before imaging.  An EVOS
®
 FL fluorescent miscroscope (Advanced Microscope Group, 
USA) with a standard FITC filter set was used to visualise the autophagic staining while a DAPI 
filter set was used to image the nuclear signal and the two images were overlayed. 
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Transmitter Release Assays – Optimisation  
Next, transmitter release by the human urothelial cells was investigated. After treatment in 24 
well plates the cells were incubated with normal Krebs bicarbonate solution and hypotonic 
Krebs bicarbonate solution and a sample of each solution collected and assayed for various 
mediators. Hypotonic Krebs can be used as an in vitro method for evoking mechanical stress 
similar to that seen with mechanical stretch or distension (Hamill and McBride, 1996, Birder et 
al., 2003).  In this way differences in both basal release and stimulated (stretch-induced) 
release of the transmitters/mediators could be measured. A range of time points was initially 
investigated to determine the optimum point for further studies.   Firstly, 150µl of normal Krebs 
solution (recipe on page 53) was applied to a well containing cells for 5, 10 or 15 minutes 
followed by the same amount of hypotonic Krebs solution (50% normal Na
+
 osmolality) for the 
same amount of time.  As shown in Figure 3.3 the measureable level of mediators in the 
samples generally increased with the incubation time.  This time course had previously been 
performed in our lab in RT4 cells (Kang et al., 2013) but not in T24 cells.  The 15 minute sample 
had greater levels of mediators present as well as a greater difference between basal and 
stimulated levels for RT4 cells and ATP in T24 cells.  Accordingly, for ease of comparison the 
15 minute time point was chosen for further mediator release studies.  The number and viability 
of the cells in each well was determined both before and after the Krebs mediator collection 
procedure to ensure that the process was not killing or detaching cells (Figure 3.4).  The 
number of cells before and after the Krebs mediator collection process did not significantly differ 
from each other (p>0.05, n=3 performed in quadruplicate) and the viability of the remaining cells 
was greater than 97%.  
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Figure 3.3: Comparison of basal and stimulated ACh and ATP release from RT4 (n=5) (A & C respectively) and 
T24 (n=6) (B & D respectively) cell lines (mean ±SEM). Data analysed by unpaired two-tailed t-test *p<0.05, 
**p<0.01, ***p<0.001.  The RT4 time course data is from previous work (Kang et al., 2013). 
 
 
Figure 3.4: Resorufin fluorescence before and after incubation with normal and hypotonic Krebs solution for 15 
minutes each.  
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Collection of Samples for Mediator Analysis After Treatment  
After treatment, each well was washed twice with Krebs solution before 150µl of normal Krebs 
solution was applied to the cells for 15 minutes followed by the same amount of hypotonic 
Krebs solution for the same amount of time.  The samples of Krebs solution were collected and 
frozen at -20°C for later analysis using commercially available assay kits to measure the levels 
of ATP, ACh, and PGE2. Samples were frozen for a maximum of three weeks before use.  
Detailed protocols for the assays can be found in Chapter 2.  Cell viability was determined for 
each well after the mediator collection procedure and mediator levels were normalised to the 
corresponding viability.   In the event that mediator concentrations were calculated from a 
standard curve only standard curves with an r
2
 value of ≥0.99 were used.  A lactate 
dehydrogenase assay was also performed to check that mediators were not simply leaking out 
of the cells due to increased membrane permeability after treatment.    
Lactate Dehydrogenase (LDH) 
The presence of LDH in samples from cultured urothelial cells was measured using a LDH 
Cytotoxicity Assay Kit (Cayman, Cat #10008882).  The kit uses the action of LDH released into 
the sample solution by cultured urothelial cells to reduce NAD
+
 to NADH and H
+
 by oxidation of 
lactate to pyruvate.  Diaphorase then uses the newly formed NADH and H
+
 to reduce 
tetrazolium salt producing a highly-coloured product (formazan).   
RT4 and T24 cells were seeded at 2 x 10
5
 and 1 x 10
5
 respectively per well in a 24 well plate 
and left to attach overnight.  Cells were then treated with acrolein (100µM) or CAA (10µM) for 
24 hours.  The mediator release protocol was performed as outlined above and the samples 
were used in the LDH kit.  The normal and hypotonic krebs samples from each well were 
combined with a reaction solution containing NAD
+
, lactate, diaphorase and tetrazolium salt and 
incubated at room temperature on an orbital shaker, protected from light for 30 minutes.  
Absorbance of formazan was measured using a Modulus Microplate Multimode Reader at 
490nm and LDH levels in treated samples were represented as a percentage of control levels.  
 Cytokine Release Assays 
The presence of inflammatory cytokines (interleukin (IL)-8, IL-1β, IL-6, IL-10, IL-12p70 and 
tumour necrosis factor (TNF) in urothelial cell incubation medium was assayed using a 
Cytometric Bead Array Human Inflammatory Cytokine Kit (BD Biosciences) according to the 
manufacturer‘s instructions. The kit uses beads, each conjugated with a specific antibody to one 
of the cytokines.  A detection agent comprised of a mixture of phycerythrin-conjugated 
antibodies provides a fluorescent signal in proportion to the amount of bound analyte.  The 
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beads, detection reagent and recognised cytokine form sandwich complexes (capture bead + 
cytokine + detection reagent) which can be measured using flow cytometry to identify particles 
with fluorescence characteristic of both the bead and the detector.  
RT4 and T24 cells were seeded at 1.5 x 10
6
 and 1 x 10
6
 cells respectively in 3ml in T25 culture 
flasks and incubated for 24 hours.  Cell free incubation medium was collected from T25 culture 
flasks following 24 hour treatment with either of the parent drugs or metabolites.  Standard and 
sample fluorescence were measured on a BD FACSVerse flow cytometer. Concentrations of 
inflammatory cytokines were normalised to controls using corresponding cell numbers 
determined by trypan blue-exclusion.    
 
Figure 3.5: Representative standard curve of mean fluorescence intensity to known concentrations of cytokines.   
 
Statistical Analysis 
Results were expressed as mean ± standard error of the mean (SEM).  Data were analysed 
using a Student t-test or one-way ANOVA with Dunnett or Tukey multiple comparisons test as 
appropriate, using Graphpad InStat (version 3.06) software (SanDiego, CA). Significance levels 
were defined as p<0.05 (*), p<0.01 (**) and p<0.001 (***).   
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3.3 RESULTS  
Effects of CPO, IFO, Acrolein and CAA on Cell Viability and ROS 
Formation  
The toxicity of CPO, IFO and the metabolites acrolein and CAA was first assessed in terms of 
their ability to induce changes in urothelial cell viability and ROS formation.  Twenty four hour 
exposure of either cell line to the parent compounds CPO or IFO at concentrations up to 100µM 
did not affect cell viability, except for 100µM CPO in T24 cells which reduced viability by 10% 
(Figure 3.6-A & B).  Neither CPO nor IFO affected ROS formation at concentrations up to 
100µM in either cell line (Figure 3.6-C & D).    
 
Figure 3.6: Effect of 24 hour cyclophosphamide (CPO) and ifosfamide (IFO) treatment on cell viability (A & B) 
and ROS production (C & D) in RT4 and T24 cells.  Data are shown as a percentage of control (mean ± SEM, n=6) 
and analysed by 1-way ANOVA with Dunnett post-test (**p<0.01 vs CPO control).   
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On RT4 cells CAA was significantly more toxic than acrolein and the mean IC50 value [10(8-
14)µM] was significantly lower (p<0.0001) than that for acrolein [67(47-95)µM] (Figure 3.7-A).  
Similarly on T24 cells, CAA was significantly (p<0.0001) more toxic than acrolein [IC50 of CAA 
4(3-5)µM compared with 15(12-19)µM for acrolein] (Figure 3.7-B).  
ROS formation after acrolein or CAA treatment tended to increase as cell viability decreased.  
Specifically, acrolein (100µM) caused a 2.6-fold increase in basal ROS levels while CAA 
(100µM) resulted in a 5-fold increase in ROS production (p<0.01) (Figure 3.7-C).  T24 cell 
viability was too low after 100μM acrolein or CAA treatment to successfully measure ROS levels, 
however at 10µM, acrolein and CAA caused a 30% and 3-fold increase in ROS levels 
respectively (p<0.01) (Figure 3.7-D). Cell viability and ROS production values can be found in 
Table 3.2.   
 
Figure 3.7: Effect of 24 hour acrolein or chloroacetaldehyde (CAA) treatment on cell viability (A & B) and ROS 
production (C & D) in RT4 and T24 cells.  Data are shown as a percentage of control (mean ± SEM, n=6) and 
analysed by 1-way ANOVA with Dunnett post-test (*p<0.05, ** p<0.01, *** p<0.001, vs acrolein control, ##p<0.01, 
##p<0.001 vs CAA control). 
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These metabolites are present in the urine together, so possible interaction between acrolein 
and CAA was also investigated.  To determine whether the reported urinary concentration of 
acrolein (100nM) (Takamoto et al., 2004) was affecting the toxicity of CAA, the toxic CAA 
concentration of 10µM was selected.  The concentration of CAA (10µM) was chosen because it 
had a measurable effect on cells and therefore interaction with acrolein (100nM) could be more 
easily determined.  In addition, this concentration is likely to appear in the urine of patients 
(Goren et al., 1986). 
CAA (10µM) alone reduced cell viability in T24 cells to 37.8±1.5% of the control.  The 
combination of acrolein (100nM) and CAA (10µM) caused a significant reduction in cell viability 
in T24 cells to 35.6±1.5% of the control which was similar to the effect seen after CAA (10µM) 
alone (Figure 3.8-A).  However, in the RT4 cells, combined acrolein (100nM) and CAA (10µM) 
treatment reduced cell viability to 64.3±2.0% of control which was significantly greater than the 
viability after CAA (10µM) alone (50.4±2.9% of control) (p<0.05).   
ROS formation was also measured after treatment with the combination of acrolein (100nM) 
and CAA (10μM).  Again in T24 cells the increase in ROS production after treatment with the 
combination of metabolites was 219±6% of control, similar to that observed with CAA (10μM) 
alone (210±7%).  Whereas in RT4 cells ROS formation in the combination treated cells was 
145±5% of control, significantly lower than after CAA (10μM) alone (167±7%) (p<0.01) (Figure 
3.8-B).  
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Figure 3.8: Effect of 24 hour acrolein (100nM), chloroacetaldehyde (CAA)(10µM) or acrolein (100nM) combined 
with CAA (10µM) treatment on cell viability (A) or reactive oxygen species (ROS) (B) in T24 and RT4 cells. Data 
are shown as a percentage of control (mean ± SEM, n=6) and analysed by 1-way ANOVA with Tukey post-test. 
### p<0.001 vs control, ***p<0.001 vs acrolein (100nM), ^p<0.05 & ^^p<0.01 vs CAA (10µM). 
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Table 3.2: Cell Viability and ROS formation in RT4 & T24 cells after treatment with CPO, IFO, Acrolein or CAA or a Combination 
  CPO IFO Acrolein CAA Combination  
  100μM 100μM 10μM 100μM 10μM 100μM 100nM Acrolein + 10µM 
CAA 
Cell Viability 
after treatment 
(% of control) 
RT4 97.3±5.3 96.1±5.7 88.9±5.3 39.8±6.7** 50.4±2.9** 13.9±5.5** 64.3±2.0*** 
T24 89.3±2.9 111±5.6 68.4±4.6** 1.63±1.6** 37.8±1.5** 8.60±4.8** 35.6±1.5*** 
ROS 
Formation 
after treatment 
(% of control) 
RT4 87.6±7.2  91.6±6.5 102±5.8  264±47**  167±12** 509±120**  145±4.8*** 
T24 105±4 84.6±6.9 128±8.2** N/A  281±13.5** N/A 219±6.4*** 
*p<0.05, **p<0.01, ***p<0.001 vs control  
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Effect of Acrolein and CAA on Autophagy & Caspase-3 Activation 
Acrolein and CAA both cause urothelial cell death and the pathway by which this happens was 
investigated next. Staining of autophagic vesicles using the Cyto-ID
®
 Autophagy detection kit 
demonstrated that both RT4 and T24 cell lines have vesicles present in control baseline 
conditions as shown by the green fluorescence in Figure 3.9 and Figure 3.10 with the nucleus 
visualised by blue fluorescence.  In particular the RT4 cell line has particularly high baseline 
autophagic activity (Figure 3.9).  Treatment with acrolein (100µM) appears to slightly increase 
autophagic vesicles with staining appearing more intense and more diffuse within the cells.  
Treatment with CAA (10µM) had a greater effect than acrolein increasing autophagic vesicle 
formation with more intense staining appearing more tightly confined within the cells.  The 
combination of acrolein (100nM) and CAA (10µM) produced a similar staining result as CAA 
(10µM) treatment alone.   
In T24 cells, the baseline autophagy staining was much less than in the RT4 cells (Figure 3.10).  
Treatment with acrolein (100µM) had little effect on the appearance of autophagic vesicles, 
whereas CAA (10µM) treatment caused vesicle staining to increase and intensify (as shown by 
arrows in Figure 3.10-C).  Treatment with the combination of acrolein (100nM) and CAA (10µM) 
produced a similar staining result as CAA (10µM) treatment alone.   
Inhibition of autophagy with 3-Methyladenine (3MA) (5mM) caused decreased survival by 35±11% 
in untreated RT4 (p<0.05) and 23±3% in T24 cells (p<0.01).  Cell death induced by acrolein 
(100µM), CAA (10µM) or the combination of acrolein (100nM) with CAA (10µM) was not 
significantly affected by co-treatment with 3MA (5mM) however there was a slight trend towards 
further cell death (Figure 3.11).  
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Control Acrolein 100µM 
  
CAA 10µM Combination (Acrolein 100nM + CAA 10µM) 
  
Figure 3.9: Staining of RT4 cells for autophagic vacuoles in green and nucleus in blue in control (A), acrolein 
(100µM) (B), CAA (10µM) (C), or a combination of acrolein (100nM) with CAA (10µM) (D) treated cells.  Images 
are representative of 5 fields of view from n=3 experiments.   
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Control Acrolein 100µM 
  
CAA 10µM Combination (Acrolein 100nM + CAA 10µM) 
  
Figure 3.10: Staining of T24 cells for autophagic vesicles in green and nucleus in blue in Control and Acrolein, 
CAA or Combination treated cells.  Images are representative of 5 fields of view from n=3 experiments.   
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Figure 3.11: Effect of 3-Methyladenine (3MA) (5mM) on cell viability in untreated, acrolein (Acro) (100µM), CAA 
(10µM) or combination (Acrolein [100nM] +  CAA [10µM]) treated RT4 (A) and T24 (B) cells. Data are expressed 
as a percentage change in viability induced by 3MA compared to the viability of matched treatments in the 
absence of 3MA.  Mean ± SEM (≥3) are shown and analysed using unpaired t-test between a treatment condition 
in the presence and absence of 3MA (* p<0.05, ** p<0.01 vs absence of 3MA). 
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The activity of the apoptosis protease, caspase-3, was significantly enhanced by CAA (10µM) 
treatment in both RT4 and T24 cells (2.5- and 3.5-fold respectively, p<0.01) (Figure 3.12).  
Acrolein (100µM) increased caspase-3 in both cells lines although only significantly in T24 cells 
(by 2.5-fold, p<0.05). The combination of acrolein (100nM) and CAA (10µM) caused increased 
caspase-3 activity in both cell lines (by approximately 2.5-fold in both cell lines, p<0.05).  
 
Figure 3.12: Effect of acrolein (100µM), CAA (10µM) or combination (Acrolein [100nM] + CAA [10µM]) treatment 
on caspase-3 activity in RT4 (A) and T24 (B) cells. Data represented as mean ± SEM (≥3) and analysed using 1-
way ANOVA with Tukey post-test (* p<0.05, ** p<0.01 vs control). 
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Effects of CPO, IFO, Acrolein and CAA on Urothelial Mediator Release 
Given the importance of urothelial mediators in bladder function, the release of ATP, ACh and 
PGE2 from human urothelial cells was investigated.  Both RT4 and T24 cells released ATP in 
basal control conditions with concentrations at 15 minutes being 41.9±2.9nM and 97.9±6.9nM 
respectively (Figure 3.13-A).  The levels of ATP increased significantly in response to 15 
minute hypo-osmotic stimulation in both cell lines to 155±14nM and 141±12nM respectively 
(p<0.01).  Similarly, both cell lines released ACh in basal control conditions (Figure 3.13-B).  In 
RT4 cells hypo-osmotic stimulation caused ACh levels to increase significantly from 
0.99±0.10μM to 2.83±0.19μM (p<0.001). While in T24 cells, ACh levels were significantly less 
after hypotonic stimulation (1.99±0.14μM to 1.31±0.10μM) (p<0.001). Similar levels of PGE2 
were observed in basal and hypo-osmotic stretch conditions in RT4 cells (15.6±1.3 and 
21.8±3.3 pg/ml respectively) and T24 cells (42.7±7.0 and 34.6±6.2 pg/ml respectively) (Figure 
3.13-C).    
Twenty four hour exposure of either cell line to 0.01-100 µM cyclophosphamide or ifosfamide 
did not affect mediator release (Figure 3.14 and Figure 3.15 respectively).  Even at the highest 
concentration (100μM) tested basal and stimulated levels of ATP, ACh and PGE2 were similar 
to controls in both cell lines.   
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Figure 3.13: Basal and hypo-osmotically stimulated ATP (A), ACh (B) and PGE2 mediator levels in RT4 and T24 
cells.  Data represented as mean ± SEM (n≥22) and analysed by unpaired two-tailed t-test (** p<0.01, *** 
p<0.001,vs basal). 
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Figure 3.14: Effect of 24 hour cyclophosphamide (CPO) (10nM – 100μM) treatment on basal and hypo-
osmotically stimulated ATP, ACh and PGE2 levels in RT4 (A, B & C respectively) and T24 cells (D, E & F 
respectively). Data are shown as mean ± SEM (n≥3). 
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Figure 3.15: Effect of 24 hour ifosfamide (IFO) (10nM – 100μM) treatment on basal and hypo-osmotically 
stimulated ATP, ACh and PGE2 levels in RT4 (A, B & C respectively) and T24 cells (D, E & F respectively). Data 
are shown as mean ± SEM (n≥3). 
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At 10µM, acrolein had no effect on ATP, ACh and PGE2 levels in RT4 or T24 cells (Figure 3.17).  
However, CAA (10µM) in T24 cells, caused a significant increase in basal and stimulated ATP 
levels (3.5-fold increase in basal samples and 5-fold increase in stimulated samples [p<0.001]) 
(Figure 3.16-A).  Basal levels of ACh were significantly reduced while stimulated levels were 
significantly increased after treatment with 10µM chloroacetaldehyde (50% decrease in basal 
levels [p<0.05] and 2.5-fold increase in stimulated levels [p<0.01]) (Figure 3.16-B).  In both cell 
lines, basal PGE2 levels were increased significantly (approximately 2.5-fold increase in both 
cell lines [p<0.05]) after chloroacetaldehyde treatment (10µM) (Figure 3.16-C).  No significant 
change in ATP or ACh release was seen in RT4 cells after CAA (10μM) treatment (Figure 3.16- 
D, E & F).  
At 10-fold higher concentrations, acrolein (100µM) treatment of RT4 cells did lead to changes in 
mediator release.  Acrolein (100µM) caused a 5-fold increase in basal ATP levels (p<0.001), 
2.5-fold increase in stimulated ATP levels (p<0.05) and a 60% increase in stimulated 
acetylcholine levels (p<0.001) (Figure 3.17–A & B).  PGE2 levels in basal and stimulated 
samples from RT4 cells were also increased after treatment with 100µM acrolein (7.5- and 4-
fold respectively [p<0.001]) (Figure 3.17-C). No changes were observed in samples from T24 
cells treated with 100µM acrolein as cell survival was too low. 
Treatment of RT4 or T24 urothelial cells with acrolein (100nM) and CAA (10µM) in binary 
combination resulted in the same level of ATP, ACh and PGE2 release as treatment with CAA 
alone (Figure 3.18).  Specifically, in RT4 cells, the combination treatment did not change levels 
of ATP or ACh but did cause a 2.5-fold increase in basal PGE2 levels (p<0.05).   
In T24 cells, basal and stimulated PGE2 levels were also increased after combination treatment 
(5.4-fold and 3.3-fold respectively p<0.01). Basal and stimulated ATP levels were increased by 
2.2-fold (p<0.05) and 4.2-fold respectively (p<0.001) after combination treatment.  Basal ACh 
levels were reduced by 50% (p<0.05) while stimulated levels were increased 3-fold (p<0.05) 
after acrolein (100nM) and CAA (10µM) combined treatment.     
The absence of lactate dehydrogenase (LDH) in the extracellular fluid after treatment with 
acrolein or CAA and following the Krebs mediator collection procedure confirmed that mediators 
in the samples were released by the cells and were not simply leaking from damaged cells.  
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Figure 3.16: Effect of 24 hour chloroacetaldehyde (CAA) treatment on basal and hypo-osmotically stimulated 
ATP, ACh and PGE2 levels in RT4 (A, B & C respectively) and T24 cells (D, E & F respectively).  Data are shown 
as mean ± SEM (n=6) and analysed using 1-way ANOVA with Dunnett post-test or Students t-test. (* p<0.05, ** 
p<0.01, *** p<0.001, vs control). 
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Figure 3.17: Effect of 24 hour acrolein treatment on basal and hypo-osmotically stimulated ATP, ACh and PGE2 
levels in RT4 (A, B & C respectively) and T24 cells (D, E & F respectively). Data are shown as mean ± SEM (n=6) 
and analysed using 1-way ANOVA with Dunnett post-test (* p<0.05, ** p<0.01, *** p<0.001, vs control). 
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Figure 3.18: Effect of 24 hour acrolein (100nM), chloroacetaldehyde (CAA)(10µM) or acrolein (100nM) combined 
with CAA (10µM) treatment on basal and hypo-osmotically stimulated ATP, ACh and PGE2 levels in RT4 (A, B & 
C respectively) and T24 cells (D, E & F respectively). Data are shown as mean ± SEM (n≥6) and analysed using 
1-way ANOVA with Dunnett post-test (*p<0.05, **p<0.01, ***p<0.001, vs control & #p<0.05, ##p<0.01, ###p<0.001 
vs acrolein). 
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Effects of CPO, IFO, Acrolein and CAA on Inflammatory Cytokine Release 
To determine if inflammation plays a role in the urologic side effects of CPO and IFO, 
inflammatory cytokines were assessed.  Specifically, levels of IL-8, IL-1β, IL-6, IL-10, IL-12p70 
and TNF in extracellular medium were measured after 24 hour CPO (100µM), IFO (100µM), 
acrolein (100µM) or CAA (10µM) treatment of RT4 and T24 cells.  
Treatment of urothelial cells with CPO, IFO or CAA had no effect on release of the 
abovementioned cytokines whereas acrolein (100µM) treatment caused a number of them to 
increase.  Specifically, in RT4 cells, IL-8 levels increased by 20-fold (Figure 3.19-A). IL-8 levels 
were above the readable range in samples from T24 cells however, IL-6 levels were increased 
2.5-fold after acrolein (100µM) treatment (p<0.01).  Furthermore, IL-1β was undetected in T24 
control samples but was detected after treatment with acrolein (100µM) (p<0.001) (Figure 
3.19-B). 
 
Figure 3.19: Effect of 24 hour acrolein treatment on cytokine levels from RT4 (A) and T24 (B) cells. Data are 
shown as mean ± SEM (n=3) and analysed using 1-way ANOVA with Dunnett post-test (** p<0.01, *** p<0.001, vs 
control). 
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Effects of Vitamin C and N-acetylcysteine on Acrolein and CAA Induced 
Toxicity 
Protecting the bladder from the damaging effect of acrolein and CAA would greatly improve the 
quality of life for patients treated with CPO or IFO.  Accordingly, the potential protective effect of 
vitamin C and N-acetylcysteine (NAC) on acrolein and CAA induced urothelial cell damage was 
explored. Firstly, the effects of vitamin C and NAC alone were determined by treating the 
human urothelial cells with either substance (30µM – 3mM) for 24 hours and measuring cell 
viability and ROS production.  The purpose of this was to determine optimal, non-toxic 
concentrations to use in further experiments.  It was not relevant to the study to compare the 
effects of vitamin C and NAC alone.  In RT4 cells vitamin C (3mM) reduced cell survival by 
26.7±3.1% (p<0.001) and increased ROS production by 27.7±0.6% (p<0.001) (Figure 3.20-A & 
C).  In T24 cells vitamin C (1mM and 3mM) was even more toxic causing cell survival to 
decrease by 21.2±5.5% and 61.2±3.0% respectively (p<0.05) and ROS production to increase 
by 18.9±1.6% and 96.6±4.5% respectively (p<0.001) (Figure 3.20-B & D).  In RT4 cells NAC 
(1mM & 3mM) reduced cell survival by 14.6±3.5% and 25.9±5.3% respectively (p<0.01) with a 
subsequent increase in ROS production of 16.2±0.7% and 34.8±1.1% (p<0.001) (Figure 3.20-A 
& C). In T24 cells NAC (3mM) treatment had no effect on cell viability or ROS production.  
 
Figure 3.20: The effect of Vitamin C and N-acetylcysteine (NAC) on cell viability (A & B) and reactive oxygen 
species (ROS) production (C & D) in RT4 and T24 cells.  Data are shown as mean ± SEM (n=6) and analysed 
using 1-way ANOVA with Dunnett post-test (*p<0.05, ** p<0.01, *** p<0.001, vs Vitamin C control, ##p<0.01, 
##p<0.001 vs NAC control). 
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Both vitamin C and NAC are acidic and the pH of McCoy‘s 5A culture medium containing 
vitamin C and NAC is shown in Table 3.3.  The higher concentrations of 1mM and 3mM of 
vitamin C and NAC appeared to affect the pH of the culture medium.  Accordingly, the effect of 
the pH change on RT4 and T24 cells was investigated.  The reduction in pH had no effect on 
T24 cell survival or ROS production (Figure 3.21-B & D).  However at a pH of 7.6 and 7.2, RT4 
cell survival was reduced by 11.0±2.6% and 14.3±3.1% respectively (p<0.05) (Figure 3.21-A).  
ROS production was increased at a pH of 7.2 by 11.9±3.3% (p<0.01) (Figure 3.21-C).  Given 
the effects of vitamin C and NAC at high concentrations, further experiments were conducted 
using the optimal concentration of 300µM.  A concentration of 1mM was also used as it only had 
modest damaging effects.  
Table 3.3: pH of McCoys 5A Culture Medium containing various 
concentrations of vitamin C or N-acetylcysteine (NAC) 
Concentration Vitamin C  NAC  
0 7.90  7.90  
30uM  7.86  7.88  
100uM 7.83  7.85  
300uM  7.80  7.81  
1mM  7.65  7.68  
3mM  7.2  7.25  
 
Figure 3.21: Effect of pH on cell viability (A & B) and reactive oxygen species (ROS) production in RT4 and T24 
cells.  Data are shown as mean ± SEM (n=6) and analysed using 1-way ANOVA with Dunnett post-test (*p<0.05, 
** p<0.01, vs control). 
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Acrolein (100µM) reduced cell survival to 37.2±2.4% in RT4 cells and 6.1±1.1% in T24 cells.  
The reduction in cell survival due to acrolein (100µM) was attenuated in the presence of NAC 
(300µM) in both RT4 and T24 cells restoring cell viability to 83.7±5.2% and 84.9±6.6% of control 
respectively (p<0.01) (Figure 3.22–A & B). Vitamin C (300µM) had no protective effects against 
acrolein (100µM) induced cell death with cell viability being similar to that seen after acrolein 
alone (26.4±3.9% and 0.8±1.3% of control in RT4 and T24 cells respectively) (Figure 3.23-A & 
B).   
Similarly, CAA (10µM) reduced cell survival in RT4 cells to 62.0±2.8% of control and in T24 
cells to 34.7±2%. Again, cell survival was restored to that of an untreated control by NAC 
(300µM) in RT4 (99.5±4.2% of control) and T24 cells (98.7±5.0%)  (p<0.01) (Figure 3.22 – C & 
D).  CAA (10µM) toxicity was not prevented by vitamin C (300µM) with viability being 62.8±2.6% 
in RT4 cells and 37.0±2.7% in T24 cells (Figure 3.23 – C & D).   
 
 
Figure 3.22: Protective effect of N-acetylcysteine (NAC) on acrolein (100µM) and CAA (10µM) induced cell death 
in RT4 (A & C respectively) and T24 cells (B & D respectively).  Data represented as mean ± SEM (n=6) and 
analysed via 1-way ANOVA with Dunnett post test (*p<0.05, **p<0.01 vs absence of NAC).   
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Figure 3.23: Effect of Vitamin C on acrolein (100µM) and CAA (10µM) induced cell death in RT4 (A & C 
respectively) and T24 cells (B & D respectively).  Data represented as mean ± SEM (n=6) and analysed via 1-way 
ANOVA with Dunnett post-test (*p<0.05, **p<0.01 vs absence of Vitamin C).   
 
Acrolein (100µM) treatment caused basal ROS levels to increase to 305±8.9% of control levels 
in RT4 cells and to 1313±26.7% in T24 cells.  NAC (300µM) prevented the increase in ROS 
production induced by acrolein in both cell lines, reducing ROS levels down to 116±3.5% of 
control in RT4 cells and 115.3±1.5% in T24 cells  (p<0.01) (Figure 3.24 – A & B).  Vitamin C 
(300µM) did not protect cells from acrolein induced ROS formation and rather had a pro-oxidant 
effect causing greater ROS levels in RT4 (650±32.5% of control) and T24 cells (8993±201% of 
control) (p<0.01) (Figure 3.25 – A & B).  
Similarly, CAA increased ROS production to 242±16.6% and 272±4.7% of control in RT4 and 
T24 cells respectively.  Again, ROS production was restored to that of an untreated control by 
NAC (300µM) (103±5.8% in RT4 and 101±2.0% in T24 cells) (p<0.01) (Figure 3.24 – C & D).  
Whereas, vitamin C had no protective effects and again had a pro-oxidant effect leading to a 
further increase in ROS formation to 199±19.7% and 299±6.4% in RT4 and T24 cells 
respectively (Figure 3.25– C & D).   
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Figure 3.24: Protective effect of N-acetylcysteine (NAC) on acrolein (100µM) and CAA (10µM) induced reactive 
oxygen species (ROS) formation in RT4 (A & C respectively) and T24 cells (B & D respectively).Data 
represented as mean ± SEM (n=6) and analysed via 1-way ANOVA with Dunnett post test (**p<0.01 vs absence 
of NAC).   
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Figure 3.25: Effect of Vitamin C on acrolein (100µM) and CAA (10µM) induced reactive oxygen species (ROS) 
formation in RT4 (A & C respectively) and T24 cells (B & D respectively).Data represented as mean ± SEM (n=6) 
and analysed via 1-way ANOVA with Dunnett post test (**p<0.01 vs absence of Vitamin C).   
 
NAC also protected RT4 and T24 cells from the increases in caspase-3 activity induced by 
acrolein (100µM), CAA (10µM) and the combination of acrolein (100nM) and CAA (10µM).  
Co-treatment with NAC (300µM) protected urothelial cells from CAA (10µM), reducing 
caspase-3 levels from 269±37% down to 83.4±8.8% of control in RT4 cells and from 355±48% 
to 179±37% of control in T24 cells (p<0.05) (Figure 3.26). The acrolein (100µM) induced 
increase in caspase-3 activity in T24 cells was also prevented by NAC (300µM) with levels 
decreasing from 248±34% to 130±18% of control (p<0.05).  NAC (300µM) also protected 
urothelial cells from increased caspase-3 activity due to the combination of acrolein (100nM) 
with CAA (10µM) reducing levels from 251±39% to 106±16% of control in RT4 cells and from 
323±33% to 91.5±20% in T24 cells (p<0.05) (Figure 3.26).  
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Figure 3.26: Effect of N-acetylcysteine (NAC) (300µM) on the increase in Caspase-3 activity induced by acrolein 
(100µM), CAA (10µM) or combination (Acrolein [100nM] +  CAA [10µM]) treatment in RT4 (A) and T24 (B) cells. 
Data represented as mean ± SEM (≥3) and analysed using unpaired t-test between treatments in the presence 
and absence of NAC (* p<0.05, ** p<0.01 vs absence of NAC). 
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Effects of Vitamin C and N-acetylcysteine on Urothelial Mediator Release 
Changes After Acrolein and CAA Treatment 
NAC can protect human urothelial cells from cell death and ROS production induced by acrolein 
and CAA, but its protective effects on the functional changes to mediator release was 
considered next.  Acrolein (100µM) treatment in RT4 cells caused a significant increase in both 
basal and stimulated ATP, PGE2 and ACh levels. These changes in mediator release could be 
prevented by co-treatment with NAC (300µM) (Figure 3.27).  Specifically, the change in basal 
and stimulated ATP levels due to acrolein (100µM) (177±32nM and 409±95nM respectively 
[p<0.05]) was prevented by the addition of NAC (300µM) producing ATP levels (18.4±8.3nM 
and 70.6±20.6nM respectively [p<0.05]) comparable to that of the untreated control 
(24.9±6.1nM and 73.3±12.9nM respectively) (Figure 3.27-A).  Similarly, basal and stimulated 
ACh release was increased after acrolein (100µM) treatment (1.78±0.23µM and 6.56±0.61µM 
respectively [p<0.05]) and this could be prevented by NAC (300µM) returning levels 
(0.83±0.06µM and 3.43±0.58µM respectively [p<0.05]) close to that of the control (1.02±0.14µM 
and 2.69±0.24µM respectively) (Figure 3.27-B).  Basal and stimulated levels of PGE2 were also 
enhanced after acrolein (100µM) treatment (212±56pg/mL and 94±23pg/mL respectively 
[p<0.001]) but again this change could be prevented in the presence of NAC (300µM) again 
maintaining levels (17.4±4.1pg/mL and 30.0±5.9pg/mL respectively [p<0.05]) similar to control 
(17.3±1.8pg/mL and 21.2±3.9pg/ml respectively) (Figure 3.27-C).  
In T24 cells CAA (10µM) treatment caused a significant increase in both basal and stimulated 
ATP and PGE2 levels.  Basal levels of ACh were reduced while stimulated levels were 
increased after CAA (10µM) treatment. Co-treatment with NAC (300µM) could prevent these 
changes in mediator release (Figure 3.28).  Specifically, the change in basal and stimulated 
ATP levels due to CAA (10µM) (304±32nM and 596±94nM [p<0.01]) was prevented by the 
addition of NAC (300µM) producing ATP levels (107±13nM and 228±56nM [p<0.01]) 
comparable to that of the untreated control (124±20nM and 163±40nM) (Figure 3.28-A).  In the 
presence of CAA (10µM) and NAC (300µM) the lowered basal ACh levels (1.24±0.12µM 
[p<0.01]) were returned to 1.96±0.13µM which was similar to control levels (1.95±0.15µM).  
Similarly, the increased stimulated ACh levels (2.62±0.25µM) due to CAA (10µM) were also 
prevented by NAC (300µM) returning levels to 2.04±0.10µM, close to that of controls 
(1.33±0.12µM) (Figure 3.28-B).  Lastly, the increased basal and stimulated PGE2 levels seen 
after CAA (10µM) treatment (109±41pg/mL and 90±25pg/mL [p<0.05]) were prevented by NAC 
(300µM) treatment, with levels decreasing to 35.3±16.2pg/mL and 49.6±11.1pg/mL respectively, 
similar to control levels (41.8±6.8pg/mL and 38.9±6.0pg/mL) (Figure 3.28-C). 
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Figure 3.27: Effect of 24 hour acrolein (100µM) treatment in the absence and presence of N-acetylceysteine 
(NAC) (300µM & 1mM) on basal and hypo-osmotically stimulated ATP (A) acetylcholine (B) and PGE2 (C) levels 
in RT4 cells. Data are shown as mean ± SEM (n≥4) and analysed using 1-way ANOVA with Tukey post-test (* 
p<0.05, ** p<0.01, *** p<0.001, vs control, 
#
p<0.05, 
##
p<0.01, 
###
p<0.001, vs acrolein (100µM) alone). 
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Figure 3.28: Effect of 24 hour chloroacetaldehyde (CAA) (10µM) treatment in the absence and presence of N-
acetylceysteine (NAC) (300µM & 1mM) on basal and hypo-osmotically stimulated ATP (A) acetylcholine (B) and 
PGE2 (C) levels in T24 cells. Data are shown as mean ± SEM (n≥4) and analysed using 1-way ANOVA with Tukey 
post-test (* p<0.05, ** p<0.01, *** p<0.001, vs control, 
##
p<0.01, 
###
p<0.001, vs CAA(10µM) alone).  
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3.4 DISCUSSION 
The urothelium has been shown to be able to communicate with the detrusor, myofibroblasts 
and sensory nerves by releasing ATP, ACh and PGE2 among other mediators (Birder et al., 
2010b). Changes in these transmitters have been linked to bladder function diseases and 
sensory changes (Kumar et al., 2010, Chen et al., 2003, Sun and Chai, 2006, Sun et al., 2001).   
Cyclophosphamide and ifosfamide are known to cause acute haemorrhagic cystitis and lasting 
urotoxic symptoms such as increased frequency of micturition, feelings of incomplete emptying, 
pain and dysuria.  The results in this study demonstrated that high concentrations of both CPO 
and IFO did not affect the survival of human urothelial cells lines. This effect was expected and 
has been observed previously in similar studies.  For example, CPO or IFO did not cause cell 
damage or death of human proximal tubule cells at concentrations up to 300µM (Schwerdt et al., 
2006).  However, more importantly this study investigated urothelial cell function not just cell 
death and treatment with CPO or IFO had no effect on the release of mediators from the 
urothelial cells.  These results support the understanding that the parent drugs are not 
responsible for their urotoxicity and that it is the urotoxic metabolites that are responsible.  
However, almost exclusively the metabolite acrolein has been blamed for the bladder toxicity 
despite another toxic metabolite, CAA, being excreted in the urine. Therefore, the effect of both 
acrolein and CAA on human urothelial cells was investigated and compared.  
Is Acrolein or CAA Toxic to Human Urothelial Cells? 
The results in this study demonstrated that urothelial cell survival was reduced by acrolein and 
CAA, confirming that both metabolites are toxic to the urothelium.  Firstly, both acrolein and 
CAA were more toxic to T24 cells, affecting cell survival and ROS formation at concentrations 
10-fold lower, than in RT4 cells.  Given what we know about the characteristics of these two cell 
lines this is not surprising.  As discussed above and as shown in Figure 3.1 the RT4 cells form 
tight connections between the cells growing in a layer similar to normal urothelium, whereas the 
T24 cells do not interact with each other and grow separately (Kabaso et al., 2011).  The 
interaction between the urothelial cells is important for the barrier function of the urothelium and 
appears to protect cells from damage due to acrolein and CAA.  As a model, the RT4 cells 
would be a better representation of normal or healthy urothelium and how it reacts to a single 
dose of CPO or IFO.  After CPO treatment the urothelium undergoes an acute period of 
damage characterised by ulceration and erosion resulting in the loss of cell to cell interaction 
and epithelial barrier function (Auge et al., 2013, Juszczak et al., 2010).  The surviving cells 
then start proliferating rapidly in order to repair the denuded areas (Boudes et al., 2011, 
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Golubeva et al., 2014, Romih et al., 2001).  CPO and IFO are often given in a repeated dose 
regimen over days, weeks or months. Accordingly, the T24 cells may act as a model of the 
urothelial cells in a proliferative state with fewer cell to cell interactions than would be present 
during subsequent treatments, after initial injury has occurred.   
It appears that chloroacetaldehyde is more toxic to urothelial cells than acrolein, affecting cell 
viability at a 10-fold lower concentration (10µM/1µM in RT4/T24 cells) than acrolein 
(100µM/10µM in RT4/T24 cells).  Given that acrolein is largely blamed for the urotoxicity of CPO 
and IFO this result was unexpected.  However, similar results have been reported in human 
renal epithelial cells wherein CAA was more potent than acrolein inducing apoptosis at lower 
concentrations (15-75µM) compared to acrolein (150-300µM) after 24 hours (Schwerdt et al., 
2006).   
Acrolein had no significant effect at concentrations below 100µM in RT4 cells while modest 
toxicity was observed at 10µM in T24 cells.  Acrolein concentrations of 100nM have been 
reported in the urine of patients (Takamoto et al., 2004), so for toxicity to occur only at 
100-1000-fold higher concentrations was unexpected.  However, similar results have been seen 
in human bronchial epithelial cells where significant loss of cell viability was observed only at 
acrolein concentrations of 50µM or higher (Nardini et al., 2002).  Additionally, in human 
keratinocytes, acrolein caused cell death at 50µM (Takeuchi et al., 2001).  Therefore, this result 
appears to be comparable with other epithelial cells.    
The reduction in cell viability after treatment with acrolein was accompanied by an increase in 
ROS production.  This supports the theory that acrolein damage in the bladder is due to ROS 
production (Korkmaz et al., 2007).  Previous studies in bronchial epithelial cells have shown that 
acrolein (25µM) increases ROS production more than 5-fold after 6 hours exposure (Nardini et 
al., 2002).  While several studies in rodents have demonstrated that antioxidants prevent CPO 
or IFO induced bladder damage including flavanoids (Ozcan et al., 2005), α-tocopherol, β-
carotene and melatonin (Sadir et al., 2007) as well as GSH and amifostine (Batista et al., 2007).   
CAA treatment at 100µM in RT4s and 10µM in T24s also caused a significant increase in ROS 
production.  This not only supports that CAA and acrolein toxicity occurs by similar mechanisms 
but also supports a role for CAA in CPO and IFO induced urotoxicity.  ROS production is 
thought to be an important mechanism in programmed necrosis by inducing lipid peroxidation or 
altering the function of certain channel proteins (Moquin and Chan, 2010). However, ROS can 
also regulate apoptosis under certain conditions.  Whether ROS triggers apoptosis or necrosis 
appears to rely on factors such as the cellular ATP level and the concentration of ROS 
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produced (Hildeman et al., 1999, Miyoshi et al., 2006).  Apoptosis will be considered in more 
detail below.  
Interestingly, ROS production did not change after CAA treatment at lower concentrations 
(10µM in RT4s and 1µM in T24s) despite cell viability being significantly reduced.  This 
suggests that CAA toxicity at higher concentrations may involve ROS, similar to acrolein toxicity, 
while at lower concentrations may induce an alternative cell death pathway.  A study by 
Macallister et al., (2012) showed that depletion of the endogenous antioxidant GSH increased 
the toxicity of acrolein but not CAA in rat hepatocytes which also supports that CAA may cause 
cell death via a pathway other than ROS production.  Furthermore, cell survival after acrolein 
and CAA treatment was investigated in normoxic (95% O2) and hypoxic (1% O2) conditions. 
Although cell survival was improved in the absence of oxygen it was still significantly less than 
control suggesting both CAA and acrolein toxicity occurs via a pathway other than just ROS 
production (Macallister et al., 2012).   
However, both acrolein and CAA would be present in the urine together and given that both 
metabolites cause damage by similar mechanisms it is logical to assume there could be a 
greater effect when exposed to a combination.  Surprisingly, combining the likely urinary 
concentrations of acrolein (100nM) and CAA (10µM) was not more toxic than CAA treatment 
alone.  Rather, acrolein (100nM) appeared to have a slight antagonistic effect protecting against 
cell death and ROS formation when combined with CAA (10µM) in RT4 cells.  At lower 
concentrations acrolein can affect transcription factors such as nuclear factor-kappaB (NF-κB) 
(Horton et al., 1999) and activator protein-1 (AP-1) (Biswal et al., 2002, Korkmaz et al., 2007). 
Both of these transcription factors can cause cell injury or cell proliferation depending on the 
tissue.  In gut epithelial cells, inhibition of NF-κB activation caused cell death indicating a 
protective effect in these cells (Chen et al., 2003). In urothelial cells, induction of AP-1 
transactivation caused increased cell proliferation (Simeonova et al., 2000).  Therefore, it is 
possible that the lower concentration of acrolein (100nM), by way of transcription factors, may 
be protecting the cells from CAA induced death. 
Twenty four hour treatment with CAA (10µM) enhanced caspase-3 activity in both cell lines.  
However, acrolein (100µM) only significantly enhanced caspase-3 activity in the T24 cell line 
and to a lesser extent than CAA.  This again suggests that CAA is more toxic to urothelial cells, 
inducing greater levels of apoptosis at a 10-fold lower concentration.  Similar results have been 
reported in proximal tubule cells where caspase-3 activity was enhanced by CAA at much lower 
concentrations (15-75µM) than acrolein (150-300µM) after 24 hours (Schwerdt et al., 2006).  
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Caspase-3 activation is an important step in the apoptotic pathway and the enhanced levels 
seen after acrolein and CAA treatment supports the concept that these metabolites can cause 
urothelial cell death by apoptosis.  Recently it has also been shown that ROS formation can 
cause apoptosis in T24 urothelial cells via the intrinsic pathway (Jo et al., 2014, Wang et al., 
2013b).  Furthermore, acrolein has also been shown to cause ROS mediated apoptosis in male 
germ cells (He et al., 2014), while CPO induced apoptosis of human granulosa cells has also 
been shown to involve ROS formation (Tsai-Turton et al., 2007).  The results in this study 
support a similar mechanism of acrolein and CAA induced toxicity in human urothelial cells.  In 
particular, given that the ROS scavenger NAC prevented both the increase in ROS production 
and the increase in caspase-3 activity it appears possible that the two mechanisms are linked.  
The protective role of NAC is discussed in more detail below.  
The chemotherapeutic cisplatin has been shown to enhance apoptosis in T24 urothelial cells by 
increasing autophagic activity (Yang et al., 2013).  Therefore, autophagy was investigated next 
as a possible contributor to acrolein and CAA induced urothelial cell death.  Autophagy is 
important in cancer as it can prevent tumorigenesis or enable survival of established tumours 
(Amaravadi et al., 2011).  As the cells used in this study were derived from human bladder 
cancers it was first necessary to establish whether autophagy was important for the cell survival.  
Inhibition of autophagy with 3-MA significantly reduced RT4 and T24 cell viability indicating that 
autophagy contributes to survival and/or proliferation in these cell lines. Treatment with acrolein 
and CAA appeared to increase staining for autophagic vacuoles in both cell lines.  However, 
inhibiting autophagy during treatment with acrolein and CAA had no significant effect on cell 
survival and if anything caused a slight decrease in survival.  This suggests that autophagy 
does not contribute to acrolein or CAA toxicity.   
Does Acrolein or CAA Affect Urothelial Mediator Release?  
Acrolein and CAA reduce urothelial cell viability but how these compounds affect the function of 
urothelial cells may be more important in terms of side effects experienced by patients.  It is now 
well established that urothelial mediators can affect the function of the bladder.  Firstly, 
urothelial ATP plays a major role in bladder sensory mechanotransduction mechanisms.  
Urothelial cells release ATP in basal or normal conditions and additional ATP release can be 
stimulated in response to stretch (Kang et al., 2013, Sadananda et al., 2009).  Urothelial ATP 
acts on P2X3 and possibly P2X2 receptors on sensory nerves to transmit the sensation of 
bladder filling to the central nervous system (Burnstock, 2009).  ATP can have effects on both 
low and high threshold nerve fibres, altering the micturition reflex and pain sensations 
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respectively (Burnstock, 2009, Rong et al., 2002).  In this study acrolein and CAA increased 
both basal and stimulated ATP release from urothelial cells.  More ATP release from the 
urothelium may lead to increased sensory nerve activity and sensations of a greater volume 
than is actually present in the bladder.  Higher basal ATP levels in patients treated with 
cyclophosphamide or ifosfamide may be responsible for the feelings of incomplete emptying 
and the subsequent urinary frequency experienced by patients.  An increase in stretch induced 
ATP levels after cyclophosphamide or ifosfamide treatment may also contribute to more 
frequent urges to urinate and could be responsible for the reported painful sensations as the 
bladder fills or during voiding.   
It has also been reported that ATP increases the excitability of afferent nerves (Burnstock, 2011) 
and enhances its own release from urothelial cells (Birder, 2010), while cyclophosphamide 
treatment enhances and sensitises P2X receptor activity on nerves (Dang et al., 2008).  
Furthermore, a P2X3 and P2X2/3 antagonist has been shown to reduce the bladder 
hyperactivity of CPO treated rats (Ito et al., 2008).  Studies of a comparable disease in cats (i.e. 
feline interstitial cystitis) have demonstrated increased stretch-evoked release of ATP from the 
urothelium as well as changes in purinergic receptor profiles in urothelial cells (Birder et al., 
2003).  Therefore, the combined effect of more ATP and more sensitive purinergic receptors on 
afferent nerves is a likely explanation of the sensory changes seen after cyclophosphamide and 
ifosfamide treatment.  Both acrolein and CAA treatment resulted in an increase in ATP release 
from human urothelial cells which may contribute to the urotoxicity of cyclophosphamide and 
ifosfamide.  However, CAA was more toxic than acrolein, inducing the changes in ATP at a 10-
fold lower concentration (10μM) than acrolein potentially making CAA the more urotoxic 
metabolite.   
The urothelium has also been shown to release ACh in response to stretch which is thought to 
act on muscarinic receptors on the urothelium and sensory nerves (Yoshida et al., 2006). The 
activation of urothelial muscarinic receptors leads to release of several substances including 
ATP and PGE2 as well as UDIF (Hanna-Mitchell and Birder, 2008, Yokoyama et al., 2011). The 
affect of ACh on afferent nerves in the bladder is still unclear with both inhibitory and stimulatory 
effects reported (Daly et al., 2010, Iijima et al., 2007).  
Acrolein and CAA treatment both caused increased stretch-induced levels of ACh, however 
CAA was again the more potent metabolite inducing this change at a concentration 10-fold 
lower (10μM) than acrolein (100μM).  The increased ACh during stretch may be acting directly 
on the detrusor muscle or the afferent nerves to affect functional and sensory changes in the 
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bladder.  Enhanced filling pressure has been reported in animals treated with CPO or IFO 
(Okinami et al., 2014, Macedo et al., 2008a, Wang et al., 2008b, Kageyama et al., 2008) and a 
possible explanation of this is excess ACh released from the urothelium causing increased tone 
of the detrusor.  However, it is also possible that the change in ACh levels alters the release of 
other transmitters from the urothelium, indirectly contributing to the bladder changes after 
cyclophosphamide or ifosfamide treatment.  Specifically, more ACh may act in an autocrine 
manner causing greater ATP or PGE2 release which in turn could lead to enhanced detrusor 
tone or altered bladder sensations in patients.   
The urothelium expresses COX-1 and COX-2 enzymes which are responsible for the synthesis 
of prostanoids including PGE2 (de Jongh et al., 2009, de Jongh et al., 2007).  The COX-1 
enzyme is active in normal conditions and COX-2 is inducible suggesting that COX-1 is 
responsible for normal physiological synthesis of prostanoids and COX-2 is activated during 
inflammation (Tramontana et al., 2000).  PGE2 causes contraction of isolated human detrusor 
muscle (Andersson, 1993) however it appears that physiologically it is not directly involved in 
efferent control of the bladder and rather plays a role as a neuromodulator of afferent and 
efferent transmission (Andersson and Arner, 2004).  
Several studies in rats and mice have found that systemic treatment with cyclophosphamide, 
ifosfamide or intravesicular treatment with acrolein induces COX-2 expression in urothelium 
within 12-24 hours of treatment (Macedo et al., 2011, Macedo et al., 2008b, Klinger et al., 2007) 
and one study found that the plasma PGE2 concentration was increased after administration of 
ifosfamide (Macedo et al., 2011).  However, the present study is the first to investigate the effect 
of acrolein and CAA on the release of PGE2 from urothelial cells. Acrolein treatment (100µM) 
caused an increase in basal and stimulated PGE2 release from the urothelial cells.  CAA 
treatment (10µM) also caused significantly more basal PGE2 to be released from urothelial cells 
and while stimulated release was increased it was not significant.  PGE2 released from the 
urothelium is thought to activate or sensitise afferent nerves (de Groat and Yoshimura, 2001) 
and cause stimulation of the detrusor muscle increasing resting tone and spontaneous 
contractions (de Jongh et al., 2007).   
CPO treatment in rats reduced intercontraction interval by almost 40% and this was restored 
when co-treated with an EP4 receptor antagonists (Chuang et al., 2012).  Mice developed 
bladder pain-like nociceptive behaviour and bladder inflammation after CPO treatment and 
preadministration of an EP1 receptor antagonist prevented the pain symptoms (Miki et al., 
2011).  These studies support a role for PGE2 production in CPO and IFO induced detrusor 
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overactivity and pain symptoms.  PGE2 may be acting directly on detrusor or afferent nerves to 
cause urotoxic side effects in patients however, it may also be acting indirectly via the 
urothelium.  For example, PGE2, caused increased ATP release from the rat urothelium during 
both distended and non-distended conditions (Tanaka et al., 2011).   
Both acrolein and CAA caused higher basal and stimulated PGE2 levels in human urothelial 
cells.  The increased PGE2 may cause sensitisation of afferent nerves, increased ATP release 
from the urothelium and increase afferent activity as a result.  This mechanism may explain the 
altered micturition reflexes, hyperactivity and abnormal or painful sensations experienced by 
patients treated with cyclophosphamide or ifosfamide.  Again, CAA appeared to be more potent 
inducing changes in PGE2 at a concentration (10µM) 10-fold lower than acrolein (100nM).   
Does Acrolein or CAA Affect Urothelial Cytokine Release?  
Various cytokines are thought to be produced by urothelial cells during cyclophosphamide or 
ifosfamide induced cystitis leading to inflammation (Gomes et al., 1995, Ribeiro et al., 2002).  
Inflammation has been shown to increase bladder afferent neurone excitability and is thought to 
contribute to bladder overactivity and pain (Hayashi et al., 2009, Wyndaele and De Wachter, 
2003, Yoshimura et al., 2002).   
Malley and Vizzard (2002), found that CPO treatment in rats caused a significant increase in the 
cytokines interleukin (IL)-1β, IL-2, IL-4, IL-6, TNF-α and TNF-β and that their inhibition, 
particularly TNF-α and IL-1β, reduced the urothelial erosion, haemorrhage, oedema, and 
leukocyte migration observed.  In addition, cytokines IL-1β, IL-6 and IL-17 were increased in the 
urine of rats treated with CPO and reducing their synthesis caused improved urodynamic 
parameters including micturition frequency, basal pressure and residual urine volume (Nasrin et 
al., 2013).  Furthermore, intravesical instillation of acrolein in rats caused increased IL-6 
production, iNOS expression and bladder haemorrhage while co-treatment with an IL-6 
neutralising antibody reduced these effects (Wang et al., 2013a).  These studies support the 
idea that inflammatory cytokines play a role in bladder overactivity and pain, however very few 
describe potential the mechanisms involved.  It has been shown that cytokines can alter gap 
junctions in bladder smooth muscle and interstitial cells thereby affecting cell-to-cell 
communication (Heinrich et al., 2011). Furthermore, inflammation increased bladder afferent 
excitability in rats with cystitis by decreasing expression of Kv1.4 α-subunits of voltage-gated K
+
 
channels (Hayashi et al., 2009). 
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The present study in human urothelial cells also found an increase in interleukin (IL)-1β, IL-6 
and IL-8 after treatment with acrolein (100µM), while CAA (10µM) did not affect the levels of 
cytokines measured. The induction of IL-1β, IL-6 and IL-8 demonstrated here may therefore be 
another factor contributing to the bladder overactivity and pain experienced by patients following 
CPO or IFO treatment. 
Does N-acetylcysteine or Vitamin C Protect Urothelial Cells From Acrolein 
and CAA Toxicity? 
Acrolein and CAA are toxic to human urothelial cells and induce changes in urothelial mediator 
release that may explain or contribute to the symptoms experienced by patients after CPO or 
IFO treatment.  Accordingly, to protect the urothelial cells from damage due to acrolein or CAA 
would be advantageous to patients, potentially preventing or reducing the adverse effects and 
even improving treatment tolerability and outcomes.   
As discussed previously, acrolein toxicity can occur by its direct binding to proteins, DNA and 
GSH or indirectly via ROS production causing further GSH depletion, protein and DNA damage 
(Korkmaz et al., 2007) and CAA toxicity is thought to act via similar mechanisms (Sood and 
O'Brien, 1993).   
The antioxidant vitamin C did not protect human urothelial cells from cell death or ROS 
production due to acrolein or CAA.  This was unexpected given that vitamin C can react with 
acrolein through Michael addition (Zhu et al., 2011) and protects human bronchial epithelial 
cells from apoptosis due to acrolein (Nardini et al., 2002).  However, a study in rats treated with 
CPO showed that leukocyte infiltration and oedema was only partially protected by oral 
administration of vitamin C while bladder haemorrhage was not prevented (Farshid et al., 2013).  
Furthermore, vitamin C was unable to protect human hepatocytes from acrolein or CAA toxicity 
and showed pro-oxidant effects at concentrations above 300µM (Macallister et al., 2012).  In 
this study vitamin C also caused pro-oxidant effects at higher concentrations (300µM & 1mM).  
The ability of high concentrations of vitamin C to cause cell death has been described 
previously and its toxicity is thought to involve increased H2O2 production (reviewed by  (Ohno 
et al., 2009).  Interestingly, the pro-oxidant effects of vitamin C appeared greater in combination 
with acrolein with milder effects seen in combination with CAA.  This suggests a possible 
interaction between vitamin c and acrolein.  However, it is thought that H2O2 detoxicification in 
response to high dose vitamin C is performed by glutathione peroxidise using GSH in the 
reaction.  Both acrolein and CAA are thought to deplete GSH due to direct binding or via 
production of reactive oxygen species and therefore should react similarly to increased 
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oxidative stress due to vitamin C.  However, the cell viability after acrolein was much lower than 
that after CAA and therefore it is possible that the cells had greater GSH depletion and were 
more susceptible to the toxicity of vitamin C.  Nonetheless, it appears that vitamin C may not be 
useful in protecting the urothelium from damage due to acrolein and CAA. Rather, the results in 
this study support a pro-oxidant role for vitamin C in urothelial cells.   
NAC is an amine-protected version of cysteine.  In the human body NAC is rapidly hydrolysed 
back to cysteine, which is the rate-limiting substrate for GSH synthesis (Sen, 2001, Gross et al., 
1993). Cysteine can also react directly with acrolein itself and it is the preferential site of 
acrolein adduct formation in proteins (Gross et al., 1993, Zhu et al., 2011). In this study, NAC 
protected the urothelial cells from acrolein and CAA induced cell death and ROS formation 
restoring cell survival and ROS levels to that of an untreated control.  Furthermore, NAC 
prevented the functional changes to acrolein or CAA in the cells, with levels of all mediators 
being the same as untreated controls.  These are promising results as it appears NAC can fully 
protect urothelial cells from acrolein or CAA damage.   
Few studies have looked at the ability of NAC to protect urothelial cells from CPO or IFO 
induced toxicity.  In exfoliated bladder cells from mice treated with CPO, with and without oral 
NAC supplementation, it was shown that genotoxicity, inflammatory infiltration and 
haemorrhage were prevented by NAC (Gurbuz et al., 2009).  However, NAC has shown similar 
protective effects in other tissues.  For example, NAC has been shown to protect rats treated 
with IFO from nephrotoxicity, improving GSH levels and preventing morphological damage to 
renal tubules and glomeruli (Chen et al., 2008) without affecting its antitumor activity (Hanly et 
al., 2012).  NAC (400µM) also protected porcine renal epithelial cells from IFO induced toxicity. 
(Chen et al., 2007).  Rat hepatocytes were protected from acrolein (100µM) and CAA (300µM) 
induced toxicity and ROS production by NAC (1mM) (Macallister et al., 2012) while acrolein 
toxicity in primary human hepatocytes was also attenuated by NAC (Mohammad et al., 2012) 
Tanel and Averill-Bates (2007) demonstrated that the mechanism by which NAC protected 
chinese hamster ovary cells from acrolein cytotoxicity was by increasing intracellular GSH and 
preventing apoptosis.  Furthermore, NAC has been shown to stop ROS induced apoptosis in 
human bladder urothelial cells due to sulforaphane and compound K (Jo et al., 2014, Wang et 
al., 2013b).  As described in the results above, NAC was able to prevent the increase in 
caspase-3 activity due to acrolein and CAA treatment of human urothelial cells supporting an 
anti-apototic mechanism of action.  However, given that NAC also reduced ROS production in 
both cells lines also suggests that the mechanism of NAC protection may be preventing 
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oxidative stress.  From these results, NAC appears to be a promising alternative or addition to 
current uroprotective co-treatments for CPO and IFO therapy.  NAC not only appears to protect 
urothelial cells from damage but also from the functional changes induced by acrolein and CAA.   
NAC given orally is excreted in the urine in the form of both NAC and cysteine (Ventura et al., 
2003) making it possible that a simple oral dose of NAC could protect patients from acrolein and 
CAA induced urotoxicity.  For patients this could mean oral supplementation during and after 
treatment with CPO or IFO could reduce the pain, urinary frequency and urgency associated 
with these drugs and potentially improve treatment tolerability and outcomes.  
Conclusions 
This is the first study to report the effect of acrolein and CAA in human urothelial cells.  Both 
acrolein and CAA are toxic to human urothelial cells and induce increased ROS production, 
apoptosis and changes in mediator release.  This study supports a role for CAA in the 
urotoxicity of CPO and IFO as it was not only damaging to urothelial cells but more toxic than 
acrolein.  Furthermore, this study has shown that NAC, but not vitamin C, appears to protect 
urothelial cells from the acrolein and CAA induced changes and accordingly may be useful in 
preventing urotoxicity in patients receiving CPO and IFO chemotherapy.   
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CHAPTER 4: Effects of Acrolein or 
Chloroacetaldehyde on the Function 
of Isolated Porcine Bladder 
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4.1 INTRODUCTION  
The previous Chapter has demonstrated that the CPO and IFO metabolites acrolein and CAA 
are capable of damaging human urothelial cells and changing their release of ATP, ACh, PGE2 
and cytokines.  However, it raises the question as to whether these metabolites cause the same 
changes in normal bladder tissue with intact urothelial, lamina propria and detrusor layers and if 
so, do they alter the function of the urothelium or the detrusor? This study aimed to address 
these questions and further investigate the effects of acrolein and CAA on bladder function 
using isolated porcine tissues.  
Comparison of Human and Pig Bladder  
The properties of the pig lower urinary tract, including efferent control, urodynamic, 
histochemical and immunohistochemical characteristics, have been shown to be similar to 
human bladder in many respects (Bridgewater et al., 1993, Crowe and Burnstock, 1989, Sibley, 
1984).  In humans, bladder contraction is mediated almost completely by ACh from 
parasympathetic nerves acting via the muscarinic (M) receptors. In mouse and human bladder 
the M2 receptor density is three times greater than that of the M3 receptor (Wang et al., 1995), 
however direct bladder contraction is almost entirely mediated by the M3 receptor (Chess-
Williams, 2002, Fetscher et al., 2002).  Yamanishi et al. (2000) found the muscarinic receptor 
expression in pig bladder to be similar to that of humans with the M2 subtype predominating 
(70-80%) over the M3 subtype, while contraction of the pig bladder was mediated by the M3 
receptor (Sellers et al., 2000, Yamanishi et al., 2000).   
Both human and pig bladder can also contract in response to ATP and the smooth muscle cells 
of both species develop similar inward currents in response to purinoceptor activation (Inoue 
and Brading, 1991, Tsai et al., 2007).  Although ATP is co-released with ACh from 
parasympathetic nerves in humans, it appears to have very little contribution to nerve mediated 
contraction.  However, in pig bladder atropine inhibits the contractile response by approximately 
80% with a small NANC contraction remaining, thought to be due to ATP (Sibley, 1984, Inoue 
and Brading, 1991).  The P2X1 is the most abundant P2X receptor subtype in the human 
detrusor  (O'Reilly et al., 2001) as well as the pig (Bahadory et al., 2013).   
Noradrenaline from the sympathetic nerves has an inhibitory action on detrusor allowing the 
muscle to remain relaxed during filling.  Human detrusor can express all three β-AR subtypes 
(Andersson and Arner, 2004), however it is the β3-AR which is mainly responsible for the 
relaxation response (Igawa et al., 1999, Takeda et al., 1999, Igawa et al., 2001, Yamaguchi, 
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2002, Badawi et al., 2007).    Similarly, β3-ARs have also been demonstrated in the detrusor of 
the pig and are the predominant mediators of relaxation to isoprenaline (Yamanishi et al., 2002c, 
Yamanishi et al., 2002d). 
Detrusor smooth muscle of pig has been shown to have similar electrical properties to those of 
humans, both exhibiting nifedipine (10µM) sensitive spontaneous action potentials followed by 
fast hyperpolarisations that can be blocked by apamin (0.1µM) (Hashitani and Brading, 2003).  
Furthermore, spontaneous contractile activity is similar in both human and pig tissue (Sibley, 
1984).  
Several studies of urothelial structure and function have demonstrated that human and porcine 
tissues share many similar features (Janssen et al., 2013, Kumar et al., 2004). The urothelium 
forms a barrier protecting the bladder wall but also plays a role in bladder function. Studies of 
mammalian uroplakin expression have shown that pig and human (among other mammals) both 
express the four uroplakins (Ia, Ib, II and III) and the urothelial plaques containing them appear 
morphologically similar (Wu et al., 1994). Furthermore, immunofluorescence studies in human 
and porcine urothelium demonstrated that the GAG expression and distribution are comparable 
between species (Janssen et al., 2013).   
Mechanical stretch during bladder filling stimulates the urothelium to release mediators which 
can communicate with underlying cells such as sensory nerves, interstitial cells and smooth 
muscle (Birder et al., 2010b) and disruption of these mechanisms is associated with bladder 
dysfunction (Kumar et al., 2010, Chen et al., 2003, Sun and Chai, 2006, Sun et al., 2001).   
Functionally, the release of ATP from the urothelium of human and porcine bladders in 
response to mechanical stretch and electrical stimulation is comparable (Kumar et al., 2004). 
The pig bladder is structurally and functionally similar to that of the human and provides a good 
model for studying the effects of CPO and IFO on the human bladder.  
The Effects of CPO and IFO on the Bladder  
The urotoxic effects of CPO or IFO include anatomical and functional effects.  The metabolites 
of CPO and IFO come into direct contact with the urothelium causing damage and resulting in 
inflammation which presents as bladder oedema, ulceration, neovascularisation and 
haemorrhage (Cox, 1979, Lima et al., 2007).  The functional effects can manifest as bladder 
pain, urinary frequency, urgency and feelings of incomplete emptying (Korkmaz et al., 2007, 
Fukuoka et al., 1991) which can persist well beyond the resolution of inflammation and damage.  
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Most of the studies into the effects of CPO and IFO on the bladder have been performed in 
rodents and more work is needed in humans or large mammals such as the pig.  Isolated 
bladder tissue from rats treated with CPO or IFO demonstrated reduced contraction in response 
to KCl and carbachol suggestive of damage to bladder smooth muscle (Macedo et al., 2011, 
Giglio et al., 2005).  However, the muscarinic receptor expression of the muscle was altered 
after treatment suggesting that functional changes may involve more than just reduced muscle 
contractility (Giglio et al., 2005).  Similarly, contractile responses to the P2X receptor agonist 
β,γ-methylene ATP (β,γ-mATP) were reduced in CPO treated animals and may also be due to 
changes in receptor expression (Mok et al., 2000, Kageyama et al., 2008).  However, the 
question remains as to whether acrolein, CAA or both these metabolites contribute to these 
changes.  Furthermore, it is the efferent nerves that control the bladder in physiological 
conditions and changes to their function has yet to be investigated.   
Changes in mediator release from the urothelium have been reported in various painful or 
overactive bladder conditions.  Previous studies in rodents have demonstrated that systemic 
CPO treatment resulted in increased urothelial ATP release in response to hypo-osmotic 
stimulation (Smith et al., 2005).  Furthermore, COX-2 expression in the urothelium and plasma 
PGE2 concentration in rats were increased 12-24 hours after administration of IFO (Macedo et 
al., 2011).  Again, it is unclear whether these changes occur in humans and whether acrolein or 
CAA is responsible.   
Evaluation of Bladder Function 
Isolated strips of pig bladder have been extensively used as a model to study human bladder 
function (Moro et al., 2011, Sadananda et al., 2008, Kumar et al., 2004, Templeman et al., 2003, 
Yamanishi et al., 2002d, Yamanishi et al., 2000, Sibley, 1984).  Recently, a technique of 
mounting full thickness bladder sections in a bath to allow separate solutions to bath the luminal 
and serosal surfaces has been described (Smith et al., 2014).  This technique allows the 
urothelial surface to be treated relatively selectively, imitating the physiological condition of CPO 
and IFO toxicity where the toxic metabolites are concentrated in the urine on the luminal surface.  
After treatment the bladder sections can be dissected into strips and used in conventional 
functional studies.   
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Aims 
The aim of the present study was to investigate the effect of acrolein or CAA treatment on the 
porcine urothelium and detrusor. Specific aims were:  
 To examine the effect of acrolein or CAA on urothelial structure;  
 To determine the effect of acrolein or CAA on urothelial mediator release;  
 To investigate whether acrolein or CAA treatment changes the contractility of the 
urothelium or detrusor;  
 To determine whether acrolein or CAA treatment causes alterations in the efferent 
nerve responses in the detrusor.  
 
 
 
  
 123 
 
4.2 METHODS 
Animals 
Mature adult female pig (sow) bladder samples were obtained from a local abattoir.  The tissues 
were immediately placed in Krebs-bicarbonate solution (composition in mmol/L: NaCl 118.4, 
NaHCO3 24.9, KCl 4.7, CaCl2 1.9, MgSO4 1.15, KH2PO4 1.15, glucose 11.7) at 4ºC until use.   
Experimental Setup and Procedures 
The bladder was opened longitudinally from the urethra to the dome and sections cut from the 
dome of the bladder and mounted in modified Ussing chambers (as previously described by 
Smith et al., (2014)) containing Krebs bicarbonate solution at 37ºC and gassed with 5% CO2 in 
oxygen (Figure 4.1).  Krebs bicarbonate solution containing acrolein (100µM) or 
chloroacetaldehyde (10µM) was applied to the urothelial side of the tissue. A volume of 5mL 
was applied to fully cover the urothelial surface and was refreshed after 2 hours.  A control 
tissue was also treated simultaneously with normal Krebs bicarbonate solution. Tissues were 
unable to be treated for 24 hours due to loss of function after this time, therefore a shorter 
treatment period of 4 hours was used.  
 
Figure 4.1: Schematic figure of the modified Ussing chamber with a piece of bladder tissue secured within the 
chamber in Krebs solution at 37ºC and gassed with 5% CO2 in oxygen. The luminal surface of the urothelium is 
treated with a Krebs solution alone or containing acrolein (100µM) or chloroacetaldehyde (10µM). 
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After treatment, the tissues were washed with Krebs solution and the bladder dome dissected 
into intact and denuded detrusor strips (with and without urothelium/lamina propria) and isolated 
urothelial/LP strips. Orientation of the tissues was marked so that tissue strips were cut 
longitudinally from the tissue approximately 10mm long and 5mm wide.   
The treated and control tissue strips were anchored in separate organ baths at 37ºC and 
gassed with 5% CO2 in oxygen.  Tissues were equilibrated for 1 hour during which time they 
were washed with fresh Krebs-bicarbonate solution every 15 minutes (Figure 4.2).  Tissue 
strips were connected to an isometric force transducer (ADInstruments, Ltd Australia) under 
20mN resting tension.  The isometric force transducer was connected to a Powerlab 8/30 
recording system (ADInstruments Ltd.) via an Octal Bridge Amp (ADInstruments Ltd) and the 
developed tension was measured using LabChart (version 7.0.3) software (ADInstruments Ltd).   
 
Figure 4.2: An organ bath with an isometric force transducer positioned above to record tension developed by 
the tissue. The side view is an illustration of the manner in which the tissue strip is set up in the organ bath, 
anchored at the base between two electrodes and attached to the transducer. 
Response to Pharmacological Agents 
After equilibration, tissues were exposed to various agonists and responses recorded as 
changes in tension from baseline, baseline being taken as the maximum tension recorded in the 
60 seconds prior to administration of the drug.  The agonists investigated included single 
concentrations of potassium chloride (KCl) (60mM) and ATP (1mM), and a cumulative 
concentration-response curve to carbachol (6nM – 180µM).  Next, a submaximal dose of 
carbachol was applied (36.5µM) and after the contraction had reached a plateau a cumulative 
concentration-response curve to isoprenaline (45pM - 45µM) was performed.  Responses from 
Transducer 
Organ bath 
Tissue 
Electrodes 
Krebs solution 
Water at 37°C 
Front View Side View 
Anchor 
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treated tissues were compared to control responses to determine if acrolein or 
chloroacetaldehyde affected the contractility of the detrusor or the urothelium/LP.   Responses 
from the detrusor strips with and without the urothelium/LP were compared to test the inhibitory 
influence of the urothelium/LP.   
Spontaneous Contractions 
As discussed above, the detrusor and the urothelium/LP develop spontaneous, phasic 
contractions and these were observed in the isolated porcine bladder strips (Figure 4.3).  The 
frequency and amplitude of spontaneous contractions were quantified.  Spontaneous 
contractions were measured during 200 seconds at the end of the initial equilibration period. 
Average frequency was represented as contractions/min and average amplitude in mN.  
 
Figure 4.3: Typical trace showing spontaneous contractions  
of a strip of isolated porcine urothelium/lamina propria during 60s. 
Urothelial Transmitter Release 
Urothelium/lamina propria tissue strips were prepared and set up in organ baths as discussed 
above.  Following equilibration, 2mL of fresh Krebs was added to the bath and collected after 2 
minutes for a basal sample of mediator levels.  The Krebs was immediately refreshed and the 
tissue stretched to 50% of its original length over 2 minutes at which time the Krebs was 
collected for measurement of stimulated mediator release.  The level of ATP, ACh and PGE2 in 
each sample was measured using the assays described in Chapter 2.  
Electrical Field Stimulation 
Denuded detrusor strips were prepared and set up as discussed above.  The tissue strips were 
electrically stimulated (40 volts and 1ms pulse-width) delivered as a 5 second train every 100 
seconds, at a frequency of 1Hz, 5Hz, 10Hz and 20hz.  The tissues were stimulated at each 
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frequency until stable contractions were obtained. Next, tissues were stimulated at each 
frequency in the presence of 100µM L-NNA (NOS inhibitor), 1µM atropine (muscarinic 
antagonist) and 10µM αβmATP (desensitises purinoceptors) to investigate the contribution of 
NO, ACh and ATP to the responses.  Responses in treated tissues were compared to controls.  
Histology 
After treatment, tissues were dissected and placed in neutral buffered formalin (10%), 
processed and stained as per the protocol in Chapter 2 in order to visualise any tissue damage 
caused by acrolein or CAA.  
Statistical Analysis 
Results were expressed as mean ± standard error of the mean (SEM).  Data were analysed 
using a Student t-test or one-way ANOVA with Dunnett or Tukey multiple comparisons test as 
appropriate, using Graphpad InStat (version 3.06) software (SanDiego, CA). Comparisons of 
whole response curves of control and treated groups were performed using two-way ANOVA 
with Bonferroni post-test. Significance levels were defined as p<0.05 (*), p<0.01 (**) and 
p<0.001 (***). 
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4.3 RESULTS  
Effect of Acrolein and CAA on Urothelium/Lamina Propria Structure and 
Mediator Release 
The effect of acrolein and CAA on porcine bladder was first investigated in terms of their 
damaging effects on the structure of the urothelium.  Representative haematoxylin and eosin 
stained sections of control, acrolein (100µM) and CAA (10µM) pre-treated bladders are shown 
(Figure 4.4).  Typical histological features were identifiable in sections of control tissues with the 
folded urothelium and lamina propria layers overlying a deeper smooth muscle layer.  However, 
minor damage was evident in acrolein and CAA treated tissues.  Both metabolites appeared to 
cause some thinning of the urothelial layer but this was not significant (Figure 4.5).  In addition, 
CAA (10µM) treatment appeared to cause some disruption to the normal folding of the urothelial 
layer while the folding was absent in acrolein (100µM) treated bladders.  
 
  
Control Acrolein (100µM) CAA (10µM) 
   
   
   
 
Figure 4.4: Histological sections of isolated porcine bladder from control tissue (A & D) and tissue treated with 
acrolein (100µM) (B & E) and CAA (10µM) (C & F) at 10x and 40x magnification respectively. The urothelium is 
indicated by an arrow.  
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Figure 4.5: Urothelial thickness (um) in control tissue (A) and tissue treated with acrolein (100µM) (B) and CAA 
(10µM) (C). Data represented as mean ± SEM (n=3). 
 
Next, the release of mediators from the urothelium/LP after acrolein and CAA treatment was 
investigated.   Initially the repeatability of mediator release was determined by performing the 
basal and stretch sample collection three times with a 15 minute recovery between each 
repetition.  Samples were tested for ATP and ACh content.  As shown in Figure 4.6, ATP and 
ACh levels in stretch samples were not significantly different from levels in basal samples.  
Pre-incubation with luminal acrolein (100µM) or CAA (10µM) for four hours had no significant 
effect on the release of ATP, ACh or PGE2 during basal or stretch conditions (Figure 4.7).  
 
Figure 4.6: Repeatability of urothelial ATP (A) and ACh (B) release from isolated porcine tissue during three 
replicates of basal and stretch conditions. 
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Figure 4.7: Basal and stretch induced ATP (A) acetylcholine (B) and PGE2 (C) levels in isolated strips of 
urothelium/lamina propria from bladder previously incubated with luminal acrolein (100µM), CAA (10µM) or 
krebs for 4 hours.  Data are shown as mean ± SEM (n≥6). 
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Effect of Acrolein or CAA Treatment on the Contractility of Tissue Strips 
The effect of acrolein and CAA on isolated porcine bladder tissue contractility was then 
investigated using urothelium/lamina propria, denuded and intact detrusor strips.  Firstly, the 
maximum response to KCl (60mM), ATP (1mM) and carbachol (180µM) were determined 
followed by the tissue response to full dose response curves to carbachol (6nM – 180µM) and 
isoprenaline (45pM - 45µM).   
The contractility of the urothelial/LP strips were unaffected by treatment with acrolein or CAA.  
Responses of detrusor strips to carbachol, KCl and ATP were all lower in tissues from acrolein 
or CAA treated bladders than control incubated bladders although none of the differences 
reached statistical significance (Figure 4.8).  Specifically, the detrusor response to KCl was 
decreased by approximately 30%, the carbachol response by 15% and the ATP response by 
approximately 50% after treatment with either metabolite.  However, the decreased contractility 
after acrolein or CAA treatment was not observed in the presence of the urothelium/lamina 
propria with similar responses observed in treated and controls strips. 
The presence of the urothelium/LP significantly inhibited the contractile responses of the control 
detrusor to KCl and ACh (p<0.05).  Responses to ATP also tended to be lower in urothelium 
intact tissues but this was not statistically significant.  Pre-treatment with acrolein or CAA did not 
change the inhibitory effect of the urothelium/LP on detrusor responses to KCl.  Specifically, the 
presence of the urothelium/LP inhibited the contraction of the control detrusor strips to KCl by 
49±8% (p<0.05) and acrolein or CAA treated contractions were inhibited by 48±19% and 50±10% 
(p<0.05) respectively.   
However, after pre-treatment with acrolein or CAA there was no statistically significant 
difference between detrusor responses to ACh or ATP in the presence or absence of the 
urothelium/lamina propria.  In the presence of the urothelium/LP detrusor responses to 
carbachol were significantly inhibited in controls strips [by 44±5% (p<0.05)] whereas no 
significant effect was observed in acrolein or CAA treated strips (inhibited by 31±11% and 
28±12% respectively).  The control tissue responses to ATP were inhibited by 52±14% (p<0.05) 
in the presence of the urothelium/LP whereas no inhibitory effect was observed in acrolein or 
CAA treated tissues.  
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Figure 4.8: Effect of acrolein (100µM) and chloroacetaldehyde (CAA) (10µM) pre-treatment on the contractility of porcine urothelium/lamina propria and denuded and intact detrusor in 
response to KCl (60mM) (A, B & C respectively), carbachol (180µM) (D, E & F respectively) and ATP (1mM) (G, H & I respectively).  Data represented as mean ± SEM (n=6) and analysed 
by one-way ANOVA with Dunnett post-test. 
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Next concentration-response curves to carbachol and isoprenaline were performed.  As the 
concentration of carbachol increased so did the contraction of the urothelial/lamina propria, 
denuded and intact detrusor strips (Figure 4.9).  The contractility of the urothelial/LP and intact 
detrusor strips to cumulative concentrations of carbachol was not different after acrolein (100µM) 
or CAA (10µM) pre-treatment (Figure 4.10 A-C).  However, the treated denuded detrusor 
demonstrated slightly less contraction over the entire curve but this was not significant.  Again, 
the presence of the urothelium inhibited the control detrusor contractions to carbachol (p<0.05) 
but did not significantly affect detrusor contractions in tissue treated with acrolein or CAA 
(Figure 4.11).  The pEC50 values of carbachol in each tissue type and treatment group were 
also similar (Figure 4.12 & Table 4.1).   
Tissue tension decreased as the isoprenaline concentration increased (Figure 4.10 D-F).  The 
response of the urothelial/LP and intact detrusor strips were unchanged by acrolein (100µM) or 
CAA (10µM) treatment.  However, the denuded detrusor again appeared less responsive after 
treatment but the difference was not statistically significant. Acrolein (100µM) or CAA (10µM) 
treatment had no effect on the pEC50 of isoprenaline in the various tissues (Figure 4.12 & Table 
4.1).  
 
 
Figure 4.9: Representative trace of isolated porcine detrusor to cumulative concentrations of carbachol. 
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Figure 4.10: Cumulative concentration response (mN) curves to carbachol (A, B & C) and isoprenaline (D, E and F) in strips of porcine urothelium/lamina propria, denuded detrusor and 
intact detrusor pre-incubated with Krebs (control), acrolein (100µM) or CAA (10µM) for four hours.  Data represented as mean ± SEM (n=6).  
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Figure 4.11: The inhibitory effect of the urothelium/lamina propria on detrusor contractions in response to cumulative concentrations of carbachol in strips of porcine detrusor 
pre-incubated with Krebs (control) (A), acrolein (100µM) (B) or CAA (10µM) (C) for four hours.  Data represented as mean ± SEM (n=6).  Maximum response of denuded and intact 
detrusor within each treatment group were compared by paired two-tailed t-test (* indicates p<0.05 vs intact response). 
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Figure 4.12: Percentage of maximum response to cumulative concentrations of carbachol (A, B & C) and isoprenaline (D, E and F) in strips of porcine urothelium/lamina propria, 
denuded detrusor and intact detrusor pre-incubated with Krebs (control), acrolein (100µM) or CAA (10µM) for four hours.  Data represented as mean ± SEM (n=6).  
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Table 4.1: The pEC50 values for carbachol and isoprenaline in porcine urothelium/lamina 
propria, denuded detrusor and intact detrusor.  
 Urothelium/LP Denuded Detrusor Intact Detrusor 
Carbachol 
Control 6.26±0.05 6.30±0.03 6.21±0.04 
Acrolein (100µM) 6.11±0.07 6.26±0.03 6.18±0.02 
CAA (10µM) 5.96±0.04 6.12±0.04 6.07±0.05 
Isoprenaline 
Control 6.73±0.15 7.19±0.09 6.99±0.12 
Acrolein (100µM) 6.67±0.13 6.91±0.07 6.77±0.13 
CAA (10µM) 6.63±0.11 6.97±0.07 6.49±0.24 
Data represented as mean ± SEM (n=6) 
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Effect of Acrolein or CAA Treatment on the Spontaneous Activity of 
Tissue Strips 
Spontaneous contractions of the detrusor and urothelium/LP after one hour equilibration of 
tissue strips were measured. Both frequency and amplitude of the spontaneous contractions 
were significantly higher in urothelial/LP tissues than in detrusor tissues (Figure 4.13).  
Treatment with acrolein (100µM) or CAA (10µM) had no significant effect on the average 
frequency (Figure 4.13-A) or the amplitude (Figure 4.13-B) of spontaneous contractions 
compared to control.   
 
Figure 4.13 : Frequency and amplitude of spontaneous contractions of porcine detrusor and urothelium/lamina 
propria from control, acrolein (100µM) and CAA (10µM) pre-treated tissues. Data represented as mean ± SEM 
(n=6).  Control detrusor and urothelial responses were compared by unpaired two-tailed t-test (*p<0.05). 
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Effect of Acrolein or CAA Treatment on Responses to Electrical Field 
Stimulation  
Electrical field stimulation was used to investigate the effect of acrolein or CAA treatment on 
efferent nerve function in the porcine bladder.  As the frequency of stimulation increased, the 
contractile response of the detrusor also increased (Figure 4.14-A).  The EFS induced 
contractions were sensitive to tetrodotoxin (TTx) (1µM) with responses being completely 
abolished in the presence of this neurotoxin (Figure 4.14-B). Removing NO with L-NNA (100µM) 
had no effect on the nerve mediated response (Figure 4.15).  Antagonism of the muscarinic 
receptors with atropine (1µM) almost completely abolished the EFS induced response leaving a 
small contraction of less than 10% of the control response at 20Hz (Table 4.2).  Desensitisation 
of the purinergic receptors with αβmATP (10µM) had no significant effect on the remaining 
contraction (Figure 4.15).  However, as indicated in Table 4.2, αβmATP tended to partially 
block contraction responses at low frequencies (1Hz) but did not affect responses at high 
frequencies (10-20Hz).  
 
Figure 4.14: Typical trace of untreated porcine bladder responses to electrical field stimulation  (40 volts, 1ms 
pulse-width, 5 second train) in the absence (A) and presence (B) of tetrodotoxin (TTx) (1µM).   
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Figure 4.15:  Contractile responses of untreated porcine detrusor strips to electrical field stimulation (40 volts, 
1ms pulse-width, 5 second train). Data represented as mean ± SEM (n=6). Analysed by one-way ANOVA with 
Dunnetts post-test (*p<0.05, ***p<0.001 atropine + LNNA vs control). 
 
Table 4.2: Response (mN) to EFS in the absence and presence of L-NNA (100µM), 
Atropine (1µM) and αβmATP (10µM).  
 1Hz 5Hz 10Hz 20Hz 
Control 7.5 ± 6.5 17.2 ± 11.5 26.2 ± 9.9 50.8 ± 9.5 
+ L-NNA (100µM) 4.4 ± 3.0 16.1 ± 9.0 30.0 ± 8.7 56.1 ± 7.8 
+ Atropine (1µM)  
+ L-NNA (100µM) 
1.4 ± 0.9 3.9 ± 1.6 4.1 ± 1.6 4.7 ± 1.9 
+ αβmATP (10µM)  
+ Atropine (1µM)  
+ L-NNA (100µM) 
0.7 ± 0.4 3.2 ± 1.2 4.0 ± 1.5 5.4 ± 1.9 
Data represented as mean ± SEM (n=6). 
 
Treatment with acrolein (100µM) or CAA (10µM) had no significant effect on the response to 
EFS (Figure 4.16).  No change in the contribution of NO, ACh, or ATP was seen after treatment 
with acrolein (100µM) or CAA (10µM).  ACh was the major contributor to the EFS induced 
contraction at all frequencies in all treatment groups however the influence of ACh tended to 
increase as the frequency increased (approximately 70% at 5Hz, 85% at 10Hz and 90% at 
20Hz) (Figure 4.17).   
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Figure 4.16: Contractile responses of porcine detrusor strips treated with Krebs (control), acrolein (100µM) or 
CAA (10µM) to electrical field stimulation (40 volts, 1ms pulse-width, 5 second train) in the absence of 
antagonists (A), in the presence of L-NNA (100µM) (B) and atropine (1µM) (C) and also αβmATP (10µM) (D). Data 
represented as mean ± SEM (n=6). 
 
 
Figure 4.17: Percentage of inhibition of control response by atropine (1µM) in control, acrolein (100µM) and 
CAA (10µM) treated porcine detrusor strips in response to electrical field stimulation (40 volts, 1ms pulse-width, 
5 second train). Data represented as mean ± SEM (n=6). 
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4.4 DISCUSSION 
This study aimed to investigate whether the CPO and IFO metabolites acrolein and CAA cause 
damage to full thickness bladder sections when applied on the luminal surface of the urothelium.   
To ensure viability of the tissues after treatment a period of four hours was used.  This 
treatment time also correlates with the average time reported for the peak urinary 
concentrations of CPO and IFO metabolites to appear in the bladder (Koss, 1967, Takamoto et 
al., 2004). 
Urothelial Effects of Acrolein or CAA 
Both acrolein and CAA caused some damage to the urothelial layer of the pig bladder tissues 
and appeared to cause a reduction in the normal folding of the urothelial/LP layer.  Intravesical 
instillation of acrolein in mice has caused similar results where doses of >10µg/15µL resulted in 
urothelial erosion and oedema in the lamina propria sufficient to cause reduction of the 
urothelial folding within four hours (Bjorling et al., 2007, Batista et al., 2007).  The damage 
caused by application of acrolein to the pig urothelium for four hours was not as severe as the 
damage observed in the previous mouse studies.  This may be due to the fact that the pig 
bladder is thicker and more robust than the thin mouse bladder thereby preventing entry of 
acrolein into the urothelium or lamina propria for longer and delaying the onset of inflammation.  
Interestingly, the results of the present study show that CAA (10µM) is also capable of causing 
damage to full thickness bladder sections, although to a slightly lesser degree than acrolein 
(100µM).  Although, this is unsurprising given that a 10-fold lower concentration of CAA was 
used.  The thickness of the urothelium tended to decrease after treatment with acrolein or CAA 
indicative of death and loss of the urothelial cells.  The urothelial thickness was not significantly 
different between control and treated tissues and caution should be taken when interpreting this 
result.  However, given the consistent findings, the low error between repeated treatments and 
the small n-value the trend may be worth commenting on.  Accordingly, a tendency toward a 
thinner urothelium after acrolein or CAA treatment provides some support to the findings of the 
previous Chapter wherein both metabolites were toxic to human urothelial cells.  Furthermore, 
these results align with findings of previous studies discussed earlier wherein both acrolein and 
CAA have been found to be toxic to renal epithelial cells (Schwerdt et al., 2006, Broadhead et 
al., 1998).  In addition, the current results do not rule out a role for CAA in the urotoxicity of CPO 
and IFO.     
Next, the effect of acrolein or CAA on the function of the urothelium/LP was investigated by 
measuring the release of ATP, ACh and PGE2 from urothelial/LP strips during basal and stretch 
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conditions.  The levels of ATP, ACh or PGE2 were unaffected by mechanical stretch of the 
tissues.  Studies using a similar method have reported an increase in ATP levels induced by  
stretch of the porcine urothelium/LP (Sadananda et al., 2012, Smith et al., 2014) whereas there 
was no change in ACh levels after stretch (Smith et al., 2014).  No studies have reported on 
stretch induced release of PGE2 in porcine urothelium. Therefore, the results of the present 
study demonstrated similar ACh levels to previous findings however, the lack of stretch induced 
ATP release is unexpected.  The ATP increase found by Smith et al., (2014) was modest and 
the samples were taken at an earlier time point in the study by Sadananda et al., (2012).  
Therefore, it is possible that stretch did induce an increase in ATP but that the later sampling 
point allowed for breakdown of the additional ATP.   
In any event, pre-treatment with acrolein or CAA had no effect on the release of ATP, ACh or 
PGE2 from the urothelium/LP.  This was unexpected given the results in the previous Chapter 
reported increased mediator release from cultured urothelial cells.  Furthermore, chronic 
treatment of rats with CPO has been shown to cause an increase in luminal ATP levels in 
response to hypo-osmotic stimulation of the urothelium (Smith et al., 2005).  As discussed 
briefly in the previous Chapter, the initial effects of CPO treatment on rat urothelium include 
ulceration and erosion resulting in the loss of cells from the urothelium (Auge et al., 2013, 
Juszczak et al., 2010).  The cells that survive start to express epidermal growth factor receptor 
(EGFR) and proliferate rapidly in order to repair the denuded areas (Romih et al., 2001).   This 
rapid proliferation of cells results in urothelial hyperplasia, composed of undifferentiated cells 
(Boudes et al., 2011, Golubeva et al., 2014, Romih et al., 2001).  After approximately a week of 
intense proliferation, differentiation of superficial cells begins and damaged cells are gradually 
removed by apoptosis until a normal three-layered urothelium is restored by two weeks 
following CPO treatment (Romih et al., 2001).  Accordingly, the increased luminal ATP release 
observed by Smith et al., (2005) after three treatments of CPO is possibly due to a greater 
number of urothelial cells releasing ATP.  The four hour incubations with acrolein or CAA 
caused the typical acute damage of urothelial erosion seen after CPO or IFO treatment.  
Accordingly, the current mediator results are actually higher than anticipated as the apparent 
urothelial cell loss after acrolein or CAA treatment would be expected to result in the release of 
fewer mediators.   However, as demonstrated in the previous Chapter, the urothelial cells are 
able to release more ATP, ACh and PGE2 per cell after acrolein or CAA treatment which may 
explain the fairly consistent mediator levels despite the loss of urothelial cells.   
Therefore, the results of the present study demonstrated that both acrolein and CAA can induce 
urothelial damage after four hours resulting in urothelial cell loss.  The results also suggest that 
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acrolein or CAA treatment may enhance mediator release from the urothelial cells, but in 
combination with urothelial cell loss this does not manifest as an increase in overall mediator 
levels.   This supports the results of the previous Chapter showing that 24 hour treatment of 
urothelial cells caused a greater release of ATP, ACh and PGE2 per cell.  The urothelial damage 
observed in the present study may have been sufficient to cause loss of the barrier function of 
the urothelium allowing the toxic metabolites to penetrate the bladder wall and potentially alter 
detrusor function.   
Effects of Acrolein or CAA on Contractility of Bladder Tissues 
As shown above, both acrolein and CAA can cause urothelial damage when applied to the 
luminal side of full thickness porcine bladder.  The urothelium can both increase or decrease 
contractile properties of the detrusor (Fry et al., 2010).   In isolated bladder preparations, the 
nerve-mediated and carbachol-induced contractions were reduced in the presence of the 
urothelium (Hawthorn et al., 2000, Chaiyaprasithi et al., 2003).  Similarly, the response of 
isolated rat bladder rings to ATP was lower in detrusor strips with intact urothelium (Khattab and 
Al-Hrasen, 2006).  However, spontaneous contractile activity is increased in the presence of the 
urothelium (Kanai et al., 2007, Sui et al., 2008).  This effect is thought to be due to waves of 
Ca
2+
 initiating in the urothelium or lamina propria which then propagate to the detrusor.  
Accordingly, damage to the urothelium/LP could result in changes to detrusor contractility and 
bladder function.  In addition, the urothelium/LP is capable of contraction (Sadananda et al., 
2008) and develops its own spontaneous contractile activity (Moro et al., 2011) and these 
functions could also be affected by acrolein or CAA induced damage.  Furthermore, if the 
barrier function of the urothelium was damaged by acrolein or CAA treatment, the metabolites 
may also have damaged the detrusor itself.   Accordingly, the contractility of the urothelium/LP, 
denuded and intact detrusor tissues was investigated after four hour acrolein or CAA incubation.  
Firstly, the maximum response of the tissues to KCl, ATP and carbachol were determined.  All 
three control tissue types contracted in response to the agonists with the detrusor generally 
producing a greater response than the urothelium/LP or the intact tissues.  In the urothelial/LP 
strips, treatment with acrolein or CAA had no significant effect on the contractions to KCl, ATP 
or carbachol.  However, the detrusor strips tended to have reduced contractile responses to all 
three agents after acrolein or CAA treatment.  This trend was not statistically significant however 
it suggests that some functional changes may be occurring after treatment.  Previous studies 
have reported reduced detrusor contractions in response to carbachol and/or ATP after 
treatment with CPO or IFO (Mok et al., 2000, Macedo et al., 2011, Giglio et al., 2005, 
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Andersson et al., 2008, Giglio et al., 2007). However, most of these studies also demonstrated 
a similar reduction in tissue contraction to KCl.  The reduced KCl response indicates a 
detrimental effect to the general contractility of the tissue after treatment rather than a change in 
the receptor mediated responses.  Therefore, it appears that the detrusor may have sustained 
some minor damage during the treatments with acrolein or CAA which could be due to direct 
injury by the metabolites entering the bladder wall through a damaged urothelial barrier, or 
could be the result of an inflammatory response in the tissues initiated by the urothelial damage.    
In the presence of the urothelium/LP the control detrusor responses to KCl, carbachol and ATP 
were lower than the denuded detrusor responses.  As discussed previously, in response to 
muscarinic receptor stimulation the urothelium releases a diffusible factor (UDIF) which inhibits 
the contraction of the underlying detrusor (Hawthorn et al., 2000) while an inhibitory effect of the 
urothelium has also been shown in response to ATP (Khattab and Al-Hrasen, 2006).  The 
presence of the urothelium/LP reduced responses of the detrusor by approximately 50% in 
control tissues, which is in line with the effect of UDIF or the urothelial inhibition reported these 
previous studies.  
The inhibitory effect of the urothelium/LP on detrusor contractions to KCl was unaffected by 
acrolein or CAA pre-treatment.  However, the urothelial/LP inhibition of detrusor contractions to 
ACh and ATP was less after pre-treatment with acrolein or CAA.  The responses to the agonist 
carbachol were reduced by only 30% in treated intact tissues indicating a loss of the muscarinic 
mediated urothelial inhibitory effect after treatment.  The responses to ATP were not inhibited by 
the presence of the urothelium/LP suggesting a complete loss of the purinergic mediated 
urothelial inhibition.  A similar result has been reported in porcine tissues treated with DMSO 
where the inhibitory effect of the urothelium/LP was reduced significantly after treatment (Smith 
et al., 2014).  Accordingly, it appears that the inhibition of detrusor contraction by the 
urothelium/LP is reduced after acrolein or CAA treatment. 
Comparable results were also obtained when full concentration-response curves to carbachol 
were performed in urothelial/LP, denuded detrusor and intact strips.  The 
concentration-response curves were almost identical in control and treated urothelial/LP and 
intact strips.  However, the denuded detrusor strips tended to have decreased contractile 
responses over the entire curve.  Furthermore, the control detrusor responses to carbachol 
were significantly lower in the presence of the urothelium whereas this effect was reduced after 
acrolein or CAA treatment.  This further supports a loss of the inhibitory effect of urothelial/LP 
after acrolein or CAA treatment.  The responses of treated and control tissues, when 
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represented as a percentage of maximum, were almost identical and the pEC50 values of 
carbachol were unchanged after treatment.  
Next the ability of the tissue to relax in response to cumulative concentrations of isoprenaline 
(β-AR agonist) was investigated.  The urothelial tissues relaxed in response to isoprenaline and 
the responses were unchanged by previous treatment with acrolein or CAA.  The acrolein or 
CAA pre-treated detrusor strips were slightly less responsive to isoprenaline whereas the 
responses of treated intact strips were the same as controls.  Previous studies have reported 
that three days after CPO treatment (100mg/kg) isolated rat bladder strips had inhibited 
relaxations to isoprenaline (Giglio et al., 2007, Vesela et al., 2012).  The immediate effects of 
acrolein or CAA treatment in the present study, although not statistically significant, support a 
loss of relaxation response after exposure to CPO or IFO.  Again, it appears that acrolein and 
CAA have a general detrimental effect on muscle function.   Furthermore, a reduced ability of 
the bladder to relax during filling could contribute to storage symptoms such as reduced bladder 
capacity and increased urinary frequency.   
The spontaneous contractions of the detrusor and urothelium/LP were also investigated to 
determine whether acrolein or CAA alter the frequency or amplitude of these contractions.  Both 
frequency and amplitude of the spontaneous contractions were significantly higher in control 
urothelial/LP tissues than in detrusor tissues (Figure 4.13).  This supports the findings reported 
by Moro et al., (2011) that porcine detrusor muscle had a significantly lower rate of spontaneous 
contractions than the urothelium/LP.  Treatment with acrolein or CAA had no significant effect 
on the average frequency or the amplitude of spontaneous contractions in the urothelium/LP or 
the detrusor compared to control tissues.  This was unexpected given that cystometry in rats 
treated with CPO have shown enhanced spontaneous activity of the bladder during filling (Pan 
et al., 2012).  However, this may represent a difference between in vivo and in vitro tissue 
responses. In isolated bladder strips from mice treated with CPO, 33% of the tissues exhibited 
spontaneous contractile activity, while the control tissues failed to show any spontaneous 
contractions  (Okinami et al., 2014). As discussed further below, the metabolism of CPO and 
IFO in vivo is likely to cause toxic metabolites to be present in the urine for up to 24 hours.  
Accordingly, the increased spontaneous activity seen in the previous studies may have been 
due to the damaging metabolites being present in the urine for longer than the four hours used 
in this study.  Furthermore, the inflammatory response may have been greater in the in vivo 
models used in these studies causing greater damage and affecting the bladder function to a 
greater extent than in the isolated bladder treatment used in the present study.  However, the 
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results of this Chapter show that acute, four hour acrolein or CAA treatment of isolated bladder 
does not affect the spontaneous activity of the detrusor or urothelium/LP.    
In the present study, an impaired urothelial inhibitory effect appears to cancel out the reduced 
detrusor contractility after acrolein or CAA treatment producing a similar result to controls in the 
intact tissues.  The implications of these changes are not clear, although both acrolein and CAA 
appeared to have similar effects and it may be possible that both metabolites contribute to 
urotoxicity of CPO and IFO.   
Effects of Acrolein or CAA on Efferent Nerve Mediated Responses of the 
Bladder 
There appears to be some reduction in contractility of the detrusor to endogenous agents after 
acrolein or CAA treatment however, it is the activity of the efferent nerves that would be 
controlling responses in physiological conditions.  Therefore, the EFS induced efferent nerve 
responses were investigated.  The EFS parameters used in the present study caused frequency 
dependent contractions that were sensitive to TTx confirming that they were nerve induced.   
In control tissues, the inhibition of NO production with L-NNA did not affect the nerve mediated 
responses. NOS has been identified in nerve fibres in the bladder (Andersson and Persson, 
1995) however, the detrusor has a low sensitivity to NO, making it unlikely to have a relaxatory 
role in normal detrusor (Andersson and Arner, 2004).  Similar results have been demonstrated 
in human and rat detrusor tissues wherein NOS inhibition did not significantly enhance EFS 
induced contractions (Ehren et al., 1994b, Persson et al., 1992, Vesela et al., 2012).  
Accordingly, the lack of effect of L-NNA in the present study is not surprising and supports that 
neuronal NO has little effect on normal detrusor contraction.    
Next, blocking the muscarinic receptors with atropine almost completely abolished the EFS 
induced contractions in the porcine detrusor.  As discussed earlier, human bladder nerve 
mediated contraction is almost completely due to ACh (Chess-Williams, 2002, Fetscher et al., 
2002), while a NANC portion of nerve induced responses appears in disease and is thought to 
be due to ATP (Palea et al., 1993).  In pig bladder ACh contributes more at high frequencies of 
nerve stimulation than low frequencies making up 83% of the response at 50Hz (Sibley, 1984).  
Given that pig bladder contracts to ATP the remaining non-cholinergic response is also thought 
to be due to ATP (Inoue and Brading, 1991).  Similar results were observed in the present study 
wherein atropine had a greater effect at high frequencies than low frequencies contributing to 90% 
of the EFS induced response at 20Hz.  In addition, desensitisation of purinergic receptors with 
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αβmATP appeared to partially reduce the contraction at low frequencies but not high 
frequencies.  This suggests that ATP and ACh may contribute to EFS induced responses in a 
combination that changes depending on frequency of nerve stimulation.  Specifically, the ATP 
portion of the EFS responses appears greatest at low frequencies of stimulation and reduces as 
frequency increases while a simultaneous increase in ACh contribution is observed.  However, 
in this work, the effect of αβmATP was small and not statistically significant which suggests that 
ATP may not have been contributing to nerve mediated contractions or that a small population 
of purinergic receptors insensitive to desensitisation by αβmATP may have be present.   
Treatment with acrolein (100µM) or CAA (10µM) had no significant effect on the response to 
EFS.  Furthermore, no change in the contribution of NO, ACh, or ATP was seen after treatment 
with acrolein (100µM) or CAA (10µM).  This supports previous findings that CPO treatment does 
not affect the contribution of ACh or ATP to nerve induced contractions.  For example, Mok et 
al., (2000) found that EFS induced contractions in isolated bladder strips from CPO treated 
Suncus murinus (shrew) were the same as in control strips and atropine and αβmATP reduced 
responses to a similar extent in both groups.  Another study in rats also found that atropine and 
αβmATP reduced responses to a similar extent in control and CPO treated bladder strips (Giglio 
et al., 2007).   However, three days after CPO treatment, Vesela et al., (2012) demonstrated 
that inhibition of NO production slightly enhanced EFS induced contractions in CPO treated 
bladder strips but not in control strips.  Previous studies have suggested that the urothelium of 
CPO treated rats (but not control rats) releases NO in response to muscarinic receptor 
stimulation reducing the associated detrusor contraction (Andersson et al., 2008). This 
mechanism may have contributed to the increased nerve mediated contraction seen be Vesela 
et al., (2012) after blocking NO production.  However, these effects were seen three days after 
administration of CPO whereas the present study investigated acute effects of acrolein and 
CAA which do not appear to change NO contribution to EFS induced responses.   
Relevance of the Treatment Period 
Although the peak urinary concentrations have been reported to appear in urine of patients four 
hours after treatment with CPO or IFO  (Koss, 1967, Takamoto et al., 2004), the metabolites 
can continue to be excreted in the urine for up to 24 hours after treatment (Bagley et al., 1973, 
Jardine et al., 1978, Sladek et al., 1980, Joqueviel et al., 1997).  Accordingly, it is possible that 
the bladder would be exposed to these metabolites for a longer period than four hours.  Granted, 
the concentrations would be varying over time as the metabolites are cleared from the 
circulation.  Accordingly, it is possible that the treatment period of four hours was not sufficient 
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to imitate the conditions of the bladder after CPO or IFO treatment.  However, given the limited 
timeframe in which isolated tissues can be used, four hours was a feasible treatment time that 
could be used as a baseline for further investigations.  The ideal model of a clinical setting is to 
treat an animal and allow normal drug metabolism and excretion to produce cystitis similar to 
what patients would experience.   
Conclusions  
The results of the present study have demonstrated that both acrolein and CAA are capable of 
causing some urothelial damage within just four hours.  This supports the findings of the 
previous Chapter suggesting that CAA and not just acrolein may contribute to the urotoxicity of 
CPO and IFO.  The damage induced by both acrolein and CAA suggest a loss of detrusor 
muscle function, but no change in efferent nerve induced responses.  This also supports 
findings of systemic CPO treatment in animals showing a significant reduction in detrusor 
contractility several days after treatment and suggests that these effects may start as early as 
four hours after metabolite excretion.  Acrolein and CAA treatment also tended to cause 
reduction in the inhibitory effect of the urothelium on the detrusor.  Whether this effect persists 
at the later stage of CPO or IFO induced cystitis is unknown but it may contribute to the bladder 
overactivity experienced by patients.  CAA and not just acrolein may have a role in the 
urotoxicity of CPO and IFO and ignoring it role may be contributing to the limited efficacy of 
preventative measures.  Accordingly, this research suggests that CAA production should be 
considered when trying to prevent cystitis in patients receiving CPO or IFO.   
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5.1 INTRODUCTION  
As covered previously, bladder afferent nerves sense chemical and mechanical changes in the 
bladder and relay information about volume during storage and the amplitude of contractions 
during voiding to the central nervous system (Kanai and Andersson, 2010).  The activity of the 
afferent nerves controls the storage and micturition reflexes of the bladder and is imperative to 
normal function of the bladder.   
Classification & function of afferent nerves 
There are two main types of afferent fibres in the bladder, myelinated A-δ fibres and the more 
common unmyelinated C-fibres (Kanai and Andersson, 2010, Birder et al., 2010a, Gabella and 
Davis, 1998).  Afferent nerves can be classified according to a variety of different characteristics.  
However, one of the most frequently used classifications is whether the fibres becomes active 
at low (<15mmHg) or high (>15mmHg) intravesical mechanical thresholds (Daly et al., 2007, 
Rong et al., 2002, Shea et al., 2000).  Nerves that do not respond to mechanical stimuli are 
termed silent afferents and may become mechanosensitive during inflammation (Shea et al., 
2000).  It is estimated that approximately 75% of mouse pelvic afferents are sensitive to stretch 
with receptive fields throughout the bladder (Jung et al., 2012).  Recently, afferent fibres in the 
mouse have been further classified on the location of their receptive field and responses to 
various mechanical stimuli (urothelial stroking, blunt probing and stretch) with four distinct 
populations being observed (muscular, urothelial, muscular/urothelial, and serosal) (Jung et al., 
2012). A more detailed description of each classification follows:  
Urothelial: Afferents that responded to fine stroking of the urothelium 
but not to bladder stretch were classified as urothelial afferents.  
Urothelial afferents made up 9% of the pelvic nerve fibres.  
Muscular: Muscular afferents were characterised as having receptive 
fields in the bladder wall and responded to probing and stretch but not 
urothelial stroking.  Muscular fibres were the most common pelvic 
nerves fibres making up 63% of the sample.  
Muscular/urothelial: Afferents that responded to both urothelial 
stroking and stretch of the bladder were characterised as 
urothelial/muscular fibres. Of the total sample of pelvic fibres, 14% 
were classified as muscular/urothelial fibres.  
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Serosal: Afferent fibres with receptive fields in the bladder wall that 
responded to probing but not to stretch or urothelial stroking were 
deemed to be serosal afferents.  This group also made up 14% of the 
pelvic fibres.   
Similar classification of afferent nerves has been made in other species such as the guinea pig.  
Zagorodnyuk et al., (2006, 2007) identified four classes of afferents including stretch-sensitive 
muscle and muscle/mucosal mechanoreceptors as well as stretch-insensitive mucosal 
mechanoreceptors and chemoreceptors. Firstly, the muscle mechanoreceptors responded to 
stretch but not mucosal stroking, which is similar to the muscular afferents described in mice.  
Secondly, the muscle/mucosal mechanoreceptors responded to stretch and mucosal stroking, a 
similar response to the muscular/urothelial afferents described by (Jung et al., 2012).  The third 
group of afferents termed mucosal mechanoreceptors responded to mucosal stroking but not 
stretch, which is similar to the urothelial afferents in mice.  Lastly the chemoreceptors were 
stimulated by acid or high K
+ 
but not stretch or stroking.  
It was originally postulated that mechanoreceptors are in series tension receptors that fire in 
proportion to intravesical pressure during both contraction and distension (Iggo, 1955).  
However, two response patterns of stretch sensitive bladder afferent nerves have recently been 
reported in rats (Shea et al., 2000).  One type demonstrated continuously increasing firing rates 
as the bladder filled to maximum distension, while the second type exhibited peak firing rates at 
lower than maximum pressure during filling followed by a plateau or a decrease in activity at 
higher pressures.  These two response patterns have also been shown in mice (Jung et al., 
2012) and were termed encoding (firing increasing to maximum stretch) and non-encoding 
fibres (peaking at lower than maximum stretch followed by a plateau).  The non-encoding fibres 
were found to be more common than encoding fibres. 
The ability of afferent nerves to sense a mechanical force may be due to direct and indirect 
mechanisms. Direct mechanisms of mechanotransduction include the opening of gated ion 
channels by deformation of the channel or by tugging on the channel protein by cytoskeletal or 
extracellular tethers (Gillespie and Walker, 2001, Hamill and Martinac, 2001).  Indirect 
mechanotransduction may also occur due to the release of mediators from the urothelium in 
response to stretch or via electrical communication from the interstitial cells (Cockayne et al., 
2000, Fry et al., 2007).   
Several studies have demonstrated the ability of afferent fibres to become sensitised to irritation 
or inflammation (Rong et al., 2002, Jung et al., 2012, Habler et al., 1990).  An increase in 
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afferent nerve response magnitude and a reduction in response threshold are features of 
afferent sensitisation (Bessou and Perl, 1969).  Sensitisation can result in an increase in the 
excitability of the receptive ending to stimuli and is thought to be important in the development 
of hyperalgesia/hypersensitivity (Bessou and Perl, 1969).  Rong et al., (2002) demonstrated in 
mice that silent fibres could be sensitised by intravesical instillation of αβmATP and become 
mechanosensitive.  Interestingly, nearly all of the high threshold fibres were also sensitised by 
αβmATP demonstrating a lower threshold of activation and increased peak activity during 
distension.  Approximately half of the low threshold fibres were also sensitised by the agonist, 
reaching a higher peak of activity while their activation threshold remained the same.  Similar 
results were reported by Xu & Gebhart (2012) using an inflammatory mixture of bradykinin, 
serotonin, histamine and PGE2 in mice.  Results showed that both high and low threshold fibres 
were sensitised by the inflammatory mixture resulting in a greater peak firing response.  In 
addition, the activation threshold of the high-threshold fibres decreased to be similar to that of 
the low-threshold fibres.  
The effect of CPO or IFO on afferent nerves in the rodent 
Treatment with CPO or IFO causes bladder inflammation (cystitis) and can result in sensory 
disturbances such as pain, feelings of residual volume or urinary frequency. Similar functional 
changes which are suggestive of hyperreflexia have been reported in animals treated with CPO 
or IFO (Okinami et al., 2014, Macedo et al., 2011, Wang et al., 2008b, Kageyama et al., 2008, 
Andersson et al., 2008, Ito et al., 2008, Juszczak et al., 2009) and even after intravesical 
instillation with acrolein (Wang et al., 2008b).  However, few studies have looked into the direct 
effects of CPO or IFO treatment on afferent nerve function and responsiveness.  Whole-cell 
patch-clamp recordings of isolated DRG neurones from CPO treated rats demonstrated lower 
thresholds for spike activation and subsequently more action potentials to a current stimulus 
compared to controls (Yoshimura and de Groat, 1999).  Dang et al., (2008) using the same 
model, reported similar results but additionally found that responses to purinergic receptor 
agonists were increased in DRG neurones from CPO treated rats.  Multiunit nerve recording in 
rats demonstrated that CPO treatment caused increased activity of the pelvic nerve afferents 
during bladder distension (Yu and de Groat, 2008).  At low intravesical pressure, the enhanced 
nerve firing could be reduced by the P2 receptor antagonist PPADS.  In addition, the threshold 
of activation of pelvic nerves to electrical stimulation was also lower in CPO treated rats.   
These studies provide evidence that afferent activity is altered after CPO treatment however it 
remains to be shown whether low or high threshold nerves are affected by treatment and 
 154 
 
whether their responses to other agonists are changed.  In addition, no studies to date have 
investigated the direct effect of IFO on bladder afferent firing.  
Evaluation of nerve function 
Measuring the characteristics and excitability of isolated DRG neurones is often used as a 
preliminary way to study nerve function.  This method is limited as it does not provide a link to 
physiological conditions in the bladder such as pressure during filling or detrusor tone.  A pelvic 
nerve preparation has been used previously to study the function of the afferent nerves in 
relation to bladder distension in mice (Rong et al., 2002, Daly et al., 2007).   The model 
maintains the whole urinary tract intact from kidney to urethra and it remains attached to the 
surrounding tissues.  A catheter inserted through the urethra allows filling of the bladder while a 
two-way catheter secured in the dome of the bladder allows emptying of the bladder and 
measurement of intravesical pressure by a pressure transducer.  The pelvic nerves can be 
dissected into fine branches and nerve impulses recorded from a branch using a suction 
electrode. This model allows recording of afferent activity in response to repeated distension of 
the bladder or application of pharmaceutical agents.  In addition, the preparation enables 
discrimination of single afferent fibres in the nerve branch and classification of each fibre into a 
low or high threshold category.  This model allows more functional investigation of bladder and 
nerve interactions and was used to test the aims of the present study.   
Aims 
The aim of the present study was to investigate the activity of pelvic afferent nerves of the 
mouse bladder after treatment with CPO or IFO. Specific aims were:  
 To determine the effect of CPO or IFO treatment on total afferent nerve activity 
during bladder distension;  
 To investigate the effect of CPO or IFO treatment on the activity of low and high 
threshold afferent nerve fibres;  
 To assess the activity of afferent nerves in response to various agonists and 
whether the responses are altered after CPO or IFO treatment;  
 To determine the contribution of muscle tone to afferent nerve responses and 
whether it changes after CPO or IFO treatment.   
  
 155 
 
5.2 METHODS  
Animals  
Young adult male C57/6B mice were obtained from the Griffith University Gold Coast animal 
house under ethics licence No. MSC/06/13 held by Dr. Roselyn Rose‘Meyer. Animal treatments 
and euthanasia were performed at the Griffith University animal house and tissues were 
transported to Bond University for all experimental procedures (Bond University ethics 
No. RO1762).  The C57/6B is a widely used inbred strain of mouse.  Three to five month old 
(young adult) male mice were used for this project. The animals were housed for at least one 
week in a controlled environment with 12 hour light/dark cycles, constant temperature 
maintained to ≈23°C with free access to food and water.  An animal was selected for treatment 
in one of three groups: control (saline treated), CPO (100mg/kg) treated or IFO (200mg/kg) 
treated.  
Several studies have used CPO or IFO to treat cancer in mice and the reported doses range 
between 30mg/kg – 200 mg/kg intraperitoneally for CPO (Kusnierczyk et al., 1999, Harnack et 
al., 2011, Ma et al., 2011) and 60 - 350 mg/kg intraperitoneally for IFO (Silbermann et al., 1990, 
Brucker and Sieg, 1999, Wang et al., 2008a, Yamada et al., 2009).  For this study, a CPO dose 
of 100mg/kg and an IFO dose of 200mg/kg were chosen which fall within the doses used for 
cancer treatment in mice.  Both drugs were dissolved in saline and injected intraperitoneally 
while, control animals were treated with an equal volume of saline.  Animals were kept 
separately after treatment and were monitored for signs of distress or pain at 6 and 12 hours 
post treatment. Animals were sacrificed humanely 24 hours after treatment by cervical 
dislocation in accordance with ethical committee approval and the guidelines of the National 
Health and Medical Research Council of Australia.  An incision was then made in the abdomen 
of the animal removing the skin and peritoneum of the abdomen.  The gastrointestinal tract 
superior to the bladder was removed revealing the kidneys.  The vertebra of the animal was 
severed above the kidneys at approximately the level of L2.  The tail and the hind limbs were 
removed and the remaining pelvic area was placed into cold Krebs solution (recipe page on 53) 
for transport.  
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Afferent Nerve Recording  
After dissection, the lower abdomen was secured in a 30mL bath and was continually 
superfused with Krebs solution gassed with 95% O2 - 5% CO2 at a rate of 6mL/min and was 
maintained at a constant temperature of 35°C.  Using a dissection microscope (WPI, PZMIII), 
the testes, prostate and surrounding connective tissues were dissected away from the bladder 
exposing the pubic symphasis. The ureters were ligated to prevent leakage of intravesical fluid. 
The pubic symphasis was cut either side of the urethra and was removed. The pelvic bone on 
either side of the urethra was also removed along with remaining bone from the hind legs.  The 
end of the urethra was cut and a catheter (OD 0.03IN) attached to a syringe pump (Genie, Kent, 
multi-phaser
TM
 model NE-1000) was inserted into the bladder and secured in place with silk 
suture to allow distension with isotonic saline (0.9%) solution.  The bladder was then partially 
filled to allow the dome to be pierced with a fine syringe needle (BD microlance
TM
,
 
19G). A two 
way catheter was inserted into the dome of the bladder to allow measurement of the intravesical 
pressure via a pressure transducer (DTX
TM
 plus DT-XX, Becton Dickinson, Singapore) and to 
allow emptying of its contents via a two-way outflow tap (see Figure 5.1).  The two-way catheter 
was secured inside the bladder using silk suture and the position of the tap (open or closed) 
allowed control over filling or emptying of the bladder.  
The bladder was distended by infusing saline at 30µl/min to a maximum intravesical pressure of 
40mmHg to check the viability of the catheterisation.  If leaks were apparent, then all suture ties 
were checked and connections in the catheter lines tightened. The infusion pump was stopped 
and the tap in the two way catheter was opened to allow complete evacuation of the intravesical 
contents of the bladder.   
Following successful catheterisation, bladder nerve bundles were identified. Bladder nerve 
bundles converge with urethral bundles as they both travel toward the spinal cord and it is at 
this meeting point that they are easiest to identify under the microscope.  Firstly, connective and 
fatty tissues were removed from the distal end of the urethra toward the bladder until the 
urethral nerve bundles were identified.  Then further tissue was removed until the urethral 
bundles join the bladder bundles and until an individual nerve branch could be divided from the 
bladder bundle. The nerve branch was then inserted into a suction electrode (tip diameter 
25-50μm) attached to a Neurolog headstage (NL100, Digitimer Ltd, UK) to allow recording of 
multi-unit afferent nerve activity (Figure 5.2). The NL100 was connected to an AC pre-amp 
(NL014, Digitimer Ltd) which amplified the nerve signals (x10,000) before they were filtered 
(NL125, band pass filter, Digitimer Ltd) and passed through a 50/60Hz electrical noise 
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eliminator (Humbug, Quest Scientific, Canada) to a Micro1401 analogue to digital interface 
(Cambridge Electronic Design, UK) and then visualised on a computer using Spike2 software 
(version 7.1, Cambridge Electronic Design, UK). Whole nerve multi-fibre afferent nerve activity 
was quantified using the Spike2 software which counted the number of action potentials 
crossing a pre-set threshold.  The bladder was again distended at 30µl/min to 40mmHg to 
ensure the nerves isolated originated in the bladder and if no signal was obtained, another 
nerve branch was isolated and placed in the suction electrode.   
 
Figure 5.1: Schematic showing the mouse afferent nerve recording set up with the bladder connected to a 
urethral catheter and a two-way catheter.  
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Figure 5.2: Photograph showing the mouse afferent nerve recording set up with the bladder connected to a 
urethral catheter and a two-way catheter (A) and a closer photograph showing the nerve branch inside the 
suction electrode (B). 
Intravesical Pressure & Bladder Distensions  
An infusion pump was used to pump isotonic 0.9% saline solution into the bladder at a constant 
rate of 30µl/min.  When the outflow tap was in the closed position the bladder filled with saline 
and intravesical pressure developed.  This pressure was measured via the pressure transducer 
in mm of mercury (Hg).  The bladder and catheter set up created a small measurable pressure 
reading even when the bladder was empty.  This baseline pressure was subtracted from the 
pressures during distension to give the change in pressure.  
Typically, the bladder distensions performed during the following experiments were to a 
maximum of 40mmHg.  As volume in the bladder increased, intravesical tension also increased. 
Bladder filling typically included two distinct phases (Figure 5.3-A).  The initial phase was 
characterised by a gentle increase in pressure to approximately 15mmHg during which time the 
bladder accommodated a large volume of saline.  This was followed by a second phase 
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characterised by a steep increase in pressure up to 40mmHg in response to a small volume.  
The bladders showed stable and repeatable pressure responses to distension at 30µl/min 
(Figure 5.3-B).   
 
Figure 5.3: Representative trace of distensions to increasing intravesical pressure to 40mmHg in a mouse 
bladder showing the two phases of filing (A) and the repeatability of the distension response (B).  
Mediator Release  
Once the preparation had been successfully set up, samples were collected for measurement of 
basal and stretch release of ATP and ACh. To collect basal samples, the outflow tap was 
opened and the infusion pump turned on to infuse saline through the bladder at 30µl/min with no 
pressure development.  The pump was left to run for nine minutes in total, the first two minutes 
were to flush the bladder and the saline flowing from the outflow tap during this time was 
discarded.  For the remaining seven minutes the saline passing through the bladder was 
collected in a tube on ice and transferred to storage at -20°C as soon as possible after 
collection for later analysis. A volume of 210µl was collected during the seven minutes which 
was a sufficient amount for analysis of ATP and ACh.  
Next, to collect samples during bladder distension (stretch) the outflow tap was closed and the 
infusion pump filled the bladder at 30µl/min.  Once the intravesical pressure reached 20mmHg, 
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the infusion pump was turned off and the outflow tap opened.  The luminal contents of the 
bladder were collected into a tube on ice and were stored as soon as possible after collection at 
-20°C. This process was repeated twice more in the presence of the ATP‘ase inhibitor 
ARL67156 (100µM) in saline, with 10 minutes recovery between each distension.  
The basal and stretch samples with and without ARL67156 were then used within three weeks 
in the assays described in Chapter 2 for quantification of ATP and ACh levels.   
Nerve Firing  
Multi unit nerve activity was quantified using Spike2 software which counted the number of 
action potentials or ‗spikes‘ that cross a pre-set threshold (Figure 5.4-C) and simultaneously 
represents the nerve activity per one second bin in a sequential rate histogram (nerve impulses 
per second [imp/sec]) (Figure 5.4-B). As the bladder fills, the electrical impulses increase and 
translate as larger spikes which then cross the threshold registering as a nerve impulse (Figure 
5.4-D & E).  The threshold can be manually set depending on the parameters to be measured.  
In the following experiments, the aim was to measure total nerve activity.  Accordingly, the 
threshold was set to measure nerve activity developed by an empty bladder. Baseline afferent 
activity was obtained by averaging the discharge in the 100 second period prior to the 
distension.  The afferent nerve response during bladder distension was calculated by measuring 
the afferent activity (imp/sec) at each intravesical pressure increment up to 40mmHg. These 
values were then subtracted from the baseline firing to give a total change in afferent nerve 
response during distension.   
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Figure 5.4: Representative traces during distension of a mouse bladder showing intravesical pressure (A), a 
sequential rate histogram of the number of nerve impulses per second (B) generated from raw nerve activity (C) 
when action potentials cross a pre-set threshold. A closer view of the raw nerve activity during low intravesical 
pressure (D) and high intravesical pressure (E).  
Compliance 
Bladder compliance is the relationship between bladder volume and bladder pressure or more 
simply, the ability of the bladder to accommodate a volume.  In the following experiments, 
bladders were filled to a consistent pressure. This ensured the bladders received the same 
mechanical stimulus and reduced variability due to bladder size.  As bladders were filled at a 
constant rate, volume could be calculated from time since the start of distension using the 
following equation:  
Volume (μl) = Rate (μl/sec) x Time (sec) 
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The ability of the bladder to accommodate a set intravesical pressure was also used as a 
measurement of compliance. In the following experiments the bladders were filled to a set 
pressure of 20mmHg and left for up to an hour for bladder pressure to reach a stable plateau.  
Changes in intravesical pressure and afferent activity were measured during filling and 
accommodation and bladder compliance was represented as an XY graph showing the 
relationship between volume and pressure in each setting.  
Spontaneous Contractions 
During bladder distension and accommodation, phasic intravesical pressure increases were 
observed (Figure 5.5 and Figure 5.6). These spontaneous contractions demonstrated 
consistent frequency and amplitude within a bladder preparation and were associated with 
phasic increases in afferent nerve activity.  The frequency and amplitude of spontaneous 
contractions during filling and accommodation were also quantified.  Spontaneous contractions 
during filling were measured during the 200s preceding intravesical pressure reaching 15mmHg 
and during accommodation were measured during the 200s at the end of the 1 hour 
stabilisation period.  Amplitude of a contraction was measured by subtracting the pressure at 
the beginning of the contraction from the pressure at the peak of the contraction and the 
average represented as mmHg.  Average frequency was represented as contractions per 
minute.  The increase in afferent activity associated with each contraction was also quantified 
and the average represented as nerve impulses per second.  
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Figure 5.5: Representative traces of a control isolated mouse bladder showing spontaneous phasic 
contractions (A) during filling and the associated nerve activity (B). 
 
Figure 5.6: Representative traces of a control isolated mouse bladder showing spontaneous phasic 
contractions (A) during accommodation and the associated nerve activity (B). 
Response to Pharmacological Agents 
To study the effect of a drug on afferent response or muscle tension, the bladder was filled to a 
set pressure of 20mmHg and allowed to stabilise for an hour.  The muscle then had a stable 
baseline tension and afferent output from which to determine the effect of the drug.  Agonists 
were then added to the bath and the effect of the drug on afferent activity was calculated by 
measuring the mean peak response (imp/sec) and subtracting the mean baseline activity 30 
seconds before drug application. Bladder, contractions were determined as the changes in 
intravesical pressure from baseline pressure and expressed in mmHg. 
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Drugs were also applied to the luminal surface of the bladder though the urethral catheter. 
Drugs were diluted in isotonic saline to the desired concentration and instilled through the 
urethral catheter via the syringe driver. With the out-flow tap open, the drug was infused at 
30µl/min so there was no change to intravesical pressure. Afferent activity was monitored during 
drug infusion as well as during distensions with the drug solution.  
Single Unit and Principal Component Analysis 
Single-unit (single nerve fibre) discrimination was performed offline using the Spike2 wavemark 
analysis function which discriminates between the distinct action potential characteristics of 
individual nerve fibres including waveform, amplitude and duration.  The action potentials were 
analysed and templates were constructed based on their distinct shape in order to identify the 
individual nerve fibres in each preparation (Figure 5.7). 
Afferent activity was sampled at 20,000 Hz such that a 1.8msec period consisting of 
approximately 28 data points was used to construct each template. Templates were used to 
allocate every action potential throughout a recording to a distinct single unit as shown by the 
wavemark trace in (Figure 5.7-C).   The parameters for a spike to match a template were 
typically <10% variability in amplitude and >60% of data points within the template boundary.   
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Figure 5.7: Characterisation of the single nerve fibres active during distension of a mouse bladder (A) wherein 
the total nerve activity (B) is differentiated into six distinct fibres (C) based on action potential shape (D).    
Principal component analysis (PCA) was then used to ensure that the spike templates identified 
were different enough to be classified as distinct nerve fibres.  PCA uses algorithms to extract 
features from the data that contribute most to differences between spike shapes such as 
amplitude, latency, area or slope (Figure 5.8-A).  PCA scales and represents the differences 
between spike shapes in 3-dimensions so that spikes having a similar shape are clustered 
together.  Figure 5.8-B is a 2-dimensional representation of this display where each coloured 
cluster represents spikes matching a single template.  The amount of overlap between the 
clusters was evaluated by eye and clusters which had significant overlap were considered too 
similar to be from distinct nerves and were classified as originating from one nerve fibre.  
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As well as total nerve activity, fibre averaging analysis was also performed in the following 
experiments. Fibre averaging analysis involves determining the activity of each individual fibre 
in a bundle and averaging them so that the impulses per second per fibre can be determined for 
each preparation.  This reduces the variation in results due to differences in the number of 
fibres in a nerve bundle.  Using templates and PCA, the number of distinct fibres isolated in 
each experiment was determined and the nerve activity was then averaged to give the nerve 
activity per single fibre. 
 
Figure 5.8: A screen shot showing the characteristics used to cluster action potentials allocated to each 
template (A) and a 2-dimensional representation of the 3-dimensional clustering of action potentials according 
to the characteristics selected, with 4 distinct single unit clusters shown (B).  
Single Unit Classification  
Once the distinct single units of each bundle were identified, the fibres were then classified 
based on the pressure at which they were activated.  Two broad classifications were used, low 
threshold fibres and high threshold fibres.  Low threshold fibres were defined as those fibres 
responding at pressures below 15mmHg and high threshold as those responding at pressures 
above 15mmHg.  Classifying nerves as high or low threshold using 15mmHg is consistent with 
previous studies (Daly et al., 2007, Rong et al., 2002) and is approximately the micturition 
threshold in the mouse (Igawa et al., 2004).  Figure 5.9 shows a recording from a nerve bundle 
containing three distinct fibres, one of which responds only to pressures above 15mmHg (D) 
and would be classified as a high threshold fibre, while the other two fibres (E & F) show activity 
at pressures below 15mmHg and would be classified as low threshold fibres.  
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Figure 5.9: Representative trace during distension of a mouse bladder to 40mmHg (A), showing total nerve 
activity (B) characterised into three distinct nerve fibres (C) and the activity of each fibre isolated and classified 
as one high threshold fibre (D) and two low threshold fibres (E & F).  
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Experimental Protocol  
At the beginning of each experiment, the viability of the preparation was checked.  If the nerve 
failed to give typical reproducible responses to distension the nerve was removed from the 
electrode and another nerve branch was selected.  The nerve preparation was left to stabilise 
for 30-60 minutes with the bladder empty.  Then, a control distension was performed by closing 
the outflow tap, filling the bladder with saline (0.9% NaCl) at 30µl/min to a pressure of 40mmHg 
and opening outflow tap allowing the bladder to empty. This was repeated every 10 minutes 
until a stable pressure and afferent response to distension was observed (see Figure 5.10).   
The bladder was then distended at 30µl/min to 20mmHg and left with the outflow tap closed for 
1 hour to allow accommodation of the volume and stabilisation of bladder tone and nerve 
activity.  After 1 hour the internal pressure and the afferent output had stabilised (Figure 5.11).   
 
Figure 5.10: Representative traces showing repeatable intravesical pressure (mmHg), raw nerve activity (µV) 
and nerve activity (imp/sec) during three distensions of a mouse bladder.  
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Figure 5.11: Representative trace of a mouse bladder showing stabilisation of intravesical pressure (mmHg) 
and nerve activity (imp/sec) during accommodation of a volume.  
After the detrusor tone and afferent activity stabilised, a variety of pharmacological agents were 
then sequentially added to the bath as per the following list, allowing at least 30 minutes 
superfusion to wash the tissue between each drug addition: 
 ATP (1mM) (purinoceptor agonist) 
 αβmethylene ATP (10μM) (P2X purinoceptor agonist) 
 ACh (1μM) (muscarinic and nicotinic receptor agonist) 
 Carbachol (10µM) (muscarinic receptor agonist) 
 Polygodial (10μM) (TRPA1 channel activator) 
 DMPP (10μM) (nicotinic receptor agonist) 
 WS-12 (10μM) (TRPM8 channel activator) 
 PGE2 (1μM) (E-prostanoid receptor agonist) 
 SNP (1mM) (NO donor) 
 Capsaicin (10μM) (TRPV1 channel activator) 
In separate experiments the responses to ATP (1µM), αβmethylene ATP (10μM), carbachol 
(10µM) and DMPP (10µM) were repeated in the absence and presence of nifedipine (1µM) an 
L-type calcium channel blocker that blocks smooth muscle contraction and associated indirect 
nerve responses, thereby uncovering the direct nerve responses to the drug alone.  These 
experiments were performed in control and CPO (100mg/kg) treated mice only.  Firstly, the 
drugs were sequentially added in the absence of nifedipine with appropriate wash times 
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between each drug addition.  Next, Krebs solution containing nifedipine (1µM) was superfused 
continuously over the tissue for 30 minutes prior to adding the drugs again in the same 
sequence with the same wash periods between each drug addition. The pressure and nerve 
responses remaining in the presence of nifedipine (1µM) were represented as a percentage of 
the response in the absence of nifedipine.  Responses in CPO treated bladders were compared 
to responses in control bladders.  
Statistical Analysis 
Results were expressed as mean ± standard error of the mean (SEM).  Data were analysed 
using a Student t-test or one-way ANOVA with Dunnett or Tukey multiple comparisons test as 
appropriate, using Graphpad InStat (version 3.06) software (SanDiego, CA). Comparisons of 
whole response curves of control and treated groups were performed using two-way ANOVA 
with Bonferroni post-test. Significance levels were defined as p<0.05 (*), p<0.01 (**) and 
p<0.001 (***). 
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5.3 RESULTS  
Before treatment, there was no significant difference in age or weight between animals in each 
treatment group while CPO (100mg/kg) and IFO (200mg/kg) treatment caused greater weight 
loss after 24 hours than in control animals (p<0.01). Average bladder volume was not different 
between the three groups (347±31µl in controls, 272±35µl in CPO treated and 365±54µl in IFO 
treated animals.    
Intravesical Pressure and Nerve Activity During Bladder Distension 
Firstly, the effects of CPO and IFO on bladder pressure and nerve activity during graded 
distensions were investigated.  As volume in the bladder increased both intravesical pressure 
and bladder sensory nerve activity increased.  Both the muscle and nerve of each mouse 
bladder demonstrated stable and repeatable responses during distensions at 30µl/min to 
40mmHg. The afferent nerve response was almost completely abolished by tetrodotoxin (TTx) 
(1µM) (Figure 5.12).  
Bladder filling typically included an initial gentle increase in tension to approximately 15mmHg 
accompanied by a large increase in afferent nerve activity.  This phase was followed by a steep 
increase in tension accompanied by a smaller increase in afferent nerve activity.  This pattern of 
filling occurred in all bladders in all treatment groups despite variations in total bladder volume 
and volumes accommodated in each phase.   
 
Figure 5.12: Representative trace (A) and graph (B) showing the effect of tetrodotoxin (TTx) (1µM) on the 
afferent nerve activity during distension of a mouse bladder (n=1).  
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Initially, IFO was examined at an equal dose to CPO (100mg/kg) to investigate the contribution 
of CAA to any changes in response.  However, at this lower dose, IFO (100mg/kg) had no effect 
on compliance of the muscle (Figure 5.13-A) or afferent nerve activity (Figure 5.13-B) during 
distensions (n=4) and the more clinically relevant dose of 200mg/kg was used for further 
experiments.   
 
Figure 5.13: Compliance (A) and afferent nerve activity (B) of mouse bladders treated with saline (control) or 
IFO (100mg/ml). Data represented as mean ± SEM (n≥4). Analysed by two-way ANOVA.  
Treatment with CPO (100mg/kg) or IFO (200mg/kg) had no effect on the compliance of the 
bladder muscle during distensions (Figure 5.14-A).  However, nerve activity after treatment with 
either CPO or IFO was enhanced throughout bladder filling (Figure 5.14-B). At maximum 
distension the total nerve activity was increased significantly from 182±13 impulses per second 
(imp/sec) in control animals, to 230±14 imp/sec in CPO treated mice (p<0.05)  and 226±17 
imp/sec in IFO treated mice (p<0.001) (n≥6).  However, the difference was even greater at 
15mmHg where CPO and IFO increased nerve activity from 122±12 imp/sec in controls to 
189±17 imp/sec and 180±22 imp/sec respectively.  
The single units were identified in each preparation and the average number of distinct nerve 
fibres was not significantly different between treatment groups.  Nerve bundles from all groups 
contained between 6-13 distinct nerve fibres with the average being 8.8±0.8 fibres in control, 
8.1±0.6 fibres in CPO and 9.2±0.5 fibres in IFO treated animals (Figure 5.15).  These single 
fibres were also classified based on their activation threshold and the number of both low and 
high threshold fibres was similar between groups.  Low threshold fibres were more numerous 
than high threshold fibres in all treatment groups ranging between 4-10 low threshold fibres 
compared to 0-4 high threshold fibres in each bundle.  Accordingly, low threshold fibres made 
up 59.8±8.8% of the total fibre population in control bladders and while not significant, treatment 
with CPO or IFO showed a trend towards an increasing population of low threshold fibres to 
76.5±7.1% and 75.8±6.3% respectively (Figure 5.16). 
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Figure 5.14:  Compliance (A) and afferent nerve activity (B) of mouse bladders treated with saline (control), CPO 
(100mg/ml) or IFO (200mg/ml). Data represented as mean ± SEM (n≥6). Analysed by two-way ANOVA (*p<0.05 vs 
comparable control activity at individual pressure interval, ###p<0.001 vs whole control curve).  
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Figure 5.15: The average number of individual nerve fibres (single units) identified in each mouse bladder 
preparation (A) as well as the number of these fibres classified as low threshold fibres (B) and high threshold 
fibres (C). Data represented as mean ± SEM (n≥6). 
 
 
Figure 5.16: The percentage of nerves classified as low threshold in saline (control), CPO (100mg/kg) or IFO 
(200mg/kg) treated mice.  Data represented as mean ± SEM (n≥6). 
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The activity of each distinct nerve fibre was determined and fibre averaging analysis performed 
to obtain the average activity per fibre in each preparation.  At maximum distension the average 
activity per fibre was significantly increased from 19.1±1.1 impulses per second per fibre 
(imp/sec/fibre) in control animals, to 29.1±1.8 imp/sec/fibre in CPO treated mice (p<0.01) and 
24.9±1.4 imp/sec/fibre in IFO treated mice (p<0.05) (Figure 5.17).   
The effect of CPO or IFO treatment on the activity of low and high threshold fibres was 
assessed next.  As intravesical pressure increased, low threshold fibres demonstrated a rapid 
increase in nerve activity up to approximately 15mmHg at which point further increases in 
activity were gradual and activity started to plateau at maximum distension (Figure 5.18-A).  
High threshold fibres became active when intravesical pressure reached approximately 
15mmHg and then continued to increase in activity at a steady rate to maximum distension 
(Figure 5.18-A).  Low threshold fibres had a greater firing rate at maximum distension 
(23.3±1.9 imp/sec/fibre) compared to high threshold fibres (14.5±1.7 imp/sec/fibre) (p<0.01). 
The activity of high threshold nerves was unchanged after treatment with cyclophosphamide or 
ifosfamide (Figure 5.18-C), whereas treatment caused enhanced activity of the low threshold 
nerves (p<0.05) (Figure 5.18-B).  Low threshold nerve activity at maximum distension 
increased significantly from 23.3±1.9 imp/sec/fibre in control animals, to 31.5±2.5 imp/sec/fibre 
in CPO treated mice (p<0.01) and 29.9±2.0 imp/sec/fibre in IFO treated mice (p<0.05) (n≥44). 
 
 
Figure 5.17: Average maximum nerve activity (imp/sec) per individual nerve fibre during bladder distension at 
40mmHg in bladders from saline (control), CPO (100mg/kg) or IFO (200mg/kg) treated mice. Data represented as 
mean ± SEM (n≥6).  Analysed by one-way ANOVA with Dunnett post test (*p<0.05, **p<0.01 vs control). 
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Figure 5.18: Afferent nerve activity of low (n=52) and high threshold fibres (n=22) in control animals (A) and the 
effect of treatment with CPO (100mg/ml) or IFO (200mg/ml) on low threshold nerve activity (B) (n≥44) and high 
threshold nerve activity (C) (n≥10). Data represented as mean ± SEM and analysed by two-way ANOVA 
(***p<0.001 vs control curve). 
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In low threshold fibres, two response patterns were observed.  In the first pattern, low threshold 
afferents continued to encode up to maximum distension (Figure 5.19-A).   The second group 
demonstrated a non-encoding pattern wherein firing rate underwent an initial increase and then 
began to plateau or even decreased in activity from approximately 15mmHg (Figure 5.19-B). 
The non-encoding fibres were more numerous than the encoding fibres in control animals 
making up 67% of the low threshold fibres.  This percentage was slightly less in CPO and IFO 
treated animals with non-encoding fibres making up 58% and 52% of all low threshold fibres 
respectively although the difference was not significant.  At maximum distension, treatment with 
CPO or IFO significantly enhanced the activity of the encoding fibres from 
22.1±2.7 imp/sec/fibre to 37.8±3.1 imp/sec/fibre and 35.4±3.7 imp/sec/fibre respectively 
(p<0.05). Treatment did not affect the activity of the non-encoding fibres.  
 
Figure 5.19: Afferent nerve activity in low threshold fibres divided into encoding (A) (n≥17) and non-encoding (B) 
firing patterns (n≥18) in control animals, CPO (100mg/ml) or IFO (200mg/ml) treated animals. Data represented 
as mean ± SEM and analysed by two-way ANOVA (***p<0.001 vs control curve). 
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Spontaneous Contractions 
Given that increased spontaneous contractions of the bladder can be associated with 
dysfunction, the effect of CPO and IFO on the frequency and amplitude of phasic activity during 
filling and accommodation were measured. Treatment with CPO (100mg/kg) or IFO (200mg/kg) 
had no significant effect on the average frequency (Figure 5.20-A) or the amplitude (Figure 
5.20-B) of spontaneous contractions compared to control.  The nerve activity showed phasic 
increases associated with the muscle contractions and the phasic nerve activity was the same 
in control and CPO treated tissues (Figure 5.20-C).  Interestingly, the spontaneous detrusor 
contractions persisted in the presence of tetrodotoxin (1μM) which abolished the nerve activity 
(Figure 5.21). 
 
Figure 5.20: Average frequency (A) and amplitude (B) of spontaneous contractions in bladders from saline 
(control), CPO (100mg/kg) and IFO (200mg/kg) treated mice during filling and accommodation. Data represented 
as mean ± SEM (n≥4). Analysed by one-way ANOVA with Tukey post-test. 
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Figure 5.21: Representative trace showing the detrusor contractions and nerve activity in a bladder pre-
distended to 20mmHg before and after tetrodotoxin (1µM) followed by a normal distension.  
Response to Pharmacological Agents 
The bladder muscle and afferent nerves can respond to various pharmacological agents and 
changes in these responses may contribute to atypical bladder function.  Initially the bladder 
was filled to 20mmHg and left until pressure and nerve activity were stable in order to quantify 
the responses to various agonists.  Compliance of the bladder muscle during accommodation 
from 20mmHg intravesical pressure was unchanged by treatment with CPO (100mg/kg) or IFO 
(200mg/kg) (Figure 5.22-A). The total nerve activity was increased at 20mmHg in both CPO 
and IFO treated animals, however the nerve activity was able to adapt over time to be similar to 
the activity in control animals (Figure 5.22-B). Control, CPO and IFO treated bladders stabilised 
to a similar intravesical pressures (6.01±0.71mmHg, 6.96±0.65mmHg and 7.00±1.62mmHg 
respectively) and nerve firing rates (32.0±16.1imp/sec, 43.5±23.2imp/sec and 24.2±7.62imp/sec 
respectively) after approximately 30 minutes.  The effect of pharmacological agents was then 
determined from this stable tension and afferent activity.    
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Figure 5.22:  Compliance (A) and afferent nerve activity (B) during accommodation from 20mmHg intravesical 
pressure in mouse bladders treated with saline (control), CPO (100mg/ml) or IFO (200mg/ml). Data represented 
as mean ± SEM (n=5). First and final time point analysed by one-way ANOVA with a Dunnett post-test (*p<0.05).  
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In control preparations, extraluminal application of ATP (1mM) caused a contraction of the 
bladder smooth muscle and an associated increase in intravesical pressure (Figure 5.23) which 
returned back to baseline tension within 10 minutes.  This was accompanied by a simultaneous 
increase in total afferent activity and recovery to baseline firing.  The addition of αβmATP (10µM) 
resulted in a larger increase in intravesical pressure and total afferent activity which also 
recovered to baseline levels within 10 minutes.   
A contraction was also observed after adding ACh (1µM) and the muscle developed phasic 
contractions (Figure 5.23).  Recovery to baseline pressure took up to 30 minutes by which time 
the phasic contractions had returned to baseline levels.  The changes in pressure were also 
associated with increases in total nerve activity and recovery to pre-drug firing over 30 minutes.  
Carbachol (10µM) induced a larger increase in nerve activity and intravesical pressure 
compared to ACh and took up to one hour to recover to baseline levels.  Phasic contractions 
seen after carbachol (10µM) were also larger and more frequent than after ACh (1µM).  
Activation of nicotinic receptors by DMPP (10µM) caused an increase in nerve activity while 
having very little or no effect on intravesical pressure (Figure 5.23). Application of PGE2 (1µM) 
typically caused a small but long lasting increase in intravesical pressure.  Baseline nerve 
activity after PGE2 application did not change, however spontaneous bursts of activity appeared.  
Capsaicin (10µM) caused a small and brief intravesical pressure increase.  Nerve activity in 
response to capsaicin also increased briefly, then decreased to a level below the baseline firing 
rate and eventually recovered back to baseline after a long washout period of at least 30 
minutes.  Typically no pressure or nerve responses were seen after application of polygodial 
(10μM), WS-12 (10μM) or SNP (1mM).  
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Figure 5.23: Representative trace of intravesical pressure (A) and nerve activity (B) in a mouse bladder in response to extraluminal addition of ATP (1mM), αβmATP (10µM), ACh (1µM), 
carbachol (10µM), DMPP (10µM) and PGE2 (1µM).  
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Compared to controls, the pressure responses to αβmATP (10µM) were not changed after CPO 
or IFO treatment and while responses to ATP (1mM) were not significantly different there was a 
slight decrease after treatment (Figure 5.24-A).  Nerve responses to αβmATP (10µM) in CPO 
or IFO treated bladders were also unchanged compared to controls and responses to ATP 
(1mM) were also not significantly different despite showing a decreasing trend (Figure 5.24-B). 
Muscle responses to ACh (1µM) were increased by 30% in CPO treated bladders and reduced 
by 40% in IFO treated bladders, however this was not significant.  Nerve activity responses to 
ACh (1µM) mirrored these effects and were slightly increased after CPO treatment (40%) and 
reduced after IFO treatment (30%).  Pressure and nerve responses to carbachol (10µM) were 
also slightly increased in both CPO and IFO treated groups (10-20%) but not significantly. 
Bladders treated with CPO or IFO also demonstrated a trend towards increased nerve activity in 
response to DMPP (10µM) and PGE2 with effects appearing greater after IFO treatment.  Finally, 
in some of the CPO or IFO treated bladders, administration of SNP (1mM) increased the 
frequency of the bursts of nerve activity induced by PGE2 and increased the rate of firing during 
those bursts, while producing a very slight increase in intravesical pressure.  Overall, changes 
in response to pharmaceutical agents were greater in IFO treated bladders than CPO treated 
however these effects were only significant for the IFO induced nerve response to SNP.    
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Figure 5.24: Effect of CPO or IFO treatment on intravesical pressure responses (A) and afferent nerve 
responses (B) to ATP (1mM), αβmATP (10µM), ACh (1µM), carbachol (10µM), DMPP (10µM) and PGE2 (1µM). Data 
represented as mean ± SEM (n=≥5).  Analysed by one way ANOVA with Dunnett post test (*p<0.05 vs control 
response for each drug). 
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In control bladders, nifedipine (1µM) significantly reduced the intravesical pressure responses to 
ATP (1mM), αβmATP (10µM) and carbachol (10µM) (p<0.05) (Figure 5.25-A).  The pressure 
responses to DMPP (10µM) were almost completely removed in the presence of nifedipine 
(1µM) but this was not significant given the initial responses were small to begin with. Despite 
the significant reduction in muscle contraction to these pharmaceutical agents, nifedipine only 
reduced the nerve activity in response to carbachol (10nM) (p<0.05) (Figure 5.25-B). 
 
Figure 5.25: The effect of nifedipine (1µM) on control bladder pressure (A) and total nerve (B) responses to ATP 
(1mM), αβmATP (10µM), carbachol (10µM) and DMPP (10µM).  Data represented as mean ± SEM (n=4) and 
analysed by paired two-tailed t-test (*p<0.05, **p<0.01 vs absence of nifedipine)   
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Table 5.1:  Intravesical pressure and nerve activity responses to various agonists in the 
absence and presence of Nifedipine (1µM) in control and CPO treated bladders 
  Controls CPO Treated 
  Pressure 
Response 
(mmHg) 
Nerve 
Activity 
(imp/sec) 
Pressure 
Response 
(mmHg) 
Nerve 
Activity 
(imp/sec) 
ATP (1mM)  -Nifedipine 3.8±1.3 123±37 5.7±1.3 114±46 
+Nifedipine 0.9±0.6 78±37 1.3±0.2 81±38 
αβmATP 
(10µM) 
-Nifedipine 5.7±2.0 111±44 6.7±1.4 126±48 
+Nifedipine 1.3±0.3 98±51 1.1±0.2 83±33 
Carbachol 
(10µM) 
-Nifedipine 19±2 174±41 23±2 224±25 
+Nifedipine 3.9±0.4 94±35 4.0±0.6 111±34 
DMPP (10µM) -Nifedipine 0.37±0.27 158±38 0.77±0.29 166±33 
+Nifedipine 0.07±0.06 188±16 0.19±0.12 235±22 
 
The intravesical pressure responses to ATP (1mM), αβmATP (10µM), carbachol (10µM) and 
DMPP (10µM) were affected by nifedipine (1µM) to a similar extent in both control and CPO 
treated bladders (Figure 5.26 & Table 5.1).  Specifically, contractions to ATP (1mM) were 
reduced in the presence of nifedipine (1µM) by 83±8% in controls and by 72±8% in CPO treated 
bladders. Responses to αβmATP (10µM) were similarly reduced by 75±5% and 78±8% in 
control and CPO treated bladders respectively.  Carbachol responses in control and CPO 
treated bladders were reduced by 80±1% and 82±2%.  The responses to DMPP were almost 
completely abolished, being reduced by 94±5% and 98±1% in control and CPO treated bladders 
respectively.  
Nerve activity was less affected by nifedipine (1µM) than the pressure responses and again was 
not different between control and CPO treated tissues (Figure 5.26 & Table 5.1).  Activity due 
to ATP (1mM) was reduced in the presence of nifedipine by 37±14% and 16±28% in control and 
CPO treated bladders.  Similar results were seen in response to αβmATP (10µM) with nerve 
activity reduced by 18±13% and 38±5% in bladders from control and CPO treated mice 
respectively while carbachol responses were reduced by 49±10% and 54±10% respectively. 
The nerve activity responses to DMPP (10µM) were not reduced by nifedipine (1µM) but were 
actually increased by 34±26% and 50±15% in control and CPO treated tissues respectively.   
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Figure 5.26:  Percentage change of the intravesical pressure and nerve activity responses to ATP (1mM) (A), 
αβmATP (10µM) (B), carbachol (10µM) (C) and DMPP (10µM) (D) in the presence of nifedipine (1µM) in control 
and CPO (100mg/kg) treated bladders.  Analysed by two-tailed, unpaired t-test (###p<0.001 vs control pressure 
change, ***p<0.001 vs CPO pressure change).  
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Mediator Release  
Given the importance of urothelial mediators in bladder function and the results in Chapters 3 
and 4, the release of ATP and ACh into the lumen of the bladders was examined.  Luminal 
contents of the bladders during basal and stretch conditions in the absence and presence of the 
ATP‘ase inhibitor ARL67156 (100µM) were analysed for total ATP and ACh content.  The total 
amount of each mediator in each sample was calculated and the basal and stretch 
concentrations compared (Figure 5.27).  Stretch induced ATP and ACh levels were not 
significantly different from basal levels.  The presence of ARL67156 tended to increase ATP 
levels while decreasing ACh levels however these effects were not significantly different.   
Treatment with CPO showed a trend towards decreased ATP release compared to controls 
(Figure 5.28-A). Basal and stretch ATP levels were reduced by 50% and 60% respectively, 
however this was not statistically significant.   ACh levels were also slightly decreased after 
CPO treatment, but again not significantly (Figure 5.28-B). 
 
Figure 5.27:  Total ATP (A) and ACh (B) in basal and stretch samples in the absence and presence of ARL67156 
(100µM) from bladders of control mice. Data represented as mean±SEM (n=4). Analysed via paired two-tailed 
student’s t-test. 
 
Figure 5.28:  Total ATP (A) and ACh (B) in basal and stretch samples from bladders of mice treated with saline 
(control) or CPO (100mg/kg). Data represented as mean ± SEM (n=4). Analysed via paired two-tailed student’s t-
test. 
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Response to Intravesical Instillation of Acrolein or CAA 
Although the parent drugs appeared to affect nerve activity, it was not apparent what metabolite 
was causing the changes.  Accordingly, intravesical instillation of acrolein or CAA was 
performed to determine if either metabolite had an effect on afferent nerve activity.  The 
following experiments were performed opportunistically when untreated bladders were available 
from other researchers in our laboratory.  Accordingly, the following results represent n=1 for 
each concentration tested. Untreated bladders were distended with 0.9% saline and then the 
distension repeated with saline containing acrolein (1µM or 100µM) or CAA (1µM).  The muscle 
developed larger and more frequent phasic contractions during distension with 1µM acrolein 
compared to control distensions (Figure 5.29-A).  Intravesical installation of acrolein (1µM) also 
caused an increase in total nerve activity at pressures above 20mmHg during distension 
(Figure 5.29-B).  At higher concentrations, acrolein (100µM) also induced larger and more 
frequent spontaneous contractions (Figure 5.30-A), however total nerve activity was almost 
halved at pressures above 20mmHg during distension (Figure 5.30-B).  Intravesical installation 
of CAA (1µM) caused an increase in total afferent activity during distension without affecting 
phasic activity in the muscle (Figure 5.31).  
 
Figure 5.29: Representative trace of an untreated mouse bladder showing intravesical pressure (A) and nerve 
activity (B) during distension with 0.9% saline in the absence and presence of acrolein (1µM).  
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Figure 5.30: Representative trace of an untreated mouse bladder showing intravesical pressure (A) and nerve 
activity (B) during distension with 0.9% saline in the absence and presence of acrolein (100µM).  
 
Figure 5.31: Representative trace of an untreated mouse bladder showing intravesical pressure (A) and nerve 
activity (B) during distension with 0.9% saline in the absence and presence of chloroacetaldehyde (CAA) (1µM).  
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5.4 DISCUSSION  
The afferent nerves in the bladder are crucial for normal bladder sensations and function.  They 
are responsible for sensing chemical and mechanical changes in the bladder and coordinating 
the control of storage and voiding functions (Kanai and Andersson, 2010).  Changes to afferent 
nerve density, receptor expression, responsiveness or activation thresholds may be associated 
with bladder dysfunction such as neurogenic or idiopathic detrusor overactivity, painful bladder 
syndrome and the detrusor overactivity associated with bladder outlet obstruction (de Groat and 
Yoshimura, 2009).  Cyclophosphamide and ifosfamide are known to cause lasting sensory 
changes in the bladder such as increased frequency and urgency of micturition, feelings of 
residual volume and pain.   
The results described above show that as volume in the bladder increased, intravesical 
pressure and bladder sensory nerve activity increased.  This is consistent with observations 
reported in other studies using the same technique (Daly et al., 2007, Rong et al., 2002) despite 
their use of faster filling rates of 100µl/min and 200µl/min respectively.  The filling rate of 
30µl/min used in this study was calculated to be a more physiological bladder filling rate given 
that cystometry studies in awake normal mice have shown an average voiding volume of 200µl 
every 380 seconds (equating to approximately 32µl/60sec) (Birder et al., 2002a).  Despite the 
differences in filling rate used, the pressure and afferent firing responses were similar to these 
previous studies, with two filling phases and a non-linear relationship between pressure and 
afferent activity observed (Daly et al., 2007, Rong et al., 2002).  The first phase of bladder filling 
(between 0-20mmHg) included a gradual increase in intravesical pressure and a marked 
increase in afferent firing while during the second phase (between 20-40mmHg) intravesical 
pressure increased quickly with a smaller increase in afferent activity.  This non-linear 
relationship is best demonstrated in Figure 5.14-B and may be explained by the features and 
contribution of low and high threshold nerves which will be discussed in more detail below. 
Does CPO or IFO Treatment Enhance the Activity of Afferent Nerves? 
The results of the present study demonstrated that pre-treatment with CPO or IFO enhanced 
total afferent nerve firing during bladder distension in mice.  This supports the results of 
previous studies discussed in the introduction of this Chapter and the theory that CPO and IFO 
induced bladder hyperactivity is due to increased afferent nerve activity. Although activity was 
enhanced at maximum distension, a greater enhancement was actually observed at lower 
intravesical pressures of around 15mmHg.  An intravesical pressure of 15mmHg corresponds to 
the approximate micturition threshold in mice (Igawa et al., 2004).  Therefore, it is possible that 
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the effects of CPO and IFO on afferent activity are most apparent during typical physiological 
filling.  
A particularly relevant study performed in CPO treated rats also showed an increase in afferent 
nerve firing (Yu and de Groat, 2008).  The study used an isolated rat bladder model and 
measured afferent activity in response to distension at 40µl/min and in response to electrical 
stimulation of the bladder.  In rats pre-treated with CPO (100mg/kg) 17 hours earlier, afferent 
nerve activity was significantly increased in response to both distension and electrical 
stimulation.  However marked variability was found between the afferent responses and this 
was thought to be at least partially due to variation in the number of fibres present in the afferent 
branch during recording. Accordingly, the present study goes further to investigate whether 
increased afferent activity after CPO or IFO treatment is due to increased firing of each fibre or 
rather an overall increase in fibre density.   
Discrimination of the single units contributing to the total nerve response in each experiment 
revealed that both CPO and IFO enhanced the nerve activity per fibre.  This result confirms that 
the increase in total activity seen was in fact due to CPO or IFO enhancing the firing rate of the 
afferent nerves.  This also supports the previous findings of increased action potentials in 
isolated DRG neurones from CPO treated rats (Yoshimura and de Groat, 1999, Dang et al., 
2008) and suggests that these findings are likely to be occurring in physiological conditions.   
Given that both CPO and IFO metabolism produces the toxic metabolites acrolein and CAA, it is 
possible that the increased nerve activity is due to one or both metabolites present in the urine 
directly or indirectly affecting nerves.  Intravesical instillation of acrolein (1µM) or CAA (1µM) 
into bladders during distension caused an increase in nerve activity.   A higher concentration of 
acrolein (100µM) appeared to damage nerves causing reduced nerve activity.  Acrolein also 
caused an increase in the frequency and amplitude of spontaneous contractions during 
distension while CAA did not.  These observations came from a single experiment with each 
concentration so should be interpreted with caution.  However, similar effects of intravesical 
acrolein have been reported previously where 0.003% acrolein increased Aδ and C-fibre 
afferent activity and appeared to increase spontaneous contractions (Aizawa et al., 2011, 
Minagawa et al., 2012). No other studies have investigated the effect of intravesical instillation 
of CAA on bladder afferent nerves.  In these preliminary investigations, the effects of acrolein on 
nerve activity were greater than CAA however they suggest that both metabolites are capable of 
increasing afferent firing during distension and further investigation would be warranted.   
  
 193 
 
The metabolism of CPO and IFO was discussed previously.  CPO metabolism occurs 
approximately 80% via an acrolein producing pathway and 20% via a CAA producing pathway 
whereas, IFO metabolism occurs by approximately 50% acrolein and CAA producing pathways.  
Initially, IFO was investigated at an equal dose to CPO (100mg/kg) to investigate the effect of 
less acrolein and higher CAA production on afferent nerve activity.  No change in afferent nerve 
activity was seen after treatment with this lower dose of IFO (100mg/kg) despite a significant 
increase in activity after CPO treatment at the same dose (100mg/kg).  Next, a higher and more 
clinically relevant dose of IFO was used (200mg/kg) and compared to changes induced by CPO 
(100mg/kg).  At these doses it was assumed that there would be similar levels of acrolein 
present in the urine of both treatment groups while CAA levels would be higher in IFO treated 
animals.  Despite the assumed differences in urinary metabolite concentration after CPO or IFO 
treatment, there was no difference between the nerve activity observed in either group. This 
supports the belief that acrolein is the major metabolite associated with CPO or IFO urotoxicity, 
however it does not rule out a role for CAA.  
To investigate the potential role of CPO or IFO in bladder muscle function, the pressure–volume 
relationship during bladder filling and accommodation was assessed as an index of compliance. 
Treatment with CPO or IFO had no effect on bladder compliance during filling while causing an 
increase in total nerve activity.  Bladder compliance during accommodation was also 
unchanged after CPO or IFO treatment.  Despite total nerve activity being increased at 
20mmHg in both CPO and IFO treated animals the nerves were able to adapt over time to a 
similar firing rate as in control animals.  Previous studies in mice and rats have shown the same 
response pattern in pelvic afferents, demonstrating dynamic responses to graded bladder 
distensions and slow adaptation to a maintained stimulus or distension (Sengupta and Gebhart, 
1994, Shea et al., 2000, Jung et al., 2012).  What is interesting is that the nerves retained this 
ability to adapt after CPO or IFO treatment and they adapted to a similar level.  However, 
physiological conditions would rarely require maintenance of a stable stimulus and rather the 
bladder volume and pressure would be continually changing.   Accordingly, CPO and IFO 
appear to enhance the afferent response to the physiologically relevant graded stimuli.  
Does CPO or IFO Treatment Enhance Activity of Low or High Threshold 
Afferent Nerves? 
As discussed previously, two populations of afferent nerves exist in the bladder (low and high 
threshold) and they contribute differently to overall bladder sensations.  The existence of both 
low and high threshold bladder afferents in the pelvic nerve has been well documented in 
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several species including mice (Habler et al., 1990, Sengupta and Gebhart, 1994, Daly et al., 
2007, Rong et al., 2002).  In mice, low threshold fibres have been reported to make up 70-80% 
of the total bladder afferent fibres (Daly et al., 2007, Rong et al., 2002).  However, the present 
study found that 60% of all fibres were low threshold, a figure slightly lower than previous 
reports.   It is possible that bladder compliance may have been affected by the faster filling rates 
used in the previous studies causing differences in afferent activation.  This could explain the 
slight differences in the ratio of low and high threshold fibres seen in this study.  Using a 
different technique in which the bladder was opened flat and stretched manually, 64% of fibres 
were found to be low threshold fibres (Jung et al., 2012) which is comparable to the results of 
the present study.   A related study in the guinea pig bladder using a similar manual stretch 
technique showed that 75% of the stretch sensitive pelvic nerve afferents had low thresholds 
(Zagorodnyuk et al., 2006).  This variation may reflect differences between species or 
differences between bladder filling and manual stretch methods.  Nonetheless, all studies agree 
that low threshold fibres are more numerous than high threshold fibres.   
Several studies have also reported that the low threshold nerves demonstrate a higher firing 
rate or greater magnitude of response than high threshold fibres (Jung et al., 2012, Daly et al., 
2007, Shea et al., 2000).  Specifically, Xu & Gebhart (2012) reported the average response of 
low threshold fibres to be approximately double the mean response of high threshold fibres at 
maximum stretch.  Similarly, in this study, the activity of low threshold fibres was approximately 
60% greater than that of the high threshold fibres at maximum distension.   
As discussed earlier, two response patterns of low threshold stretch sensitive afferents have 
been reported in rats (Shea et al., 2000) and mice (Jung et al., 2012) and have been termed 
encoding and non-encoding fibres.  In the present study, both filling patterns were observed in 
the low-threshold nerves and the non-encoding response was more common.  All high threshold 
fibres however demonstrated an encoding pattern with activity increasing continuously up to 
maximum distension both in the present study and that by Xu & Gebhart (2012).  The 
occurrence of these two different response patterns in low threshold fibres could potentially 
explain the non-linear relationship between pressure and afferent activity described above.  All 
low threshold fibres increased in activity up to 10-15mmHg at which stage the more common 
non-encoding fibres started to plateau or even decrease in activity having the effect of flattening 
the pressure-response curve as can be seen in Figure 5.19.  The firing rate of the less common 
encoding low and high threshold fibres then continued to increase at pressures above 15mmHg 
contributing to the more gradual increase in the pressure-response curve up to maximum 
distension.    
 195 
 
Treatment with CPO or IFO enhanced the activity of the low threshold fibres but not the high 
threshold fibres.  This is the first study to report the effect of CPO or IFO on activity in the 
distinct populations of low and high threshold bladder afferents.  Rong et al., (2002) 
demonstrated a similar increase in stretch induced firing of low threshold fibres after exposure 
to αβmATP (1mM).  Furthermore, in high threshold fibres αβmATP exposure led to a decrease 
in activation threshold and an increase in firing rate during distension.  Xu & Gebhart (2012) 
also demonstrated sensitisation of low and high threshold fibres in response to a mixture of 
inflammatory mediators.  In particular, the response threshold of the high threshold fibres was 
reduced after exposure to the mixture to a level comparable to that of the low threshold fibres.  
Interestingly, the response pattern of some non-encoding low threshold fibres changed after 
exposure to the inflammatory mediators exhibiting encoding responses up to maximum stretch.    
In the present study separate mice were treated with saline, CPO or IFO and accordingly, it was 
not possible to determine whether the drugs lowered the activation threshold of high threshold 
fibres.  However, the percentage of low threshold fibres did show an increased trend after CPO 
or IFO treatment suggesting that some of the high threshold fibres may have been sensitised 
becoming active at low threshold pressures.  Similarly, it was not possible to determine if 
response patterns of specific low threshold fibres were altered by CPO or IFO treatment.  Again 
the percentage of encoding fibres increased after treatment suggesting that some non-encoding 
fibres may have been altered by CPO or IFO.   In addition, it was not possible to determine 
whether CPO or IFO treatment caused any silent afferents to become mechanosensitive.  
However, given that cystitis induced by intravesical instillation of acetic acid, turpentine oil or 
inflammatory mediators does appear to sensitise silent afferents, it is possible that the same 
would occur after CPO or IFO induced cystitis.    
Typically, low threshold fibres are thought to contribute to normal micturition reflexes and high 
threshold fibres to painful sensations.  However, given that low threshold fibres can encode 
stretch stimuli into the pain/noxious range (>15mmHg) and can sensitise, it appears possible 
they may also contribute to painful sensations.  Accordingly, the increased activity of low 
threshold fibres after CPO or IFO treatment may explain the bladder hyperactivity (urgency, 
frequency), abnormal sensations (residual volume) as well as the painful sensations 
experienced by patients.  Furthermore, high threshold fibres becoming active at lower threshold 
could also explain abnormal sensations of fullness and pain at lower bladder volumes.  
The mechanism of how CPO or IFO causes sensitisation of the bladder afferent nerves is 
unknown.  As discussed in Chapter 3, various mediators released by the urothelium such as 
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ATP and PGE2 can activate and sensitise afferent nerves and levels of both these mediators 
was enhanced in the human urothelial cells in Chapter 3.  Therefore, it is possible that 
increased ATP and/or PGE2 from the urothelium may be causing afferent sensitisation and 
increased responses during bladder filling.  Specifically, activation of the P2X3 receptors can 
sensitise bladder afferents (Rong et al., 2002) and excess urothelial ATP may be responsible 
for such an effect in CPO or IFO induced hyperactivity.  However, the results in this Chapter did 
not demonstrate increased luminal ATP levels in the mouse.  Accordingly, the increased 
afferent activity observed in this study does not appear to be associated with increased ATP 
release from the urothelium.  This was unexpected as Smith et al., (2005) have previously 
reported increased ATP release from rat urothelium after CPO treatment.  However, the model 
used a 50% higher dose of CPO administered chronically every three days for a total of three 
treatments.  Therefore, the increased ATP release seen by Smith et al.,(2005) may be a long 
term effect of CPO or may be a result of greater urothelial changes due to a higher dose than 
used in the present study.   
Interestingly in DRG from CPO pretreated rats, P2X3 receptors were up-regulated with 68% of 
pelvic neurones expressing these receptors (up from 40% in controls) suggesting de novo 
synthesis in neurones that do not normally express them (Dang et al., 2008).  Furthermore, a 
greater number of neurones responded to purinergic agonists with more action potentials, 
greater current density and slower desensitisation kinetics.  Accordingly, it appears that CPO 
not only increases P2X3 receptors in bladder afferents but also sensitises and enhances the 
activity of these receptors.  Therefore, even normal levels of stretch induced urothelial ATP 
release could cause more afferents to be activated and their responses to be enhanced.  ATP 
appeared to play a role in the increased afferent firing to rat bladder distensions after CPO 
treatment as purinergic antagonists significantly reduced the afferent firing at low intravesical 
pressure (10cm H2O) (Yu and de Groat, 2008).  The increased activity at pressures of 20cm 
H2O and higher were not significantly affected by blocking the purinoceptors.  Therefore, it is 
possible that increased urothelial ATP or enhanced responses to ATP may partly contribute to 
the increased nerve activity after CPO or IFO treatment.  However, the results of the present 
study and those of (Yu and de Groat, 2008) suggest that there is another mechanism involved 
in the afferent sensitisation seen after treatment with these chemotherapeutics.  
Intravesical administration of PGE2 enhances the micturition reflex in mice increasing frequency 
of micturition and micturition pressure (Ishizuka et al., 1995b). Furthermore, an EP3 receptor 
antagonist reduced afferent firing in rats in response to bladder distension directly implicating 
PGE2 in afferent responses to bladder filling (Su et al., 2008).  Various EP receptor antagonists 
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have also been shown to attenuate CPO induced hyperactivity and pain in rodents (Chuang et 
al., 2012, Miki et al., 2011).  These studies used a single high dose of CPO (200mg/kg and 
300mg/kg respectively) to study the effect of PGE2 on bladder function.  The dose used in the 
present study (100mg/kg) was lower than in these previous studies and luminal samples were 
too small to allow measurement of PGE2 content.  However, initial results in Chapter 3 in human 
urothelial cells indicated that acrolein and CAA can both enhance PGE2 release.  Accordingly, it 
is possible that PGE2 release from the urothelium may be contributing to the increased afferent 
response observed by activating or sensitising afferent nerves to mechanical stimulation.   
Muscle and Nerve Response to Pharmacological Agents 
Although nerve activity was increased at 20mmHg after CPO or IFO treatment, the firing rate in 
both treatment groups was able to accommodate over time to a level comparable to controls.  
This gave a fairly consistent baseline firing rate from which responses to various agonists could 
be assessed.  It is acknowledged that the addition of various mediators in succession may lead 
to possible interactions in the tissue.  When planning these experiments, care was taken to 
choose an order of addition of these agents that minimised possible interactions.  Given the 
difficulty in setting up these experiments it was important to investigate as many agents as 
possible and determine potential avenues for further investigation.  To overcome the potential 
limitation of drug interaction, the agents were always added in the same order in every animal 
and responses were allowed to come back to baseline before adding another agent.  Some 
potential interactions have been discussed further below.  
Afferent nerves responded to purinergic activation with fast increases in firing rate that peaked 
quickly and then recovered back to baseline within 10 minutes.  The nerve responses to 
αβmATP (10µM) were greater than the responses to ATP (1mM).  Both purinergic responses 
were associated with a similar increase in intravesical pressure, generally increasing at the 
same time and taking the same time to recover to baseline.  This was expected as previous 
studies have reported similar responses to purinergic activation.  Specifically, Yu & de Groat 
(2008) demonstrated in rats that ATP (2mM) elicited a bladder contraction and an associated 
burst of afferent firing.  In guinea pig bladder, αβmATP (30µM) also evoked contractions and 
associated firing in stretch sensitive afferents (Zagorodnyuk et al., 2006).     
Both muscle and nerve responses to αβmATP (10µM) were unchanged after treatment with 
CPO or IFO.  Responses to ATP (1mM) were also unaffected by treatment and if anything 
showed slight decreases.  The nerve results are unexpected as CPO treatment has been 
shown to increase the P2X3 density in afferent neurones and enhance the activity of these 
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receptors (Dang et al., 2008).  However, these effects were seen after chronic CPO treatment 
with 3 doses of 100mg/kg each two days apart.  Therefore, it is possible that purinergic 
enhancement does not contribute to the acute afferent sensitisation observed in the present 
study but rather comes into play during chronic irritation.   
In addition, the muscle responses to purinergic agonists in the present study are also 
unexpected based on previous publications.  Specifically, Mok et al., (2000) demonstrated in the 
house musk shrew that contractile responses of isolated bladder strips to β,γ-mATP were 
reduced by almost 50% after a single high dose of CPO (200mg/kg), however only at a 
concentration of 300µM.  It is possible that the lower dose of CPO (100mg/kg) used in the 
present study did not cause sufficient bladder damage to reduce the purinergic response to the 
same extent.  However, given that a slight reduction was observed, it is also possible that the 
responses to higher doses of ATP could have revealed a significant decrease in response.   
In any event, the increased afferent activity observed in the present study does not appear to be 
due to enhanced responsiveness to purinergic activation and although this mechanism may 
contribute to changes after chronic CPO or IFO treatment, there appears to be another 
mechanism contributing to enhanced afferent responses at least during the acute stage of 
urotoxicity.  However, the results of the present study do not rule out the possibility that 
increased local urothelial ATP release in association with afferent nerve endings could 
contribute to the enhanced activity.  Accordingly, performing distensions in the presence of a 
purinoceptor antagonist could shed light on whether the enhanced activity in CPO or IFO 
treated bladders is due to excess ATP.      
Muscarinic receptor stimulation with ACh (1µM) or carbachol (10µM) also caused an increase in 
nerve firing but the responses were slower to peak and took much longer to recover back to 
baseline (approximately 45 minutes) than purinergic responses.  The carbachol responses were 
also greater than the responses to ACh.  Muscarinic nerve responses were also associated with 
a similar increase in intravesical pressure, generally increasing at the same time and taking the 
same time to recover to baseline.    
Bladder muscle contraction in response to muscarinic receptor stimulation is well known 
whereas the effect on afferent nerve activity is still unclear.  Intravesical administration of a 
muscarinic receptor agonist oxotremorine-M did not stimulate afferent nerve activity in the 
absence of bladder distension but increased the firing induced by bladder distension (Yu and de 
Groat, 2010).  However, Daly et al., (2010) found that muscarinic receptor stimulation during 
bladder distension significantly inhibited afferent firing and this was independent of muscle tone.   
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Accordingly, the effects of muscarinic receptor stimulation on afferent firing are still unclear.  
The results from the present study indicate the presence of afferent activity in response to 
muscarinic agonists, however whether this is solely due to muscle tone is uncertain.  The effect 
of uncoupling muscle tone from afferent activity using nifedipine is discussed below.   
In the present study, CPO or IFO pre-treatment did not significantly affect any of the responses 
to muscarinic receptor stimulation.   Pressure and nerve responses to carbachol were 
marginally increased in CPO and IFO treated bladders whereas responses to ACh were slightly 
increased after CPO treatment and slightly decreased after IFO treatment.  No studies have 
previously looked at the muscarinic response of nerves in CPO or IFO treated tissues.  However 
for muscle, these results are opposite to what has been previously reported in isolated bladder 
strips from rats.   Two studies have shown reduced contractions of isolated bladder strips from 
CPO or IFO treated animals to both carbachol (>1µM) and KCl (Macedo et al., 2011, Giglio et 
al., 2005).  The reduced responsiveness to KCl observed previously also suggests that a 
general reduction in muscle contractility may be contributing to the reduced responses to 
carbachol rather than a specific muscarinic depression.  In the present study, neither CPO nor 
IFO pre-treatment caused any significant change to muscarinic responses in the muscle or the 
nerve.   It is possible that the differences between the previous studies in isolated bladder strips 
and the present study in whole bladder could be due to greater preservation of efferent and 
afferent innervation in whole bladder tissue, measuring intravesical pressure as opposed to 
direct contractile force of strips or even due to application of pharmacological agents on the 
serosal surface of the whole bladder as opposed to both urothelial and serosal sides of a tissue 
strip.    
The nerves also demonstrated a large increase in firing rate in response to nicotinic receptor 
stimulation with DMPP (10µM) which peaked quickly and recovered within 10-15 minutes.   
However, this response was not associated with an increase in intravesical pressure.  Therefore, 
the responses to DMPP are a good measure of nerve activity separate from muscle tension.   
Nicotinic receptors are present in nociceptive, sensory neurones and nicotine can induce 
inwards currents in rat DRG neurones (Haberberger et al., 2004).  Furthermore, mRNA 
expression of various nicotinic receptor subtypes has been recently shown in bladder sensory 
nerves in mice (Nandigama et al., 2013).  In particular, the α3-containing subtype was 
expressed in 69% of sensory nerves.  Patch clamp recordings of rat bladder sensory DRG 
neurones demonstrated nicotine (300µM) induced inward currents (Masuda et al., 2006).  
Afferent nerve responses have also been reported previously in multi-unit nerve recordings in 
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rats where intra-arterial injection of nicotine caused bladder afferent nerve activity to increase 
without any increase in bladder pressure (Kontani et al., 2009).    
Furthermore, nicotinic receptor mediated sensitisation mechanisms have been shown to be 
present in the bladder and can induce bladder hyperactivity.   Specifically, a high dose of 
intravesically administered nicotine caused overactivity in anaesthetised rats decreasing the ICI 
and this could be prevented by pre-treatment with capsaicin or a nicotinic antagonist (Masuda et 
al., 2006).  Beckel & Birder (2012) also demonstrated a functional role of nicotinic receptors on 
afferent nerve endings below the urothelium.  Specifically, they used protamine sulphate to 
disturb the urothelial barrier and allow intravesically applied agents to pass into the underlying 
tissue.  Before protamine sulphate, intravesical nicotine had an inhibitory effect on bladder 
reflexes decreasing urinary frequency.  However, after protamine sulphate intravesical nicotine 
caused excitation of reflexes and subsequent overactivity suggesting that the urothelium 
releases an inhibitory mediator in response to nicotinic activation and that its removal then 
uncovers a direct stimulatory effect on afferent nerves.  
After CPO and IFO treatment in the present study, muscle responses to nicotinic stimulation 
with DMPP did not change and while afferent activity showed an increased trend, the 
differences were not significant.  This is the first study to investigate the nicotinic response of 
afferents after CPO or IFO treatment.  Given that DMPP does not affect muscle tension, the 
nerve effects appear to be directly due to changes in nerve function.  Therefore, the increased 
response to nicotinic receptor stimulation may be a result of increased excitability of the afferent 
nerves.   This result supports the hypothesis that the increase in total nerve activity after CPO or 
IFO treatment is also due to sensitisation of the afferents lowering their activation threshold and 
increasing their firing rate to stimuli.   
In the present study, PGE2 application induced a slight increase in muscle tension accompanied 
with bursts of afferent activity.  These results support previous studies such as those reviewed 
by Maggi, (1992) including the finding that topical application of prostanoids to a partially filled 
rat bladder induced a small tonic-type increase in bladder tone and a series of reflex bladder 
contractions mimicking the micturition reflex.  Although direct nerve activity was not measured, 
the appearance of a series of micturition type contractions is suggestive of bursts of afferent 
activity stimulating the effects.   
As outlined above, CPO or IFO pre-treatment had no effect on the muscle response to PGE2 
administration.  However, both CPO and IFO treated bladders demonstrated a trend towards 
enhanced nerve activity in response to PGE2.  This is the first study to look at the effect of CPO 
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or IFO on afferent nerve responses to PGE2 whereas most previous studies have only looked at 
a role for PGE2 in the development of bladder hyperactivity to these chemotherapeutics.  There 
appears to be a role for PGE2 in sensitisation of afferent nerves to CPO as various EP receptor 
antagonists have also been shown to prevent the hyperactivity and pain (Chuang et al., 2012, 
Miki et al., 2011).  The expression of the EP receptors is changed in bladders from rats treated 
with CPO showing increased EP4 expression, decreased EP1 expression and no change in 
EP2 or EP3 (Chuang et al., 2012, Chuang et al., 2010). The whole bladders were used in these 
studies so it is difficult to say what affect expression changes would have on function, however 
it is possible that altered receptor density could lead to altered responses to PGE2.  The present 
study indicates that the afferent nerves may have an altered response to PGE2 after CPO and 
IFO treatment and this may be due to receptor expression changes or a change in excitability to 
receptor activation.   
In untreated bladders the NO donor SNP had no effect on muscle or nerve responses which is 
similar to previous findings (Yu and de Groat, 2013).  However, the present study demonstrated 
that administration of SNP in CPO or IFO treated bladders increased the frequency and firing 
rate of the bursts of afferent nerve activity induced by PGE2.  Furthermore, SNP caused a very 
slight increase in intravesical pressure in the treated bladders.   This is unexpected given that 
several studies have reported NO as having an inhibitory effect on bladder hyperactivity induced 
by CPO (Yu and de Groat, 2013, Andersson et al., 2011).  Specifically, blocking NO production 
in CPO treated rats caused an increase in the micturition frequency, but not in untreated 
animals (Andersson et al., 2011).  In addition, application of a NO donor also caused inhibition 
of the afferent nerve activity during bladder distension after CPO treatment without significantly 
reducing maximum intravesical pressure (Yu and de Groat, 2013).  
However, the present study used SNP after PGE2 application which meant these two mediators 
may have been interacting.   In rabbit bladder damaged by ischemia, the nitric oxide donor 
L-arginine caused a contraction that could be blocked by a COX-2 inhibitor, a response not 
seen in control bladders (Masuda et al., 2010).  In addition, levels of PGE2 present in tissues 
were higher after L-arginine in ischemia damaged bladder but not controls.  This suggests that 
COX-2 expression is increased after ischemia and NO activates the enzyme to produce PGE2.  
This mechanism may explain the results seen in the present study wherein an NO donor 
caused a slight increase in bladder pressure and an increase in nerve activity induced by PGE2.  
These effects were only seen in CPO and to a greater extent IFO treated tissues and may be 
due to NO increasing PGE2 production or enhancing the effects of previously administered 
PGE2.      
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The Effect of Muscle Tone on Afferent Firing 
As discussed above, the afferent nerve responses to ATP (1mM), αβmATP (10µM) and 
carbachol (10µM) were accompanied by similar increases in intravesical pressure suggesting 
that the nerve and muscle responses to purinergic and muscarinic activation are linked.    The 
coupling of muscle tone to afferent firing is also supported by the phasic increases in 
intravesical pressure and corresponding afferent firing rate observed in the present study.  
Accordingly, the effect of muscle tone on the afferent responses was investigated by blocking 
muscle contraction with nifedipine (1µM).  The effect of CPO or IFO on the contribution of 
muscle tone to afferent responses was also of interest.   
In control bladders of the present study the phasic nerve activity mimicked the phasic muscle 
activity.  In the presence of TTx (1µM) the phasic muscle contractions persisted but the nerve 
responses were abolished.  This clearly demonstrates that afferent nerve activity can be 
influenced by muscle tension and supports previous findings (McCarthy et al., 2009, 
Zagorodnyuk et al., 2007).  Specifically, Zagorodnyuk et al., (2007) demonstrated that some 
stretch-sensitive bladder afferents in the guinea pig show occasional bursting activity associated 
with spontaneous muscle contractions.  In addition, McCarthy et al., (2009) observed 
spontaneous bladder contractions in both normal and spinal cord transected mice that were TTx 
insensitive, but could be blocked with nifedipine.  The contractions were larger and less frequent 
in spinal cord transected mice and were associated with corresponding increases in afferent 
nerve activity. The results of the present study demonstrated that treatment with CPO or IFO did 
not significantly affect the frequency or amplitude of spontaneous contractions during filling or 
accommodation of the bladder.  Furthermore, the nerve activity associated with the 
spontaneous contractions was not different after CPO or IFO treatment.  The spontaneous 
contractions seen after CPO or IFO treatment will be discussed further in the next Chapter.  
Nifedipine reduced the intravesical pressure responses to ATP and αβmATP while nerve 
responses were not reduced significantly.  This suggests that the nerve responses to purinergic 
activation are almost completely due to direct activation of afferents rather than indirect 
mechanical activation due to muscle contraction.  This is expected given that afferent nerves 
express purinergic receptors and activation causes neurone depolarisation triggering action 
potentials (Dang et al., 2008).  The effect of nifedipine on purinergic responses was the same in 
controls and CPO treated bladders, reducing both the pressure and nerve responses to a 
similar extent.  Accordingly, the contribution of muscle tone to the afferent nerve response is the 
same after CPO treatment.    
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Both the pressure and nerve responses to carbachol (10µM) were significantly decreased after 
the addition of nifedipine (1µM).  However, nifedipine reduced pressure responses by 
approximately 80% while afferent responses were only reduced by 50%.  This suggests that the 
afferent response to muscarinic receptor stimulation is largely due to muscle tone during the 
associated contraction.  However, the muscle and nerve responses were not reduced to the 
same extent suggesting there are other muscarinic effects influencing nerve activity.  It is 
unlikely that carbachol had any direct effect on afferent nerves as previous studies have 
demonstrated a lack of afferent firing in response to muscarinic agonists (Daly et al., 2010, Yu 
and de Groat, 2010).  A possible explanation is that carbachol activated muscarinic receptors 
on the urothelial cells causing the release of excitatory mediators such as ATP and PGE2 (Nile 
and Gillespie, 2012, Yokoyama et al., 2011) causing indirect activation of the afferent nerves.   
In terms of muscle tone contributing to afferent nerve response, both control and CPO groups 
demonstrated similar reductions in pressure and nerve responses after nifedipine.  Again, 
supporting that in CPO treated bladders the relationship between muscle tone and nerve 
responses is unchanged.  
The small pressure increases in response to DMPP were abolished in the presence of 
nifedipine, whereas the nerve responses tended to increase.  This is an unexpected result and 
the mechanism behind this observation is not apparent.  The same reduction in muscle 
responses and increase in nerve responses were seen in the control and CPO treated bladders.  
Therefore, the effect of muscle contraction on nicotinic induced nerve responses was 
unchanged by CPO treatment.  
Conclusions 
CPO and IFO treatment enhanced total nerve activity in the mouse bladder during graded 
distensions and this was due to enhanced activity of the low threshold fibres.  Lowering of the 
activation threshold of some high threshold fibres may contribute to the increased nerve activity.  
In addition, an increased ability of low threshold fibres to encode into noxious ranges of bladder 
pressure may also be involved in the enhanced activity.  This is the first study to report the 
effects of CPO and IFO on low and high threshold pelvic sensory nerves in the mouse bladder.  
The increased afferent activity does not appear to be due to enhanced responses to ATP, ACh 
or PGE2 but rather appears to be due to sensitisation of the nerves making them more 
responsive to distension.   
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6.1 INTRODUCTION  
Afferent activity in the bladder is important for normal function.  As discussed in the previous 
Chapter, alterations in afferent activity have been linked to various overactive and painful 
bladder disorders.  Various factors can affect the activity of the afferent nerves including 
mediators released from the urothelium as well as detrusor muscle tone and spontaneous 
contractions.  This study aimed to further investigate potential sources of afferent overactivity 
after CPO or IFO treatment by examining urothelial mediator release, detrusor contractility and 
efferent nerve function.  
Comparison of Human and Mouse Bladder Function 
Contraction of human and pig bladder is attributed almost completely to the release of ACh from 
parasympathetic nerves which act via the M3 receptor (Chess-Williams, 2002, Fetscher et al., 
2002, Yamanishi et al., 2000, Sellers et al., 2000).  Mouse urinary bladder responses differ from 
those of human or pig in that contractions are mediated by two transmitters acting on different 
receptors.  In mice, the parasympathetic nervous system co-releases ACh and ATP to cause 
contraction (for review see Burnstock (2007)).  Detrusor contraction to ACh has been shown to 
be mediated primarily by the M3 receptor in every species investigated (Uchiyama and Chess-
Williams, 2004).  This has also been confirmed in mice by Matsui et al., (2000) who found that 
M3 receptor knockout mice develop urinary retention. In addition, carbachol induced 
contractions of the bladder were reduced in M3 receptor knockout mice to only 5% of those 
seen wild type mice despite having comparable responses to KCl.  Furthermore, in isolated 
mouse bladder strips various muscarinic receptor antagonists demonstrated binding affinities 
consistent with the M3 receptor being the primary mediator of direct muscarinic bladder 
contraction (Choppin and Eglen, 2001).  
Although ATP is co-released with ACh from parasympathetic nerves in humans, it appears to 
have very little contribution to nerve mediated contraction however, a purinergic component 
emerges in various lower urinary tract disorders (Ford et al., 2006). The P2X1 is the most 
abundant P2X receptor subtype in the adult human bladder (O'Reilly et al., 2001) and may be 
up regulated in disease contributing to a purinergic component of nerve mediated contraction.  
In mouse, the ATP contraction is also thought to be mediated by the P2X1 receptor (Vial and 
Evans, 2000, Young et al., 2008).  Immunoreactivity for the P2X1 receptor was found in smooth 
muscle of the mouse bladder while contractions to P2X agonists were abolished in P2X1 
receptor deficient mice.  Similarly, nerve induced responses in P2X1 knockout mice were 
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mediated solely by muscarinic receptors with no purinergic component remaining (Vial and 
Evans, 2000).  
Control of human and pig bladder relaxation during filling is primarily due to noradrenaline 
release from sympathetic nerves acting on β3-ARs in the detrusor (Badawi et al., 2007, 
Yamanishi et al., 2002d).  The nonselective β-AR agonist isoprenaline has been shown to 
decrease micturition pressure and increase the time taken to empty the bladder in 
anaesthetised mice (Zhou et al., 2010).  The isoprenaline induced relaxation of isolated mouse 
bladder strips was antagonised by a β2-AR antagonist (Wuest et al., 2009).  However, 
functional β3-ARs have also been reported with selective β3-AR agonist causing relaxation of 
mouse bladder strips (Deba et al., 2009). 
The Effect of CPO or IFO on Bladder Function in the Rodent 
Humans experience bladder pain and dysfunction after treatment with CPO or IFO.  Rodents 
experience similar symptoms making them a useful animal model for studying the effects of 
these drugs.  A single intraperitoneal injection of cyclophosphamide is sufficient to induce 
urotoxicity in mice and many of the typical features of urotoxicity appear within 24 hours after 
injection including pain, urinary frequency and activation of inflammation (Auge et al., 2013, 
Leventhal and Strassle, 2008).  Rodents treated with CPO or IFO demonstrate typical urotoxic 
storage symptoms including increased urinary frequency and decreased contractile force 
leading to decreased voiding pressure (Okinami et al., 2014, Macedo et al., 2011, Boudes et al., 
2011, Everaerts et al., 2010b, Wang et al., 2008b, Kageyama et al., 2008, Juszczak et al., 2007, 
Hu et al., 2003).  In addition, animals also demonstrated enhanced intravesical pressure during 
filling and reduced bladder capacity. However, very little is known about what contributes to 
these functional changes in the bladder.  
Maximum contraction to carbachol was reduced by approximately 45% in isolated bladder strips 
from CPO treated house musk shrew without any effect on muscle contractility to KCl (Mok et 
al., 2000).  However, isolated bladder strips from rats with IFO-induced cystitis showed 
decreased contractile force development to both KCl and carbachol (Macedo et al., 2011).  
Similarly, in isolated bladder strips from rats with CPO induced cystitis, the maximum contractile 
effects to both carbachol and KCl were approximately half those of the control animals (Giglio et 
al., 2005).  Interestingly, in the presence of L-NNA to block the production of NO, the responses 
to carbachol were increased to be similar to control responses.  Levels of eNOS were 
significantly increased in the urothelium of CPO treated animals suggesting that the reduced 
contractions to carbachol were due to a cholinergic interaction causing NO release from 
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urothelial cells (Giglio et al., 2005).  This was supported by Andersson et al., (2008) who 
showed that reduced cholinergic contractions in CPO inflamed bladders were partially restored 
by removal of the mucosa.  In another study, the urodynamics of anaesthetised rats found that 
CPO treatment caused decreased voiding volume which could be normalised by the M3 
antagonist 4-DAMP (Andersson et al., 2011).  Furthermore, blocking NO production with 
L-NAME significantly enhanced the frequency of micturition in CPO treated rats with no effect in 
controls.  Therefore, the CPO induced changes to bladder function involve enhanced NO 
production and alterations in muscarinic effects and interaction between the two systems seem 
likely.    
Muscarinic receptor expression also appears to be affected by CPO treatment (Giglio et al., 
2005).  Using Western blotting and immunohistochemistry, all five (M1-5) receptor subtypes 
were found in both normal and CPO treated rats.  However, the expression of M5 receptors was 
significantly increased in the smooth muscle and particularly the urothelium after CPO treatment.  
This suggests the changes in muscarinic responses in CPO induced cystitis are most likely due 
to enhanced M5 receptors on the urothelium leading to increased NO release.  
Even less is known about the changes in response to purinergic contractions of the bladder 
after CPO or IFO treatment, with most of the effects attributed to sensory changes.  However, in 
isolated bladder strips from CPO treated animals contractile responses to the P2X receptor 
agonist β,γ-methylene ATP (β,γ-mATP) were reduced by almost 50% without any effect on KCl 
induced contractions (Mok et al., 2000).    Kageyama et al., (2008) found a loss of binding sites 
to [3H]-αβ-mATP without a change in Kd suggesting that a down-regulation in P2X receptors 
may be responsible for the reduced P2X induced contractions. 
Although these studies provide evidence of post-junctional alterations of the P2X and M3 
receptors causing decreased contractile responses to exogenous agonists, little is known about 
the effect of CPO or IFO on efferent nerve induced responses. 
Evaluation of bladder function 
Clinically, the coordination of the bladder is evaluated by assessing the pressure to volume 
relationship during filling and pressure and urine flow rate during emptying.  Many of the studies 
into bladder function use bladder muscle strips which are functionally limited to measuring 
contraction or relaxation in one plane. Recently, an isolated whole bladder model in mice was 
developed to offer a more physiological option to study bladder function (Fabiyi and Brading, 
2006).  This model involves using a whole, isolated bladder from the mouse which maintains 
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intact urothelium, interstitial cells, detrusor and intramural ganglia and allows measurement of 
volume-pressure relationships.  The whole bladders were distended submaximally and allowed 
to equilibrate for one hour to provide a stable intravesical tension from which to investigate the 
effects of various exogenous agonists as well as electrical stimulation of the intramural nerves 
releasing endogenous transmitters.  The model was found to be viable and robust and has been 
used in the work forming this Chapter in order to study the effects of CPO or IFO on the function 
of the whole mouse bladder.  The parameters tested were altered to suit the aims of the present 
investigation.  
Aims 
The aim of the present study was to investigate the function of the whole mouse bladder after 
treatment with CPO or IFO. Specific aims were:  
 To investigate the effect of CPO or IFO treatment on spontaneous bladder 
contractions;  
 To determine the release of ATP, ACh and PGE2 from the urothelium and serosa of 
bladders treated with CPO or IFO;  
 To determine the whole bladder response to electrical field stimulation of intramural 
nerves after CPO or IFO treatment;  
 To assess the relaxatory adrenergic response of the whole bladder after treatment 
with CPO or IFO.  
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6.2 METHODS 
Animals 
Young adult male C57/6B mice were treated and sacrificed as outlined in the previous Chapter.   
Isolated Bladder Experiments 
The pelvis was placed into a bath of Krebs solution for setup as described in the previous 
Chapter.  However, in this setup, a three way catheter was inserted through the urethra and 
secured in the bladder using silk suture.  One port of the catheter was attached to an infusion 
pump to fill the bladder, another to a two-way outflow tap to allow emptying of the bladder and 
the third to a pressure transducer to measure intravesical pressure. The pressure transducer 
was attached to a Neurolog headstage (NL100, Digitimer Ltd, UK) connected to a pressure 
amplifier (NL108, Digitimer Ltd, UK) which amplified the pressure signals before they were 
passed to a Micro1401 analogue to digital interface (Cambridge Electronic Design, UK) and 
then visualised on a computer using Spike2 software (version 7.1, Cambridge Electronic Design, 
UK).  
The ureters were ligated to prevent leakage of intravesical fluid. The bladder and urethra were 
dissected from the surrounding tissue and placed in a 10mL organ bath containing Krebs 
solution at 37°C, gassed with 95% O2 - 5% CO2. The bladder was distended with the infusion 
pump containing isotonic saline (0.9%) solution at 30µl/min to a maximum pressure of 40mmHg 
to check the viability of the catheterisation.  The infusion pump was stopped and the outflow tap 
was opened to allow complete evacuation of the intravesical contents of the bladder.  Figure 
6.1 shows the final setup of the isolated bladder.   Baseline pressure when the bladder was 
empty was subtracted from the pressures during distension to give the change in pressure. 
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Figure 6.1: Schematic (A) of the isolated mouse bladder set up showing the bladder connected to the three-way 
catheter and a calibrated photograph (B) of a mouse bladder connected to a three-way catheter.  
Observation of Inflammation 
During dissection and setup, visual and microscopic observations of bladder inflammation were 
recorded.  Specifically, the area and extent of haemorrhage was noted as well as the presence 
of visible vasculature in the bladder wall.  Control bladders tended to be a consistent milky white 
colour with no visible vasculature, while the bladders treated with CPO or IFO tended to have 
patches of redness with visible vasculature as per the typical images shown in Figure 6.2.   
Control CPO IFO 
 
Figure 6.2: Typical images of control, CPO and IFO treated bladders with arrows indicating areas of 
inflammation and increased visble vasculature in treated bladders.  
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Measurement of Urothelial Mediators 
Once the preparation had been successfully set up, samples were collected for measurement of 
ATP, ACh and PGE2.  The bath was washed and 8mL of fresh Krebs added, the outflow tap 
closed and the infusion pump turned on to start filling the bladder.  The bladders were filled to a 
set pressure of 20mmHg. This was to ensure that each bladder received the same mechanical 
stimulation and reduced variability due to bladder size. Once the intravesical pressure reached 
20mmHg, the infusion pump was turned off and the outflow tap opened.  The luminal contents 
of the bladder were collected in a tube on ice and were stored as soon as possible after 
collection at -20°C. A sample of the Krebs in the bath in contact with the bladder serosa was 
also collected and stored at -20°C for later analysis. This process was repeated twice more to 
obtain luminal and serosal samples in triplicate with 10 minutes recovery between each 
distension.  The luminal and serosal samples were then used in the various assays described in 
Chapter 2 for quantification of ATP, ACh and PGE2 levels.   
Electrical Field Stimulation  
To study the efferent nerve response, the bladder was filled to a set pressure of 20mmHg and 
allowed to stabilise for an hour.  The muscle then had a stable baseline tension from which to 
determine the effect of electrical field stimulation (EFS) by placing platinum electrodes either 
side of the bladder (Figure 6.3). The bladder was electrically stimulated (40 volts and 0.2ms 
pulse-width) delivered as a 5 second train every 100s, at frequencies of 5Hz, 10Hz and 20Hz.  
The tissues were stimulated at each frequency until stable responses were obtained. Initial 
responses for each frequency were obtained followed by responses at 20Hz only in the 
presence of 100µM L-NNA (NOS inhibitor), 1µM atropine (muscarinic antagonist) and 10µM 
alpha,beta-methylene ATP (αβmATP) (desensitises P2X purinoceptors) to investigate the 
contribution of NO, ACh and ATP to the contraction.  In the previous Chapter, αβmATP (10µM) 
was used as an agonist, however after the initial response the P2X receptors are quickly 
desensitised and do not respond again for up to 30 minutes enabling it to block a further P2X 
mediated response (Fabiyi and Brading, 2006).  In this experiment, αβmATP (10µM) was 
present in the bath for at least 15 minutes before EFS was performed to ensure desensitisation 
of the P2X receptors.  Responses to EFS in CPO or IFO treated tissues were compared to 
controls.  
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Figure 6.3: Schematic of the isolated mouse bladder electrical field stimulation set up showing the bladder 
connected to the three-way catheter between a positive and negative electrode for stimulation of the whole 
bladder. 
Response to Pharmacological Agents 
To study the effects of drugs on muscle tension, the bladder was filled to a set pressure of 
20mmHg and allowed to stabilise for an hour.  The muscle then had a stable baseline tension 
from which to determine the effect of drugs.  Isoprenaline (non-selective β-adrenoceptor agonist) 
was then added to the bath cumulatively (1ng - 100µg) in half log intervals and the effect on 
muscle tension was calculated as the change in intravesical pressure from baseline.  
Spontaneous Contractions 
During bladder distension, phasic intravesical pressure increases were observed as the overall 
pressure increased (Figure 6.4).  These spontaneous contractions demonstrated consistent 
frequency and amplitude within a bladder preparation (Figure 6.4-A & C).  Similar spontaneous 
detrusor activity was also observed when a bladder was distended to 20mmHg and left to 
accommodate the volume (Figure 6.4-B & D).  The frequency and amplitude of spontaneous 
contractions during filling and accommodation were quantified.  Spontaneous contractions 
during filling were measured during the 200s preceding the intravesical pressure reaching 
15mmHg.  During accommodation activity was measured during the 200s at the end of the 
1 hour stabilisation period.  Average frequency was represented as contractions per min and 
average amplitude in mmHg.  
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Figure 6.4: Representative traces of a control isolated mouse bladder showing spontaneous phasic 
contractions during a full distension (A), accommodation from 20mmHg distension (B), and a close up during 
200s filling up to 15mmHg (C), a close up during 200s at the end of accommodation (D).  
Histology 
After experimentation, the whole isolated mouse bladders were fixed in 10% neutral buffered 
formalin for 24 hours. A catheter attached to a syringe containing formalin was inserted into the 
bladder through the urethra and secured using silk suture. The bladder was filled with formalin 
using the syringe and then submerged fully in formalin so that the bladder was fixed in a gently 
distended state.  After 24 hours the bladder was cut in two removing the lower half containing 
the urethra and keeping the dome of the bladder for processing, sectioning and staining as 
outline previously (Chapter 2).  
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6.3 RESULTS  
General Effects of Treatment on Animals 
Prior to treatment, there was no significant difference in age or weight between animals 
allocated to each treatment group.  After treatment animals in all three groups experienced 
weight loss.  However, animals in the drug treatment groups lost significantly more weight 
(3.1±0.3% and 3.4±0.5% after CPO or IFO treatment respectively) than control animals 
(0.8±0.4%) (p<0.01) (Figure 6.5). On visual observation, 13 out of 16 CPO treated mice and 12 
of 17 IFO treated mice exhibited macroscopic signs of urinary bladder inflammation including 
redness, increased visible vasculature and areas of haemorrhage (as described in the methods 
and shown in Figure 6.2).  CPO or IFO treatment also led to development of considerable 
oedema in the lamina propria or suburothelial layer resulting in detachment of urothelial cells 
from the detrusor as can be seen in Figure 6.6.  
 
 
Figure 6.5: Age (A), weight (B) and % change in weight 24 hours after treatment (C) with saline (control), CPO 
(100mg/kg) and IFO (200mg/kg) in mice. Data represented as mean ± SEM (n≥8). Analysed by One-way ANOVA 
with a Dunnet post-hoc test (** p<0.01, ***p<0.001 vs control).  
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A Control 
 
B CPO (100mg/kg) 
 
C IFO (200mg/kg) 
 
 
Figure 6.6: Representative images of haematoxylin and eosin staining of isolated mouse bladders treated with 
saline (control) (A), CPO (100mg/kg) (B) or IFO (200mg/kg) (C).  Images representative of n=3 results.  
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No observable differences were noted in the pressure/volume relationship during distension 
between the different treatment groups.  All treatment groups displayed an initial phase of 
gradual increase in pressure to 15mmHg followed by a second steep pressure increase beyond 
that pressure (Figure 6.7).  This pattern of filling occurred in all bladder groups despite 
variations in total bladder volume and volumes accommodated in each phase.  Average bladder 
volume was not significantly different between each treatment group (402±21µl in controls, 
329±44µl in CPO treated and 277±77µl in IFO treated mice [n≥5]). 
 
 
Figure 6.7: Representative traces showing full distension of isolated bladders from saline (control) (A), CPO 
(100mg/kg) (B), and IFO (200mg/kg) (C) treated mice.  
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Mediator Release  
Samples taken from the lumen of distended bladders and from the serosal solution were 
analysed for ATP, ACh and PGE2 content.  The concentration of each mediator in each sample 
was calculated and the luminal and serosal concentrations compared (Figure 6.8). Luminal 
ATP concentrations were 1.5-fold higher than the serosal ATP concentrations (p<0.05) (Figure 
6.8-A).  Whereas, luminal concentrations of both ACh and PGE2 were less than half of the 
concentrations in serosal samples (p<0.05) (Figure 6.8-B & C respectively).  
However, the volumes of fluid in the lumen and surrounding the serosa of the bladders were 
different (<0.5mL and 8mL respectively).  Therefore, each mediator concentration was then 
normalised to volume to obtain the total amount present in the total volume of each sample.  
More than 10 times the amount of ATP (pmoles) was released from the serosa than the lumen 
(p<0.001) (Figure 6.8-D).  Similarly, the total amount of ACh and PGE2 was significantly higher 
(30-fold and 40-fold respectively) in serosal samples than in luminal samples (p<0.01) (Figure 
6.8-E & F respectively).   
Three distensions were performed consecutively, with 10 minutes recovery in between, and 
samples were taken after each to test the repeatability of mediator release in response to 
stretch.  As shown in Figure 6.9, total ATP, ACh and PGE2 release was consistent from both 
the lumen and serosa of the mouse bladders. 
Treatment with CPO (100mg/kg) did not affect the total amount of ATP, ACh or PGE2 released 
from either the lumen or the serosa of the mouse bladder (Figure 6.10).  However, treatment 
with IFO (200mg/kg) caused a reduction in the luminal ATP levels by 50% (p<0.05) and serosal 
PGE2 levels by 75% (p<0.05).  Luminal PGE2 levels were also reduced by approximately 50% 
but this was not significant. IFO treatment had no significant effect on ACh levels in luminal or 
serosal samples.  
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Figure 6.8: ATP, ACh and PGE2 concentrations (A, B & C) and total release (D, E & F) in luminal and serosal 
samples from isolated mouse bladders. Data represented as mean ± SEM, n=6. Analysed using a two-way 
paired Student’s t-test (*p<0.05, ***p<0.001 vs control). 
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Figure 6.9: Repeatability of total ATP (A), ACh (B) and PGE2 (C) in three consecutive luminal and serosal 
samples during stretch of mouse bladders. Data represented as mean ± SEM (n≥3). Analysed via one-way 
ANOVA with Tukey post-test.  
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Figure 6.10:  Total ATP (A), ACh (B) and PGE2 (C) in luminal and serosal samples from bladders of mice treated 
with saline (control), CPO (100mg/kg) or IFO (200mg/kg) at maximal distension. Data represented as mean ± 
SEM (n≥3). Analysed via one-way ANOVA with Dunnett post-hoc test (*p<0.05 vs control). 
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Bladder Contractility & Electrical Field Stimulation  
Bladders were infused with saline at a rate of 30µl/min until intravesical pressure reached 
20mmHg at which point infusion was stopped and the outflow tap remained closed.  The 
bladders were then left for approximately 1 hour for the muscle tension to stabilise.  All bladders 
relaxed from their initial pressure of 20mmHg and reached a plateau within an hour (Figure 
6.11).  The volume of the bladders at 20mmHg intravesical pressure was not different between 
treatment groups (328±38µl in control, 308±37µl in CPO treated and 318±56µl in IFO treated 
mice respectively [n=6]).  There was no difference in compliance of the bladders in each 
treatment group during filling to 20mmHg or during accommodation of the volume at 20mmHg.  
In addition, there was no significant difference between the intravesical pressures at plateau of 
each group (Figure 6.11).  
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Figure 6.11: Bladder compliance during filling (A) and during accommodation from 20mmHg (B) in mouse 
bladders treated with saline (control), CPO (100mg/ml) or IFO (200mg/ml). Data represented as mean ± SEM 
(n=6). Final time point analysed by one-way ANOVA with a Dunnett post-test.  
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After intravesical pressure had stabilised, the whole bladder was then electrically stimulated and 
changes in intravesical pressure recorded.  Electrical stimulation of the isolated mouse bladder 
caused a transient increase in intravesical pressure as shown in Figure 6.12.  As the frequency 
of stimulation increased the pressure response also increased (Figure 6.12-A & B).  The 
pressure responses at 5, 10 and 20Hz were stable and repeatable (Figure 6.12-A) and were 
completely sensitive to 1µM tetrodotoxin (TTx) (Figure 6.12-C).  
Responses to EFS were reduced by 30-50% in CPO (100mg/kg) or IFO (200mg/kg) treated 
bladders but this reduction was not significant (Figure 6.13).  Specifically, at 5Hz responses 
after CPO or IFO treatment were 4.24±0.53mmHg and 4.47±2.17mmHg respectively which was 
slightly lower than control responses of 8.23±3.17mmHg.  Similar results were seen at 10Hz 
where responses in CPO or IFO treated bladders were 5.51±0.65mmHg and 6.98±3.25mmHg 
compared to control responses of 11.0±3.10mmHg.  Responses at 20Hz were also a little lower 
in CPO or IFO treated bladders (8.04±0.91mmHg and 9.14±3.39mmHg respectively) than in 
control bladders (13.4±3.21mmHg).  These differences were not statistically significant and 
whether this effect was due to any change in efferent nerves or muscle contractility was not 
apparent.     
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Figure 6.12: Response to electrical field stimulation (EFS) (40 volts and 0.2ms pulse-width, 5 second train every 
100s) of a control isolated mouse bladder. A: Representative trace of intravesical pressure increases to EFS at 
5, 10 and 20Hz. B: Intravesical pressure response to EFS in an isolated mouse bladder. C: Representative trace 
of intravesical pressure response to EFS (20Hz) of a mouse bladder in the absence and presence of 
tetrodotoxin (TTx) (1µM).  
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Figure 6.13: Intravesical pressure responses to electrical field stimulation at 5, 10 and 20Hz in isolated mouse 
bladders treated with saline (control), CPO (100mg/kg) or IFO (200mg/kg). Data represented as mean±SEM, n=3 
and analysed by two-way ANOVA.   
 
Full frequency curves were performed for each bladder and then responses at 20Hz only were 
investigated to determine the contribution of NO, ACh and ATP to responses.  In control 
bladders, the baseline response to EFS at 20Hz was 10.3±1.5mmHg (Figure 6.14-A).  
Removing the effect of NO by adding L-NNA (100µM) typically caused minor increases in the 
pressure response (12.3±2.4mmHg).  When the muscarinic contribution to the response was 
removed after the addition of atropine (1µM) the responses were similar to baseline 
(9.0±2.4mmHg).  However, after using αβmATP (10µM) to desensitise the P2X1 purinoceptors, 
the response to 20Hz EFS was almost eliminated, leaving a response of only 0.7±0.4mmHg, 
which was significantly lower than baseline (p<0.001).  
 
In mice treated with CPO (100mg/kg) or IFO (200mg/kg) the baseline response to EFS at 20Hz 
was similar to that in control animals (10.8±2.4mmHg and 11.3±1.5mmHg respectively) (Figure 
6.14-B). CPO or IFO treated mice also exhibited responses similar to control after the addition 
of L-NNA (100µM) (10.9±1.4mmHg and 10.8±1.3mmHg respectively) and atropine (1µM) with 
pressure remaining similar to baseline (7.7±1mmHg and 7.6±1.3mmHg respectively). Lastly, 
after the addition of αβmATP (10µM), only a minor pressure response to 20Hz EFS remained in 
CPO or IFO treated mice which was again similar to that in control animals (0.8±0.5mmHg and 
1.4±0.5mmHg respectively).  
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Figure 6.14: Intravesical pressure response to electrical field stimulation at 20Hz at baseline, after L-NNA 
(100µM), atropine (1µM) and αβmATP (10µM) in an isolated mouse bladders treated with saline (control) (A), 
CPO (100mg/kg) or IFO (200mg/kg) (B). Data represented as mean ± SEM, n≥4 and analysed by one-way ANOVA 
with a Dunnett post-test (**p<0.01 compared to the baseline response of each treatment group). 
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Responses to Pharmacological Agents 
Bladders were infused with saline at a rate of 30µl/min to an intravesical pressure of 20mmHg 
and then left for approximately 1 hour to accommodate the volume and for the muscle tension 
to stabilise.  After plateau, a cumulative dose response curve to isoprenaline (β-adrenoceptor 
agonist) was performed on each bladder to study the relaxation response (Figure 6.15).  
Bladders treated with CPO (100mg/kg) showed no difference in response to isoprenaline 
compared to control.  However, IFO (200mg/kg) treated bladders had a significantly reduced 
relaxation response (p<0.001) compared to the control response.  Mean maximum relaxation 
responses in the IFO treated bladders were approximately 30% less than controls.  The pEC50 
values for each group were not significantly different (control: 8.1±0.09, CPO: 8.3±0.09, 
IFO: 8.4±0.1).  
 
Figure 6.15: Relaxation responses of whole bladders from saline (control), CPO (100mg/kg) and IFO (200mg/kg) 
pre-treated mice to cumulative doses of isoprenaline. Data represented as mean ± SEM for each dose (n≥4).  
(*p<0.05 treated bladder response to isoprenaline vs corresponding control response analysed by one-way 
ANOVA with Dunnett post-test) (### p<0.001 treated curve vs control dose response curve by two-way ANOVA 
with a Bonferonni post-test).   
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Spontaneous Contractions 
Spontaneous contractions of the isolated bladders during filling and during accommodation 
were also measured. Treatment with CPO (100mg/kg) or IFO (200mg/kg) had no significant 
effect on the average frequency (Figure 6.16-A) or the amplitude (Figure 6.16-B) of 
spontaneous contractions compared to control.  
 
Figure 6.16: Average frequency (A) and amplitude (B) of spontaneous contractions in bladders from saline 
(control), CPO (100mg/kg) and IFO (200mg/kg) treated mice during filling to 40mmHg and accommodation at  
20mmHg pressure. Data represented as mean ± SEM (n≥4). Analysed by one-way ANOVA with Tukey post-test.  
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6.4 DISCUSSION  
The activity of afferent nerves in the bladder can be influenced by various factors including 
urothelial mediators, detrusor tone as well as the sensitivity of the nerves themselves (de Groat 
and Yoshimura, 2009). The previous Chapter demonstrated an increase in afferent activity 
during distension in CPO and IFO treated bladders.  Accordingly, the present study aimed to 
investigate whether urothelial function or muscle contractility changes after treatment with these 
drugs could be contributing to the increase in afferent activity.    
Increasing age has also been shown to be associated with increased afferent excitability in 
humans and mice (Gregorini et al., 2015, Daly et al., 2014).  In the present study there was no 
difference in the age or weight of the animals before treatment.  However, CPO and IFO 
treatment caused the animals to lose weight over the following 24 hours.   Lower body weights 
of animals treated with CPO have been reported previously and therefore this was not an 
unexpected result (Mok et al., 2000, Boudes et al., 2011).  Given that initial weight, age and 
bladder volume did not differ between the groups any differences in tissue responses was 
assumed to be due to treatment with CPO or IFO. 
Urothelial Effects of CPO and IFO  
Treatment with either CPO or IFO caused macroscopic signs of bladder inflammation including 
redness, increased visible vasculature and areas of haemorrhage.  Treatment with these drugs 
also caused substantial swelling and oedema in the lamina propria layer resulting in detachment 
of the urothelial layer from the detrusor.  The effects appeared to be slightly more severe after 
IFO treatment.  It should be noted that these effects were observed subjectively and were not 
quantified.  However, similar inflammatory effects have been observed in rats treated with CPO 
or IFO (Macedo et al., 2011, Juszczak et al., 2010, Macedo et al., 2008a, Giglio et al., 2007, 
Giglio et al., 2005). Specifically, acute treatment with CPO caused bladder redness, oedema, 
urothelial erosion and ulceration in rats (Juszczak et al., 2010). Swelling of the lamina propria 
sufficient to cause detachment of urothelial cells from the detrusor has also been reported in 
mice treated with CPO (Golubeva et al., 2014). Similarly, after 24 hours, IFO treatment in rats 
induced severe haemorrhagic cystitis showing marked oedema, intense urothelial damage and 
loss of folding, leukocyte infiltration, and haemorrhage (Macedo et al., 2008a, Macedo et al., 
2011). Similar haemorrhage, oedema, urothelial ulceration and inflammatory cell infiltration has 
also been reported up to 24 hours after intravesical instillation of acrolein in rats and mice. 
(Macedo et al., 2008b, Batista et al., 2006, Wang et al., 2008b).  This confirms that the CPO 
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and IFO treatments used in the present study effectively caused cystitis consistent with previous 
studies.   
As discussed previously, after CPO treatment in rats the urothelium undergoes an acute period 
of damage characterised by ulceration and erosion (Auge et al., 2013, Juszczak et al., 2010) 
followed by a period of rapid proliferation which results in urothelial hyperplasia (Boudes et al., 
2011, Golubeva et al., 2014, Romih et al., 2001).  Approximately a week after the initial CPO 
treatment, the hyperplastic urothelium starts differentiating and apoptosis increases to remove 
cells until a normally differentiated three-layered urothelium is restored by day 14.  Chronic CPO 
treatment (four injections over seven days) in mice has been shown to cause urothelial 
hyperplasia due to an increased number of cells (Boudes et al., 2011, Golubeva et al., 2014).  
Typical signs of oedema, swelling and leukocyte infiltration were also present, but no signs of 
urothelial erosion or ulceration were observed after chronic CPO treatment. Loss of urothelial 
cells or hyperplasia during the early and late stages of CPO or IFO induced damage could alter 
the levels of mediators released by the urothelium and affect the activity of afferent nerves.  In 
particular, the release of ATP and PGE2 from the urothelium has been linked to bladder 
hyperactivity due to the possible activation or sensitisation of sensory nerves (de Groat, 2004).  
The present study demonstrated release of ATP, ACh and PGE2 into the lumen of the bladder 
as well as from the serosal side of the bladder during stretch.  Mediator levels in luminal and 
serosal samples from control bladders were consistent and repeatable.  Interestingly, the 
amount of each mediator in the serosal samples was greater than the amount in the luminal 
samples.  This supports previous findings in rabbit urinary bladder showing that ATP is released 
from the baso-lateral surface of the urothelium during stretch rather than the apical/luminal 
surface (Dunning-Davies et al., 2013, Ferguson et al., 1997).  More specifically, Ferguson et al., 
(1997) demonstrated basal ATP release from both luminal and serosal surfaces of the rabbit 
bladder, however stretch induced an increase in ATP release from the serosal side only. They 
also demonstrated that the source of this ATP was the urothelium and not the muscle.  Similarly, 
Dunning-Davies et al., (2013) showed that distension of isolated rabbit urothelium caused an 
increase in ATP release from the serosal surface.  This is understandable given that the target 
tissues of urothelial mediators are under the urothelium and not in the lumen.  Furthermore, the 
surface of the urothelium is a barrier that prevents entry of molecules into the bladder wall from 
the lumen and therefore it is logical that it also prevents movement of molecules in the opposite 
direction.   
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Treatment with CPO did not affect the levels of ATP, ACh or PGE2 in luminal or serosal samples 
from the mouse bladder.  However IFO treatment caused a reduction in luminal ATP levels and 
serosal PGE2 levels but did not affect ACh levels.  This is unexpected given that Smith et al., 
(2005) have previously reported increased ATP release from rat urothelium after CPO treatment.  
However, the model used a 50% higher dose of CPO administered chronically every three days 
for a total of three treatments.  Therefore, the increased ATP release seen by Smith et al., 
(2005) may be due to the presence of a hyperplastic urothelium with more cells releasing ATP 
or may be a result of greater urothelial damage allowing ATP leakage into the lumen.  In the 
present study, urothelial damage appeared to be greater after IFO treatment.  This damage may 
have caused more death or loss of urothelial cells resulting in a decreased number of cells 
releasing ATP and therefore lower luminal ATP levels.   No studies have reported on the luminal 
release of PGE2 after CPO or IFO treatment despite several studies in rodents demonstrating 
an increased expression of COX-2 in urothelial cells 12-24 hours after treatment with either drug 
(Macedo et al., 2011, Macedo et al., 2008a, Klinger et al., 2007).  One study using a very high 
dose of IFO (400mg/kg) in rats found that the plasma PGE2 concentration was increased 24 
hours after treatment (Macedo et al., 2011) however the exact source of this PGE2 in the 
bladder is not clear.  Again, the present study demonstrated a decreased serosal level of PGE2 
after IFO treatment. This may be due to detachment of the urothelium from the detrusor making 
it more difficult for PGE2 to be released from the serosa.  However, luminal PGE2 levels also 
tended to decrease after IFO treatment suggesting that a loss of urothelial cells may be 
responsible for the lower levels.  Urothelial damage after CPO or IFO treatment would be 
expected to disrupt the barrier function allowing mediators to move into the lumen resulting in 
higher levels of all mediators in the luminal samples.  This was not observed in the present 
study suggesting that the barrier function was not compromised or that urothelial cell loss was 
sufficient to result in overall lower levels in the lumen.   
In any event, the increased afferent activity seen after treatment with CPO or IFO in the 
previous Chapter does not appear to be due to increased ATP or PGE2 release from the 
urothelium.  Therefore, the acute stage of CPO or IFO bladder hyperactivity may involve a 
non-urothelial mechanism of nerve sensitisation.  The urothelial hyperplasia reported in other 
studies appeared several days after CPO administration or during chronic CPO administration.  
This suggests that increased mediator levels may appear due to more numerous urothelial cells 
at this later stage when afferent nerves are already sensitised, resulting in further enhancement 
of afferent activity.  
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Muscle Effects of CPO and IFO  
The detrusor smooth muscle has myogenic tone and modulation of this tone may influence the 
ability of the bladder to accommodate urine during filling (Andersson, 1999).  Furthermore, 
enhanced muscle tone during filling may also cause enhanced afferent nerve activity resulting in 
abnormal sensations or dysfunction.  Bladder muscle tone can be influenced by a number of 
different mechanisms including urothelial transmitter release, receptor expression, altered 
efferent or afferent nerve activity, altered excitability or coupling of smooth muscle cells and ICs 
or changes to spontaneous contractile activity (Fry et al., 2010, Andersson, 2004). 
As discussed previously, rodents treated with CPO or IFO demonstrate enhanced intravesical 
pressure during filling, reduced bladder capacity, increased urinary frequency as well as 
decreased contractile force during voiding (Okinami et al., 2014, Macedo et al., 2011, Boudes et 
al., 2011, Everaerts et al., 2010b, Wang et al., 2008b, Kageyama et al., 2008, Juszczak et al., 
2007, Hu et al., 2003).  Basal pressure of the bladder has also been shown to be increased in 
rodents treated with these drugs (Boudes et al., 2011, Macedo et al., 2011, Juszczak et al., 
2007).  Furthermore, in conscious rats, CPO treatment (200mg/kg) has also been shown to 
enhance the spontaneous activity of the bladder, particularly during the filling phase (Pan et al., 
2012).  Isolated bladder strips from CPO treated mice also showed enhanced spontaneous 
contractile activity after application of an L-type Ca
2+
 channel activator (Okinami et al., 2014). 
Accordingly, it appears that both CPO and IFO affect detrusor tone leading to storage 
symptoms.  In the present study, treatment with CPO or IFO did not affect compliance of the 
isolated mouse bladder during filling or during accommodation as the respective 
pressure-volume curves were almost identical between each group.   In addition, the frequency 
and amplitude of spontaneous contractions were unchanged after CPO or IFO treatment.  
However, the present study used an isolated bladder technique whereas the storage symptoms 
reported in rodents were in anaesthetised or awake animals with intact nervous systems.  
Accordingly, it appears that enhanced bladder tone due to CPO or IFO treatment is dependent 
on the presence of efferent or afferent nerve activity.   
In addition, the ability of the detrusor to relax in response to β-AR stimulation may also be 
altered manifesting as an increase in tone.   Therefore, the effect of CPO or IFO on the bladder 
relaxation to the β-AR agonist isoprenaline was investigated.  The distended bladder relaxed in 
response to isoprenaline and the relaxation was concentration dependent.  CPO treatment did 
not affect the ability of the bladder to relax to isoprenaline whereas IFO treatment inhibited the 
relaxation response.   Previous studies have reported that 3 days after CPO treatment 
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(100mg/kg) isolated rat bladder strips had inhibited relaxations to isoprenaline (Giglio et al., 
2007, Vesela et al., 2012).  The results in the present study in mice used the same dose of CPO, 
but looked at effects 24 hours after treatment.  The responses seen after 24 hours do not 
support the previous findings in rats suggesting these effects either do not occur in mice or 
develop at a later stage of CPO induced cystitis.   However, IFO treatment (200mg/kg) did affect 
isoprenaline relaxations suggesting that IFO induced cystitis causes similar changes to CPO in 
rats.  However, Giglio et al., (2007) found that there was no postjunctional β-AR mediated 
relaxation in response to electrical field stimulation in control or CPO treated bladder strips.  
Therefore, although CPO or IFO treated bladder tissue may have a reduced ability to relax to 
β-AR stimulation, this mechanism does not appear to play a role in nerve evoked responses 
and is unlikely to be responsible for the storage symptoms seen in animals after treatment.  
Therefore, the question is whether there are altered excitatory nerve responses that may 
contribute to altered detrusor tone.   In whole mouse bladders, stimulation of the efferent nerves 
by electrical field stimulation produced repeatable, transient, TTx sensitive and frequency 
dependent contractions.   This is similar to a previous study using EFS (50V, 0.2ms pulse width, 
3 second train) on whole mouse bladders (Fabiyi and Brading, 2006) and responses in whole 
bladders were found to be comparable to isolated bladder strips. In the present study, blocking 
NO production with L-NNA had no effect on EFS induced responses, although an increased 
trend was apparent.  Atropine did not significantly reduce responses, while αβmATP almost 
completely abolished EFS induced contractions.  These results suggest that ATP makes up the 
large majority of the EFS induced contraction in whole mouse bladder and that NO and ACh 
potentially contribute to a small relaxation and contraction response respectively.    
These results do not fully agree with previous findings in whole bladders or isolated bladder 
strips from mice where atropine and αβmATP reduced EFS (20Hz) induced contractions by 
approximately 50% each, suggesting ACh and ATP contribute equally to nerve induced 
contractions in the mouse bladder (Fabiyi and Brading, 2006, Mok et al., 2000).  Similar results 
have been reported for isolated bladder strips from rats with atropine causing almost 50% 
reduction of the EFS induced contraction and αβmATP almost eliminating the remaining 
response (Giglio et al., 2007).  NO has been reported to have both excitatory and inhibitory 
effects on detrusor muscle and therefore, the influence of NO in the bladder is complex (Meng 
et al., 2012, Yanai et al., 2008). Specifically, it appears that a cGMP-dependent pathway causes 
relaxation of the detrusor smooth muscle while a cGMP-independent pathway involving Ca
2+ 
release increases spontaneous activity of the detrusor (Yanai et al., 2008).  However, blocking 
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NO production with L-NNA has previously been shown to have no effect on EFS induced 
responses in healthy rat bladder strips (Vesela et al., 2012).  
Bladders from mice treated with CPO (100mg/kg) or IFO (200mg/kg) showed no significant 
difference in responses to EFS compared to control bladders although a general decrease in 
contraction was noted.  These results support previous findings that show no difference in EFS 
induced responses during the acute stage (<1 day) of CPO induced cystitis, but a reduction in 
responses at a later stage (3 days) in rodents.  Specifically, the acute effects of CPO (200mg/kg) 
induced cystitis were investigated in isolated bladder strips from shrew and there was no 
change in the frequency response curves (1-16Hz) compared to controls (Mok et al., 2000). 
Two studies have used isolated bladder strips from rats treated with CPO (100mg/kg) three 
days earlier and found that responses to EFS were approximately half those of control 
responses (Giglio et al., 2007, Vesela et al., 2012).  However, general contractility to KCl was 
affected to a similar extent as the EFS induced contractions suggesting CPO treatment affects 
muscle function rather than efferent nerve function.   
The results of the current study also demonstrated no difference in contribution of NO, ACh or 
ATP to the EFS induced responses in CPO or IFO treated bladders compared to controls.  
These results support findings from both acute and late stage models wherein atropine and 
αβmATP reduced responses to a similar extent in control and CPO treated bladder strips (Giglio 
et al., 2007, Mok et al., 2000).  However, in the late stage model, inhibition of NO production 
enhanced EFS induced contractions in CPO treated bladder strips but not in control strips 
(Vesela et al., 2012).  Previous studies have suggested that muscarinic receptor stimulation on 
the urothelium causes enhanced NO release reducing the muscarinic detrusor contraction in 
CPO treated rats (Andersson et al., 2008). Therefore this mechanism may be responsible for 
the increased nerve mediated contraction seen by Vesela et al., (2012) after blocking NO 
production.  However, these effects were observed during the later stage of CPO induced 
cystitis and the present study suggests that enhanced NO production does not contribute to 
EFS induced responses during the acute (24 hour) stage of CPO or IFO induced urotoxicity.   
Therefore the results of the present study support previous findings that, 24 hours after CPO 
treatment, the efferent nerve mediated bladder responses are not significantly different from 
controls.  Responses in IFO treated bladders were similar to CPO treated bladders.  However, 
treatment with either CPO or IFO did cause a slight reduction in contraction to EFS supporting a 
transition to reduced muscle contractility at a later stage of cystitis.   
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Implications for Afferent Nerve Activity and Bladder Hyperactivity 
As mentioned earlier, the activity of afferent nerves in the bladder can be influenced by various 
factors including urothelial mediators, detrusor tone as well as the sensitivity of the nerves 
themselves (de Groat and Yoshimura, 2009). The results of the present study have 
demonstrated that CPO or IFO treatment, despite causing an increase in afferent activity during 
distension, does not cause an increase in stimulatory urothelial mediator release and does not 
affect bladder muscle tone or contractility.  Therefore, it appears that CPO or IFO treatment 
leads to enhanced sensitivity of the afferent nerves themselves resulting in enhanced activity 
during filling.  This also supports the previous findings of increased action potentials in response 
to current injection in isolated DRG neurones from CPO treated rats (Yoshimura and de Groat, 
1999, Dang et al., 2008).   
In the present study, there was no increase in detrusor tone during filling of bladders treated 
with CPO or IFO despite in vivo studies reporting reduced bladder compliance and increased 
basal pressure leading to decreased bladder capacity and increased micturition frequency.  
Similarly, in the previous Chapter, no compliance changes were observed despite there being 
an increase in afferent firing during filling.  In the nerve recording preparation, the afferent 
nerves were cut in order to record afferent firing in an electrode, thereby removing any effect of 
spinal reflexes on the results.  Similarly, the whole bladder preparation requires isolation of the 
bladder thereby removing any afferent reflexes.  Therefore, it is hypothesised that the changes 
to detrusor tone are due to enhanced afferent activity causing reflex activation of a tonic efferent 
pathway.   
Afferent and efferent responses are difficult to investigate simultaneously in vitro however a new 
in situ technique in rats has been developed in which the bladder is dissected along the midline 
from dome to urethra to create two separate parts while maintaining the blood vessels, pelvic 
nerves and spinal reflexes intact (Aronsson et al., 2013).  This preparation enables investigation 
of reflex effects by applying mechanical or electrical stimuli to one side of the bladder or its 
afferent nerves while measuring the response from the other side.  Using this technique, 
Aronsson et al., (2014) then examined the effect of CPO pre-treatment on the responses of the 
rat bladder.  Responses to electrical stimulation of the efferent pelvic nerves were reduced in 
the CPO treated rats.  However after CPO treatment, mechanical stretch of one side of the 
bladder elicited significantly larger contractions of the contralateral side compared to control 
responses.  This supports the hypothesis that enhanced bladder tone after CPO or IFO 
treatment is due to enhanced afferent activity causing reflex activation of an efferent tonic effect.  
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The reflex induced responses almost instantaneously disappeared after removal of the stretch 
force in control bladders, but the responses in CPO treated bladders demonstrated a gradual 
decline and spontaneous contractions persisted for several minutes (Aronsson et al., 2014).  
Accordingly, it appears that enhanced spontaneous activity seen after CPO or IFO treatment 
could also be due to enhanced afferent reflex activity in response to stretch.  Furthermore, 
electrical stimulation of the afferent pelvic nerve produced similar responses in control and CPO 
treated bladders suggesting that the sensitisation may be occurring at the mechanoreceptor 
level.   The results in the previous Chapter support this finding as afferent activity was increased 
during filling in response to bladder distension presumably activating mechanoreceptors.   
Conclusions 
CPO and IFO treatment did not increase the release of stimulatory urothelial mediators ATP or 
PGE2 from whole mouse bladders during stretch from either the luminal or serosal side of the 
bladder.  In addition, detrusor compliance during filling or accommodation was not altered after 
CPO or IFO treatment.  Similarly, the bladder response to EFS was similar in controls and 
treated bladders.  Therefore, the enhanced total nerve activity in the mouse bladder during 
graded distensions observed in the previous Chapter appears to be due to direct sensitisation of 
the nerves themselves and not as a result of altered urothelial or detrusor function.  These 
nerve results are supported by previous findings and are most likely due to sensitisation of the 
mechanoreceptors resulting in enhanced activity at equivalent bladder volumes.  These findings 
potentially explain the pain, frequency and abnormal sensations experienced by patients after 
treatment with CPO or IFO.  
  
 239 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 7: General Discussion 
 
 
 
 
 
  
 240 
 
  
 241 
 
The aim of this thesis was to increase our understanding of the bladder toxicity caused by 
cyclophosphamide and ifosfamide and the implications of this toxicity on bladder function.  
Accordingly, a body of work is described investigating the effects of cyclophosphamide, 
ifosfamide and their toxic metabolites on the function of the urothelium, detrusor and the 
afferent and efferent nerves in the bladder.  A variety of techniques and tissue types were used 
to investigate how these substances affect the function of isolated parts of the bladder as well 
as the function of the bladder as a whole.  Therefore the final discussion focuses on the 
interaction between the tissue types and how each may contribute to overall bladder function.   
As discussed throughout this thesis, CPO and IFO are cytotoxic drugs used extensively in the 
treatment of cancer and autoimmune diseases (Furlanut and Franceschi, 2003, Brode and 
Cooke, 2008).   A major limiting factor in their use is the resulting bladder toxicity which can 
cause both anatomical damage and bladder function changes.  The metabolites of CPO and 
IFO come into direct contact with the urothelium causing urothelial damage followed by severe 
bladder inflammation (Cox, 1979, Lima et al., 2007).  The functional effects can manifest as 
bladder pain, urinary frequency, urgency, dysuria, and feelings of incomplete emptying 
(Korkmaz et al., 2007, Fukuoka et al., 1991) and these effects can last beyond the resolution of 
inflammation and damage.  These lasting effects significantly affect the quality of life of patients 
both during chemotherapy and after treatment.  The current protective measures have limited 
efficacy and a significant percentage of patients treated with CPO or IFO are still likely to suffer 
from urotoxic side effects of these drugs. Understanding how these drugs cause bladder 
damage and what functional changes occur as a result may reveal future targets for preventing 
the adverse effects of these drugs or restoring normal bladder function after treatment.   
Inflammation has been shown to increase bladder afferent neurone excitability and is thought to 
contribute to bladder overactivity and pain (Hayashi et al., 2009, Wyndaele and De Wachter, 
2003, Yoshimura et al., 2002).  Accordingly, the inflammation during CPO or IFO induced 
cystitis may be intimately linked to the long term changes in bladder function.  Patients with 
painful bladder syndrome (PBS) exhibit very similar urinary symptoms to those with CPO or IFO 
induced cystitis including urinary frequency, urgency and pain (Parsons, 2007) and evidence 
suggests these symptoms may be a result of bladder inflammation (Amaravadi et al., 2011, 
Erickson et al., 2002, Keay, 2008, Erickson et al., 2008, Wyndaele et al., 2009, Ogawa et al., 
2010, Peters et al., 1999).  The results in this thesis, in combination with previous findings, 
support the concept that inflammation may have a role in the bladder dysfunction seen after 
CPO or IFO induced cystitis.  Therefore, the following discussion will address whether 
inflammation may play a role in the bladder symptoms occurring after CPO or IFO treatment.  
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Sources of Damage and Inflammation in CPO or IFO Induced Cystitis 
Increased Urothelial Permeability 
After CPO treatment the urothelium undergoes an acute period of damage characterised by 
ulceration and erosion resulting in the loss of the epithelial barrier function (Auge et al., 2013, 
Juszczak et al., 2010).  The permeability barrier of the urothelium is compromised in various 
urinary bladder disorders such as PBS and overactive bladder (Hauser et al., 2008, Hurst et al., 
1996, Parsons, 2007, Parsons, 2011, Teichman and Moldwin, 2007).  Specifically, in patients 
with PBS a loss of urothelial barrier function was demonstrated by an increase in urea 
movement across the urothelium (Parsons et al., 1991).   However, in these patients it is not 
clear whether the loss of barrier function causes the associated inflammation or is a secondary 
effect of inflammation.  A recent study in rats used intravesical instillation of protamine sulphate 
to disrupt the urothelial barrier function and found that inflammation resulted (Soler et al., 2008).  
However, in rats where urine production was inhibited no inflammation occurred.  Accordingly, it 
appears that disruption of the urothelial barrier itself does not cause inflammation, but allows 
noxious substances in the urine to move into the bladder and cause inflammation.  This may 
explain the mechanism of toxicity of CPO or IFO in the bladder whereby acrolein and/or CAA 
causes damage to the urothelium resulting in loss of the barrier function and allowing further 
penetration of the metabolites and other urinary irritants into the bladder wall causing or 
exacerbating inflammation.   
The results in this thesis also support disruption of the barrier function of the urothelium.  
Specifically when acrolein or CAA was applied to the luminal surface of porcine bladder, not 
only was the urothelium damaged, but the contractility of the detrusor tended to be reduced.  
This suggests that both metabolites were capable of causing sufficient damage to the 
urothelium to allow penetration into the detrusor where they affected muscle responsiveness.  
Given that this damage occurred after only a four hour incubation it appears likely that acrolein 
or CAA can cause direct disruption of the urothelial barrier function and detrusor damage prior 
to the development of inflammation.  Accordingly, inflammation may be a result of tissue 
damage after infiltration of the toxic metabolites and may worsen the direct damage caused by 
the metabolites.  Although excretion of the toxic metabolites is complete by 24 hours 
post-treatment, the peak in inflammation and the greatest effects on contractile responses have 
been shown to occur at 60 hours post-treatment (Giglio et al., 2005, Vesela et al., 2012).  
Accordingly, this suggests the metabolites are responsible for urothelial damage and initiating 
inflammation which is then responsible for changes to detrusor responsiveness.  
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Urothelial Release of Inflammatory Mediators 
Acrolein or CAA treatment was demonstrated to cause cultured human urothelial cells to 
release more ATP and PGE2 during basal and stretch conditions (Chapter 3).  These two 
mediators can have a proinflammatory effect in the bladder.  Save & Persson (2010) 
demonstrated that human urothelial cells released IL-8 in response to P2Y receptor stimulation.  
Furthermore, they demonstrated that urothelial cells infected with Escherichia coli had 
enhanced extracellular ATP and IL-8 levels and that the increased IL-8 could be reduced by 
increasing breakdown of the endogenous ATP with apyrase.  This suggests that enhanced ATP 
from the urothelial cells can act in an autocrine manner to stimulate release of cytokines such 
as IL-8.  PGE2 release from urothelial cells has also been shown to have a proinflammatory 
effect and blocking EP4 receptors during CPO induced cystitis caused a reduction in 
inflammation and inflammatory cell infiltration (Chuang et al., 2012).     
Urothelial cells have also been shown to release various cytokines, including IL-1β, IL-6 and 
IL-8 in response to infection or cytotoxic damage which have various inflammatory effects in the 
bladder (Funfstuck et al., 2001, Kang et al., 2013).  The effects of these cytokines include 
actions such as recruitment of inflammatory cells, induction of phagocytic activity, cellular 
proliferation and angiogenesis.  Furthermore, oxidative stress has been shown to cause 
increased IL-8 production in intestinal epithelial cells (Yamamoto et al., 2003).  Therefore, given 
that acrolein caused increased oxidative stress and urothelial cell damage it is not surprising 
that it also caused an increase in IL-1β, IL-6 and IL-8 release in the present study.  Additionally, 
the increased ATP release from the urothelial cells may also have caused increased cytokine 
release, in particular IL-8.  Therefore, the urothelial cells themselves may be the initial 
mediators of the inflammatory response to CPO and IFO induced cystitis due to acrolein or CAA 
enhancing the release of mediators such as ATP, PGE2 and cytokines.  
Neurogenic Inflammation 
Neurogenic inflammation includes both vascular and non-vascular inflammatory effects 
triggered by the release of proinflammatory neuropeptides from sensory nerve terminals in 
response to noxious stimuli (Geppetti et al., 2008).  The inflammatory neuropeptides in sensory 
nerve terminals include substance P, CGRP and neurokinin A and they can cause arteriolar 
vasodilation, plasma extravasation and oedema as well as alterations in smooth muscle activity 
(Morrison, 1999, Geppetti et al., 2008).   
The release of neuropeptides from sensory nerves has been associated with the activation of 
various receptors and channels on the nerves including α1-ARs, TRPV1 and TRPA1 (Geppetti 
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et al., 2008).  Phenylephrine caused release of neuropeptides from sensory nerves and 
subsequent plasma extravasation in the bladder of the rat (Trevisani et al., 2007a).  Similarly, 
activation of TRPV1 or TRPA1 channels has also been shown to cause neurogenic 
inflammation in guinea pig lung and rat oesophagus respectively (Trevisani et al., 2005, 
Trevisani et al., 2007b).   
TRPV1 channels are expressed on sensory neurones in pain pathways and their activation by 
various stimuli (such as capsaicin) causes sensations of pain or discomfort (Rosenbaum and 
Simon, 2007).  TRPA1 channels are coexpressed with TRPV1 in sensory nerves supporting 
their role in the nociception pathway (Bautista et al., 2005).  TRPA1 are activated by cold stimuli 
and various irritant chemicals including pungent organosulfur compounds and noxious 
unsaturated aldehydes such as acrolein (Guimaraes and Jordt, 2007) and have been shown to 
cause notable neurogenic inflammation, hyperactivity and nociception (Trevisani et al., 2007b, 
Du et al., 2007b, Streng et al., 2008).  In cultured neurones from wild type mice, acrolein 
triggers Ca
2+
 influx whereas no response is seen in neurons of TRPA1-deficient mice (Bautista 
et al., 2006).   
Accordingly, the bladder inflammation, extravasation and oedema observed after CPO or IFO 
administration may be neurogenically mediated.  Plasma extravasation after CPO 
administration was partially inhibited by an α1-AR antagonist (Trevisani et al., 2007a).  In 
addition, intravesical botulinum toxin A has been shown to improve symptoms of PBS patients 
(Pinto et al., 2013) presumably due to decreased neuropeptide release and nociception 
(Chuang et al., 2004).  Furthermore, TRPA1 antagonists inhibited extravasation in the urinary 
bladder of rats treated with CPO (Geppetti et al., 2008).  Therefore, it is possible that acrolein 
may directly activate TRPA1 receptors on sensory nerves contributing to neurogenic 
inflammation and enhanced nociception.  However, TRPA1 channels can also be activated by 
molecules produced during oxidative stress and endogenous inflammation (Trevisani et al., 
2007b, Streng et al., 2008) such as that occurring after CPO or IFO treatment. Accordingly, the 
evidence suggests that the symptoms of CPO or IFO induced cystitis may be at least partially 
due to neurogenic inflammation triggered directly or indirectly by the toxic metabolites of CPO or 
IFO.   
Mast Cells 
Mast cells are also important contributors to the development of an inflammatory response.  
Their activation results in the release of mediators that trigger inflammation and neuronal 
hyperexcitability (Theoharides et al., 2001).  Several studies have demonstrated a close 
 245 
 
relationship between mast cells and afferent nerves and it is thought that mast cells play an 
important role in neurogenic inflammation (Harvima et al., 2010, Keith et al., 1995, Yano et al., 
1989).  Mast cells appear to be involved in CPO and IFO induced inflammation.  An increased 
number of mast cells have been reported after acute and chronic CPO administration in mice 
and rats (Golubeva et al., 2014, Juszczak et al., 2010, Sakthivel et al., 2008, Hu et al., 2003).  
However, most importantly, Deberry et al., (2014) reported an increase in the number of 
degranulated mast cells one day after CPO administration in mice.  Mast cell degranulation has 
been demonstrated in response to neuropeptides released from afferent nerves (Yano et al., 
1989, Saban et al., 2002), acrolein administration (Hochman et al., 2014) and muscarinic 
receptor stimulation (Spanos et al., 1996).  Damaged urothelial cells also produce cytokines or 
growth factors that can stimulate proliferation and activation of mast cells (Theoharides et al., 
2001).  Increased numbers of mast cells have been reported in painful bladder syndrome 
(Theoharides et al., 2001).  The release of proinflammatory or nociceptive molecules from mast 
cells is postulated to cause sensitisation of nerves and further release of transmitters and 
peptides which can continue to stimulate mast cells.  It is this cycle of perpetual stimulation 
between nerves, mast cells and urothelial cells that is thought to contribute to the ongoing 
symptoms of PBS (Theoharides et al., 2001). 
The results outlined in this thesis provide evidence for increased ACh and cytokine release from 
urothelial cells after acrolein or CAA treatment.  Accordingly, it is possible that the inflammation 
and afferent sensitisation caused by CPO or IFO is due to an increased number of mast cells 
and increased activation either directly by toxic metabolites or indirectly by the release of 
neuropeptides or transmitters from nerves or urothelial cells.  
Effects of CPO or IFO Induced Bladder Damage and Inflammation  
Effects on the Urothelium 
Normal urothelium has a low turnover rate and is unresponsive to epidermal growth factor (EGF) 
in urine because the superficial cells lack epidermal growth factor receptors (EGFRs) (Romih et 
al., 2001).  However, the partially differentiated cells in the basal or intermediate urothelial 
layers do express EGFRs and when exposed during injury the urinary EGF can stimulate their 
proliferation giving the urothelium its regenerative ability (Romih et al., 2001, Varley and 
Southgate, 2008, Jost et al., 1989).   
Previous studies have demonstrated that CPO treatment leads to an acute period of urothelial 
damage resulting in loss of cells (Auge et al., 2013, Juszczak et al., 2010).  This thesis has also 
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reported similar results and has shown that acrolein and CAA are capable of causing damage to 
the urothelium.  This damage exposes the partially differentiated urothelial cells and would lead 
to intense proliferation and urothelial hyperplasia (Boudes et al., 2011, Golubeva et al., 2014).  
A normal three layered urothelium is restored within 2-3 weeks (Romih et al., 2001).  These 
various stages of urothelial damage and recovery have different implications on bladder function.  
As demonstrated in cultured human urothelial cells and porcine tissues the urothelial cells are 
capable of secreting various mediators that can influence the underlying smooth muscle and 
nerves.  Treatment with acrolein or CAA was capable of causing enhanced release of various 
mediators from individual cells.  During the early stages of damage fewer urothelial cells were 
present to release mediators and the overall mediator levels were mostly unchanged.  However, 
the implications of these changes in the setting of a hyperplastic urothelium could mean much 
higher levels of the inflammatory and stimulatory mediators ATP, ACh and PGE2 causing further 
urothelial dysfunction, changes in detrusor activity and afferent sensitisation and activation.  It is 
unknown whether these effects remain long term in the restored urothelium and it would be 
interesting to determine whether urothelial mediator release remains high 2-3 weeks after CPO 
or IFO treatment.   
Effects on Spontaneous Activity  
CPO treatment has been shown to cause enhanced spontaneous activity in the bladder of 
rodents (Pan et al., 2012, Eser et al., 2012, Okinami et al., 2014).  The results in this thesis did 
not show any effect of CPO, IFO or their toxic metabolites on spontaneous activity after acute 
treatment whereas, most of the previous studies have demonstrated enhanced activity several 
days after CPO treatment.  Accordingly, this may be a long term effect of CPO or IFO induced 
inflammation in the bladder.  In support of this theory, similar increases in spontaneous activity 
have also been reported in inflammatory conditions such as interstitial cystitis and 
lipopolysaccharide (LPS) induced inflammation (Ikeda et al., 2009, Tambaro et al., 2014).   
Bladder strips from cats with feline interstitial cystitis had significantly more spontaneous Ca
2+
 
transients in the urothelial/LP layer compared to controls and the transients subsequently 
moved into the detrusor (Ikeda et al., 2009).  In mice, LPS induced bladder inflammation and 
enhanced the amplitude of spontaneous bladder contractions of isolated whole bladders 
(Tambaro et al., 2014).  An anti-inflammatory cannabinoidergic compound was found to reduce 
the inflammation in the bladder and also reduced the amplitude of spontaneous contractions.  
Accordingly it appears that inflammation may affect the urothelium/LP or possibly the detrusor 
making it hyperactive and causing increased spontaneous activity.  The lack of change in 
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spontaneous activity during the acute stage of cystitis observed in this thesis also supports that 
this may be an inflammation dependent change that occurs at a later stage of cystitis.  
Effects on Afferent Nerves  
CPO and IFO treatment causes irritation and inflammation of the bladder as well as altered 
sensations and pain and these two effects may be closely related.  Chronic irritation or 
inflammation can cause various changes throughout the sensory pathway which may contribute 
to the symptoms experienced by patients after CPO or IFO treatment (Forrest et al., 2013, de 
Groat and Yoshimura, 2009) and Figure 7.1 shows an overview of these mechanisms.  
 
Figure 7.1: A summary of the events involved in chronic inflammation of the bladder and their contribution to 
hyperexcitability of the afferent neurons. The events that occur following chronic bladder inflammation (1) are 
indicated by sequential numbers (2–7). DRG dorsal root ganglia, PGE prostaglandin E, NGF nerve growth factor. 
Adapted from (de Groat and Yoshimura, 2009).  Original author manuscript accessed via public domain through 
the Pubmed Central database. 
 
Changes in the Properties, Transmission and Organisation of Afferent Nerves 
Several studies have demonstrated increased immediate early gene expression (c-fos) in spinal 
neurones and altered expression patterns in regions of the lumbosacral spinal cord after CPO 
treatment (Vizzard, 2000, Dinis et al., 2004, Trevisani et al., 2007a, Lanteri-Minet et al., 1995). 
Expression of c-fos is thought to link short-term signals from extracellular stimuli to long term 
changes in gene expression and is considered a marker for increased neuronal activity (Sagar 
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et al., 1988).  Furthermore, changes in c-fos expression may also be indicative of altered 
sensory pathway organisation and micturition reflexes.  After CPO treatment of rats, CGRP and 
substance P immunoreactivity was significantly increased in fibres in L6-S1 spinal cord as well 
as in DRG involved in micturition reflexes and supports the idea that changes in 
neurotransmission may contribute to altered sensations during cystitis (Vizzard, 2001).   
CPO treated rats have also demonstrated increased bladder afferent nerve firing (Yu and de 
Groat, 2008), while isolated DRG neurones demonstrated enhanced excitability to a current 
stimulus (Yoshimura and de Groat, 1999, Dang et al., 2008).  This suggests that CPO treatment 
sensitises individual nerve fibres resulting in higher total nerve activity.  The data in Chapter 4 
supports this theory and indicates that sensitisation of individual low threshold fibres is 
responsible for the overall increase in activity.  However, total nerve activity may be increased 
further as a result of a lower activation threshold in the high threshold fibres and altered 
response profiles of non-encoding low threshold fibres to an encoding response.  The 
mechanism responsible for this afferent sensitisation is not yet clear.   
Urothelial Release of Neuromodulatory Mediators 
As discussed throughout this thesis, various mediators released by the urothelium can activate 
and sensitise afferent nerves such as ATP and PGE2 (Rong et al., 2002, Ishizuka et al., 1995b, 
Su et al., 2008).  Although initial results in cultured human urothelial cells indicated that release 
of both excitatory mediators was enhanced after acrolein or CAA treatment, the effects of 
systemic CPO and IFO treatment in mice did not show increased levels of either mediator.  This 
may be due to the fact that metabolism of the parent drugs in vivo takes time and the mice 
bladders would not have been exposed to toxic metabolites for as long as the cultured cells.  
Similarly, the concentrations of acrolein and CAA in the urine in vivo may not have been as high 
as the concentrations applied to the urothelial cells.  In any event, the increased sensory activity 
seen after CPO or IFO treatment in the mice does not appear to be mediated by ATP or PGE2 
from the urothelium.  However, this does not rule out a role for these mediators in the later 
stage effects of CPO or IFO induced cystitis, but indicates that another mechanism of afferent 
sensitisation contributed to the acute effects seen in this thesis.   
Another compound released by the urothelium during inflammation is NGF which is thought to 
alter pain signalling.  Intravesical administration of NGF can induce nociceptive responses and 
bladder hyperactivity (Chuang et al., 2001, Dmitrieva et al., 1997).  Urinary NGF concentrations 
have been shown to be increased after CPO treatment in mice (Boudes et al., 2011) and 
NGF-sequestering molecules have been shown to reduce the CPO induced bladder overactivity 
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in rats (Hu et al., 2005).  NGF binds to tyrosine kinase receptors (Trks) and their expression and 
phosphorylation was enhanced in lumbosacral nerves of rats after CPO treatment (Qiao and 
Vizzard, 2002).  The density of both parasympathetic and peptidergic sensory fibres was 
enhanced in the urothelium/lamina propria and detrusor of rats treated with CPO suggesting 
that an increase in the density of afferent and efferent nerves could contribute to the urinary 
symptoms experienced by patients treated with this drug (Dickson et al., 2006).   Furthermore, 
the parasympathetic and sensory fibres were often found wrapped around each other with close 
association of the varicosities making it possible that interactions between these two fibre 
populations is altered by CPO induced cystitis.  It is likely that increased NGF expression 
contributes to the increased density of nerves seen after CPO treatment.  NGF can also cause 
up regulation of P2X receptor transcripts in afferent nerves which may sensitise them to ATP 
and increase bladder sensations in the inflamed bladder (Ramer et al., 2001).   
Reactive Oxygen Species  
ROS have been implicated in afferent nerve sensitisation in several organs and the mechanism 
of this could be via direct actions on the nerves or indirectly by stimulating production of 
neuromodulatory mediators.  The reactive oxygen species hydrogen peroxide (H2O2) has been 
shown to activate TRPA1 receptors in mouse DRGs causing Ca
2+
 influx and non-selective 
cation currents (Sawada et al., 2008).  As TRPA1 channels are expressed in some nociceptive 
sensory neurones this suggests that ROS may be able to directly alter afferent activity and pain 
sensations.  Futhermore, ROS formation was found to cause sensitisation of rat lung vagal 
afferents to capsaicin and ATP (Shen et al., 2012).  Application of H2O2 to rat larynx also 
resulted in enhanced reflex activity in this tissue (Tsai et al., 2007).  However, the sensitisation 
of the laryngeal afferent nerves could be prevented by ATP scavengers or a P2X antagonist 
suggesting involvement of ROS induced ATP release activating neuronal P2X receptors.  
Intravesical application of H2O2 in rats induced bladder overactivity characterised by a reduction 
in the intercontraction interval (Masuda et al., 2008).  Capsaicin prevented the change in 
intercontraction interval suggesting sensitisation of the afferents was responsible for the 
overactivity.  The detrusor overactivity could also be blocked by hydroxyl radical scavengers 
and COX inhibitors suggesting that the sensitisation could be partly mediated by ROS induced 
prostaglandin synthesis.  The data presented in Chapter 3 of the present study demonstrated 
that both acrolein and CAA are capable of causing ROS production in urothelial cells.  
Accordingly, it is possible that ROS production after CPO or IFO treatment may be directly 
sensitising bladder afferents or even contributing to sensitisation indirectly via ATP or PGE2 
production. However, given the findings in Chapters 5 and 6, the increased afferent activity after 
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CPO or IFO treatment was not accompanied by an increase in ATP or PGE2 suggesting that 
ROS may be having a direct effect on bladder afferents sensitising them to mechanical 
stimulation during bladder filling.  
Altered Receptor or Channel Activity 
Chronic bladder inflammation can also alter the responses of chemosensitive receptors such as 
the TRP channels in sensory neurons.  For example, isolated DRG neurons from cats with 
interstitial cystitis show larger responses to the TRPV1 agonist capsaicin and slower 
desensitisation compared to controls (Sculptoreanu et al., 2005).  Furthermore, the altered 
TRPV1 receptor activity could be reversed by inhibiting protein kinase C suggesting that 
changes to the intracellular signalling pathway were responsible for the enhanced responses.  
Systemic CPO or intravesical acrolein treatment in wild type mice caused bladder hyperactivity 
and sensitisation of the paw withdrawal response to mechanical stimulation whereas these 
effects were not seen in TRPV1 knockout mice (Wang et al., 2008b).  In mice, systemic IFO 
treatment resulted in visceral nociception and this could be inhibited by the TRPA1 antagonist 
HC-030031 suggesting a role for acrolein or inflammatory products in activating nerves (Pereira 
et al., 2013). Therefore, it appears that TRPV1 and TRPA1 receptors may be involved in the 
afferent hyperactivity due to CPO or IFO.   
Capsaicin sensitive C-fibre afferents from rats treated with CPO exhibited lower thresholds for 
spike activation and demonstrated a tonic rather than phasic firing pattern (Yoshimura and de 
Groat, 1999).  These neurones also had an increased somal diameter and suppressed A-type 
K
+
 channel currents.  A reduced A-type K
+
 current could be a key contributor to the afferent 
hyperexcitability in CPO induced cystitis.  No studies have looked at the changes to Aδ-fibres 
after CPO or IFO treatment, however in cats with interstitial cystitis the Aδ-fibres were more 
sensitive to pressure changes than in controls (Roppolo et al., 2005).  This suggests that both 
C-fibres and Aδ-fibres are likely to undergo functional changes in response to CPO or IFO 
induced cystitis.   
Concluding Remarks 
As with any avenues of scientific research, the work in this thesis has generated a number of 
questions and interesting avenues for future investigation.  Firstly, the results presented here 
support a role for CAA and not just acrolein in the urotoxicity of CPO and IFO.  Specifically, both 
acrolein and CAA were found to be toxic to human urothelial cells and caused damage to 
porcine bladder sections when applied luminally.  Both acrolein and CAA induced urothelial cell 
death was associated with an increase in ROS production providing support for the theory that 
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oxidative stress is a major contributor to the urotoxicity of CPO and IFO.  Furthermore, ROS 
production appeared to be linked to apoptotic death of urothelial cells in response to both 
acrolein and CAA.   
Very little information is available about the urinary concentrations of these metabolites in a 
clinical setting.  Accordingly, it would be advantageous to measure the actual concentrations of 
acrolein and CAA appearing in the urine of animals and humans treated with CPO or IFO.  This 
would confirm the clinically relevant concentrations for future studies and would allow 
assessment of the significance of previous studies. Confirming whether CAA appears in the 
urine after CPO or IFO treatment and elucidating the concentrations of the metabolites would 
also have significant ramifications for correct dosing of protective agents.   
The work in this thesis has provided support for the theory that CPO and IFO treatment both 
cause increased bladder afferent nerve activity due to an enhanced firing rate of individual low 
threshold nerve fibres (Yu and de Groat, 2008).  It also suggests that total nerve activity may be 
increased further as a result of a lower activation threshold of high threshold fibres and/or an 
altered response profile of non-encoding low threshold fibres.  Determining actual urinary 
concentrations of CAA and acrolein would also allow for intravesical application of these agents 
in the mouse model and further investigation of their effects on individual nerve responses.  This 
would enable clarification of which metabolite is responsible for the afferent sensitisation.  
As discussed in the previous Chapters, detrusor tone, spontaneous contractile activity and 
excitatory urothelial mediators can alter afferent nerve activity.  However, the enhanced afferent 
nerve activity seen in this thesis was not associated with increased excitatory urothelial 
mediator release or altered detrusor tone.  This suggests that CPO or IFO treatment is able to 
enhance nerve activity via a mechanism independent of bladder function and that the bladder 
pain and urinary hyperactivity experienced by patients is primarily due to sensitisation of the 
afferent pathways.    It is my hypothesis that this may be due activation of TRP channels directly 
by the toxic metabolites acrolein or CAA or by a secondary effect due to mediators produced 
during inflammation and oxidative stress.    
The antioxidant and GSH precursor NAC demonstrated promising protection of the human 
urothelial cells to acrolein and CAA induced damage.  It would be interesting to determine 
whether oral supplementation of the mice before and/or during CPO or IFO treatment could 
prevent the changes in afferent nerve activity.   
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The bladder inflammation caused by CPO and IFO treatment appears to have a significant 
impact on the function of the bladder as well as the afferent nerve activity.  Further research into 
how inflammation in this setting alters urothelial and sensory nerve contribution to overall 
bladder function could further our understanding of other overactive and inflammatory bladder 
conditions.   
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